var title_f22_62_23520="Gram stain sputum 4A answer";
var content_f22_62_23520=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F58744&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F58744&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Haemophilus influenzae in sputum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 364px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gram stain of sputum (x1000) shows inflammatory cells and very small, Gram negative coccobacilli. Haemophilus influenzae grew from this specimen on chocolate agar and was shown to utilize X and V factors.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_62_23520=[""].join("\n");
var outline_f22_62_23520=null;
var title_f22_62_23521="Patient information: Sepsis in newborn babies (The Basics)";
var content_f22_62_23521=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?39/40/40578\">",
"         Patient information: Fever in children (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/62/22498\">",
"         Patient information: Jaundice in babies (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?36/23/37235\">",
"         Patient information: Fever in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Sepsis in newborn babies (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/sepsis-in-newborn-babies-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H30342881\">",
"      <span class=\"h1\">",
"       What is sepsis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Sepsis is an infection in the blood. It is a serious illness that affects the whole body. Sepsis needs to be treated right away because it can be life-threatening.",
"     </p>",
"     <p>",
"      Sepsis can happen in babies, children, and adults. &ldquo;Sepsis in newborn babies&rdquo; is when sepsis happens in babies younger than 1 month old. Doctors and nurses call it &ldquo;neonatal sepsis.&rdquo;",
"     </p>",
"     <p>",
"      This article is about sepsis in newborn babies who were born after 34 weeks of pregnancy.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H30342896\">",
"      <span class=\"h1\">",
"       What are the symptoms of sepsis in newborn babies?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Symptoms of sepsis in newborn babies can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        A fever &ndash; But some babies have a low or normal body temperature instead of a fever.",
"       </li>",
"       <li>",
"        Trouble breathing or breathing faster than normal",
"       </li>",
"       <li>",
"        Feeding less than usual",
"       </li>",
"       <li>",
"        Vomiting",
"       </li>",
"       <li>",
"        Jaundice &ndash; Jaundice is the word doctors use when a baby&rsquo;s skin or white part of the eye turns yellow.",
"       </li>",
"       <li>",
"        Sleeping more than usual",
"       </li>",
"       <li>",
"        The fingertips and lips looking slightly blue",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H30342911\">",
"      <span class=\"h1\">",
"       Should I call my baby&rsquo;s doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If your baby has any of the symptoms above, or isn&rsquo;t acting normally, call his or her doctor or nurse right away.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H30342926\">",
"      <span class=\"h1\">",
"       Will my baby need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. The doctor or nurse will ask about your baby&rsquo;s symptoms and about his or her birth, and do an exam. He or she will do blood tests, including a test called &ldquo;blood cultures.&rdquo; Blood cultures can check for an infection in the blood.",
"     </p>",
"     <p>",
"      Many babies also need other tests to check if they have an infection in another part of their body. These tests might include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        A lumbar puncture (sometimes called a &ldquo;spinal tap&rdquo;) &ndash; During this procedure, a doctor will put a thin needle into your baby&rsquo;s lower back and remove a small sample of spinal fluid. Spinal fluid is the fluid that surrounds the brain and spinal cord. He or she will do lab tests on the sample.",
"       </li>",
"       <li>",
"        Urine tests",
"       </li>",
"       <li>",
"        A chest X-ray",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H30342941\">",
"      <span class=\"h1\">",
"       How is sepsis in newborn babies treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Sepsis in newborn babies is treated in the hospital. The doctor will give your baby antibiotic medicines that go into his or her vein through a tube called an &ldquo;IV.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H30342956\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?39/40/40578?source=see_link\">",
"       Patient information: Fever in children (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/62/22498?source=see_link\">",
"       Patient information: Jaundice in babies (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?36/23/37235?source=see_link\">",
"       Patient information: Fever in children (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?22/62/23521?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 17189 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-5D5ABCD1C5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_62_23521=[""].join("\n");
var outline_f22_62_23521=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30342881\">",
"      What is sepsis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30342896\">",
"      What are the symptoms of sepsis in newborn babies?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30342911\">",
"      Should I call my baby&rsquo;s doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30342926\">",
"      Will my baby need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30342941\">",
"      How is sepsis in newborn babies treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30342956\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?36/23/37235?source=related_link\">",
"      Patient information: Fever in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/40/40578?source=related_link\">",
"      Patient information: Fever in children (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/62/22498?source=related_link\">",
"      Patient information: Jaundice in babies (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_62_23522="Pelvic anteroposterior compression fracture type II";
var content_f22_62_23522=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F62560&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F62560&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pelvic anteroposterior compression fracture: Type II",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 299px; height: 489px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAHpASsDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5Zt4JLiURwqXc9AKvx6DqchGy0c/iP8av/D9IH8UWq3as0JVwwXqPlPNez2/hdiFmsWF3BnPyj5l+ooA8Tj8I67L9zT5D/wACX/GpH8F+IUQO2mSBT33r/jX0Jp+mojqChVgOhGK1bvS0k044yG69KAPmGPwnrkjYTT3J/wB9f8ak/wCEM8QYJ/s2TA6/Ov8AjXvmm6WftJGAcDuKnubBVlzMrYXrjjIoA8Ag8D+I51DQ6XI4PcOn+NTN8PfFSgE6PNg9PnT/ABr3ZIZEjWewjw6NtEYJYN/9eultIGaxWTVS8LkbvLTljz39KAPmiH4b+LpmCxaLMxPPDp/8VS/8K18X7iBosxI64kjP/s1fTq3UzBYbVFij6bR1/E1pwDy4VUIN2OcUAfKP/CsvGH/QEm/7+R//ABVMb4b+LV+9osw/7aJ/8VX1oHywBTjGaSSIBN235vrQB8lP8OvFaDL6NMP+2if/ABVRP4C8TIpZtJlCjvvT/GvqvURuVcLhu/vXOX8RynmO4j3ZYL6UAeA6f8MvGGof8eeiSyHGcebGOPxarf8AwqHx3gn/AIR6fjr++i/+Kr6R8PjybxJkuAI0wSPau0v7qNSjRF/m+bjAzQB8a2/wo8b3DlYfD9wzDqBJH/8AFUj/AAq8bJJsfQJ1bOMGWP8A+Kr7X0W/heQ+YgjOOX6/mKbq+FuiZIztJBDDoaAPjBPhB47f7vh2c/8AbaL/AOKqlc/DbxdbTNFPosyyL1HmRn+TV9sfaUSCWXJAA9K4DXbgSNIyMSOfqBQB8yH4ceLARnRpv+/if/FUq/DbxcxwuizH/ton/wAVX0hCN0Eb/MDjknvVqBzuwGJz2FAHzOfhn4wBwdEmz/10j/8AiqZJ8OfFkYy+jTD/ALaIf/Zq+qHHq+HqldOwQdSc9hQB8sXXgvxBa/8AHxpsid/vof61QbQtSVgGtWBPuP8AGvevEMu+6l8zIy2MfSuTW2ee4Yqh2g8UAeYtoWpK202rA/7w/wAacmgao5O20ckdfmH+Nei3to4kxna3X6Vu+HtOjmUuVLMvytkfkaAPHf7A1QtgWjk/Uf41InhnWHOFsZCfqv8AjXuS6aGkysYUdOlX7XS1V1IHOfSgDwM+EddGc6dLx/tL/jUEnhvV4zh7JwfqP8a+i7ixGWGc1z2pad5b5JzntigDw2XSL+L/AFls6/iKga0nXrGRXquq2Y8skDpxzXL3VoV5AyO9AHHGGQdVNMrpZbcbTx1rHu7YoxyOaAKNFFFAHSfDxd/iq1AOPlf/ANBNe9aIkkM8TwytGc9Qa8I+HK7vFlsMkfI//oJr3/SojlDgnng0Ac9b/EG4k+KUdtd3dvNon2n+zfs2FDmTb/rPXHmcZziva/stjJbkhJUGMnHNcfaeEtHbShYHTIza+b520k7t+c7t2d2c+9ddAjmBs56dqAKVnpmnpMzJLL05BUUmp6XYbd5gedgchXPH5UkG4TlecY4NXgzbMOckHNAGRCt3vMUcUMMX8LIP0pItKa7bzmciZTwR3Hoa10to2dC4PBzwa1kSCNB5anJPagDBTSxEu4kEnoKkjs3Uk4GM1rGNm+8OnSrKQjywABkigDFt7YhssM/Wi6TCtgdK6BIMjIXj6VTubYtnAGP50ActdlixLLx/OsmSJGcblzuOMDtXWz2mUwBjnjFVlsVe4jXnAOcgd6ALmiaAZI8CHO8AZOOa0L3RZ0ATZwp9a6KyMcFhbsgJcnBOehqxfJGYxJL3BIx3oA5Wx0m4EFw5C4IAAz71dSynjCCcK8RABUt0q7pse9pSqjD4yp7Cobg7L1Z9o2j5dvbFAEi6ITbHaN0bgnk9BXD+LdPa0Q7IiFPQgdxXqkFzFHaJIv8Aqu+O1YfiyZDHGrouHGVOOtAHk1qJZIyFRiD7VdsbS4kAJUjPrXQiMKFKIAD7VYUbcDABz6dKAMp7GRsE4x9KqT6eI43aRnKqM8V0aIWbJBAJpmoxg2coI6gigDxvxSqNqhkQfIw4HoaxJHKN+6GMc8966HxBH5VwRzjd37VlQQfaJwgOcnAJoA565SSR2Zwdxrq/BUUn2O45yMjg1pzaBA1qckBgO3Wr/gzS/s9tdibG0lcEd6AHLDyAy4NW7aDEobIwOwq3LaxA53MPwqSG3IlG1vloApzQggg1hapBlhgA4PJrp7qIhwSACc9KxdSXHVfzoA43VbZdjAjCn0rkrq2JBGRmu+1FFZD8pJrk72L5zgUAcpdW7L0wfWsm+hLAEda6e6iPJ7Vi3MX3h2NAHK3C7ZDUVXL5NrH61ToA6n4a4/4S61z02Sf+gmvovRTl4zsIA55NfPPwriM3jO1VRyI5W/JCa+h9KKmSMdCO1AHWQSHYSDjFaVvOTb8+nFY6HEZ559K0oWU2xHfFAGe8p84nOOe1Wd3mJzzVC4IUn5cAVct3Vh0HTigCxZhmmK84FaykIMVQgkAnwcAYqyj7hj9BQBYjO9iADj1q1HGeAMYqgCUX5Op/SnwzmNxklj19qANQgrGR6cdaqyhWYAnike53cZ5xVSSbJAx70AKuzdgsMVPZRwvLtxnJzVB2HDA8jt6Vc0hGnHHRvWgDqdKa3+z84JHOSetR3eydstkEduwqa1hjSFV2gEDr61XuAisSGAz+lADUmS0jldVUnbxmqE9yjSjIUZUHp1NQ3M9vMsyI7AhgCD0I9qzpbuxS8SIyOW4BwOBQB1lgYRjKE7hnHY1keJZUnnEOwL8vyHHetOHayQFDuwMYNV9UtlZTJgB1ORQByiFtoEgIIOPpUh+dgataxEPklX7rjkD1qpbjdgnJHtQBYgA2gkkntxSXSCSF1/Q1OijaOecc5qtqFx5MW5cEjigDzbxfGgyVCjnnNc5pEAebzg4yp+6K3/FFyJZdi/M3UjFcojzQzMIyVPXA70Ab00jCNlDjP061u6AS2kK+cFnOeK4+51MSsIhHIJDgAEYNdrYKINOhgPysoG7PqaACVnEhAbJHTipI7h0dckGqsw2vgNnHemMSGAB44IHpQBoXUxO4kAHtWVelWjIZwTVi5yQWDcVnXAIBOeM4z60AZdzGpJPUeorkr8LvPBx2zXV3TAMwIz6kVy97NH5rBV4HTPWgDEukynUE+lYeoKQrdj610MqB8kZBNZF+nBBFAHH6mOORzWbWxrAwprHoA7T4P3C2vj2wkcZTbIrfQoRX0GVS1vigJ253IexU183fDk48WWuDj5X/APQTX0FaSNeaeFzm6tuR/tL6UAdTFMCg4475NXzOq2/XqOK5HS2nnb91uZc856V1tvaNJEPM4GPyoAzJ5MHg0izTiSAxpuXkZFavkWsTHKBsHvSG9jBKwoigHgmgCxE7NseOKQ+vy1bTzk4Mb57YHSobe+kCjywnHUVctdUkYgFRzxQArBwBlWz9KQpKqhyjBe/FXxdo5w4NWI2DDGevagDIjfErl8gH9aN4Y8frWjdWalSUOCO2ayuEl5IGO1ABNlVb5Rk8DFb2jKi2yAf6xOozWHLsJ68dq3tAii35lLbDQBsJMZQqgrz1z0FVL4O0MgiVXbHJrZht4otpUDA6Cq2qeXFEx8wIW6YFAHI/Y3IZ2Pkp1O3kmq39jZnRoXyh5BIyc1uxkFxu+ZG4yamFvFEiOz8ducUAW7GJo7VUc7GXnIFR38gCMCxJPA461oWl1C6kr98DkNzxUeorbPDkkHHIANAHM3y7lKE8rhvpVK3iIGSeDT5JD9rmjc5Xaarw3kaxc9RQBaeTanGPwrnPEWobI/Lj5PU1rNc+YwCr1PSud1KEmeR2GDu5oA5iz0+9v55pcCNMYDSHk09vDKtKHe5ZXHIIWuntVEca+/OKjnbcwbHGcUAOs7SOcgXKB3iHyyEDPFSPZQMRvZyfXPanWsigHkAngUgwT15zQBWm0i3b5lmdWPbNVbjRpsExSBuOhNahb5QVXPpUazgZIyOlAGBdQzQJiYH2rIubldoXB3Z4zXazSxTR7ZMH8K5jWdHdgZLXIcZOOuaAMO5ZSrHnkY4rl71VyxDHPTpW1NIy7kkyrDjB61jXh9vegDPkyAMVlXx+U+taVwDjisi5J2nJoA5nWlxET71iVuaz/qW+tYdAHSfD1gvim2J/uv8A+gmvePCatNrMJGSi8nn+deB+BTjxLbH2f/0E19KeB7UQwG6cAjGf8KAOvltobGMSIoWJ+gA/So/txlJVQAvT6VXS8+1jyLgbUY/KT2NNWJoZGRuo7+tAEV0zDPzZqva5PQ9ck0+9U5Ug8Z6VCGC89c0AasPAVnfGfSrUEqhyFHQce9U4GyqkKT+Har9vFkEnjP6UAXLUlyN3BrShzvwp56n0rOhUjHOa17eMhQOM0APclkGRggdqoX1uCN2Pn9K1Z0ERC9WA65qs4BJDZOepoA5yZWjmUrnYfvD0rY8OagFlK7s4PT296oajG8EoY8o3TBq1pao0m9UXeRgnoaAOx+1hl+8M1h6vNJKGYZC54GauRQpGAzyYPcU7UbNJoFETjjnk0AYVrcMr7GAA7Z7VLeTb8ckgCqs0TxtgryD1HepY4zLgkZ4xjFAEumXEsd0qjJBBHXtVy5u8F89OmDUtraxKu/o44FQXMEO5lcnpyaAMiQrK08ihztU4wOtZkKlJA0nQj7vpW/IyQWj+VxuOOO9Y0j/Nwv4mgC1aRCVywTAHANV9YtSN5289TWrYx7bUOcgZzUl5EZ4NyAFl9e/tQBwr3PkKFkOF5AJPWqk3mXJ8uFgCSME9DXQeINMWW23BArdSPQ1iWynyAzkZA5wKAJLbT5LWVZZpt5UEAZ4qZnZHwxyD0Aqgt4rO2TkD3q9xJEXHagCOSYqy7SQPSop7gM7Hafl4qOTI+ZuRzxnmopMdicYweKAFEjO2SP1qxbzrxHIcBiOvaqSnDDGPc+tLPwN2Qec5FAGd420jzSbq3ADoucD+IV55cSYBznPp6V6yGN3plyv3Zo1JQk9eK8p12MRSl1/5aDJHoe9AGRM45OcVm3h3Ak81amOe1Z1yxGcdaAMHWRm3J9xWHW3rB/0c/UViUAdF4AAPii1B6Yf/ANBNfTEINnotvABiSUB29h2r5t+GgDeMbEMAR83X/dNfSV7814wAwFUAAemKALlm3mQDHQHp6VtQEXkBRsecn3T6j0rKto2MQUADPHHerkUToAc4IPagCrOhycg5HUVAEOc9q32RLpSDtW4A/wC+qxrlWQlSCrZwRQBcs24GBgfWtWKUBO2e2KwraUdCOfrWrAOBg8gUAaUJ4HGT/KtiwHzD1zxWLExwBjnvWzphwecevvQBNIqmSQk8g9CaqS8c9DVlnDO7BeO9Zt3chcgc4NACXUfnwMP4hyDUOnoVZVzhvWhrjy4tzH9arLPiQOpzg5oA2DcMj7ZenrV6K7jbkMMYrHa6SVSTgZ65HFPjU5AUZGOSKAL1zh9xUD2xUkCERKUIz3FVYSp7A9quBwFLbQB0+tADbqdYExu69lrOublp2VU+8e9TXQzw6gZ6e9Zt3OLW2LHAdhjn+GgBs048wIxO1ePxqC5UFwYySBziufn1B42bZ8wJ5JOTS2uoyB+TnFAHZQzboEK5GBj8anEpEYLc5IFY2nXaSx7lGDnDIeoNahkQhQG+VTub2oAmvlWSKVCoOK4K9h2XMmQV9u1dx9rjZ2BONw4rB1SyS5BKMFYd6AONu3jEhKx4cdGrT0y6E1mwKEYODUM+hsJMvMcdT3zU1pAbeMhyDls8UASsmUOBjA49qrzRll2KTwKsOwZSPmqS3YN1XANAFF7Yqy/Lz0OKbcxYXCDrySOfwrbiiRmPHuTVa6iyPlIH6UAY8EmydUwSjAq341wnii0ELyoxBKnIOev0rvZylqks0pClVwM1534gvluTktubOSRQByE3DHJOaoXHfHU1fvcB8+tZ8rAA+1AGHrC/6Ox56isOt7WHzasMdx/OsGgDo/h823xVaN6Bj/46a+jILwXIglIxuGGHoRXzp8PRnxTa467X/wDQTXtmnXhV2hZhnOVz3NAHoln9xSuT+NaMqAhW4wR+VYWjXYcAOSOcYxXTBVeybHQc0AZrqVclTjvSTvDcACc7ZRwH7H608jIOecVVaLczDJ29qAIjbvDKAw5PRh0P41q2hGMk8VUtrny1KSfPH6GtCGGOXm3b5iOUbigC9F/CeufWtO1cL7HFZ8aOgwy4PuKtQkEMuO2KAH+YBG2OWY1XubZmKsv3SMmljPlyfMfl6EVdbG1e69jQBiX0QQ9OO1R26A9BkntWhqYOOdoI6VzetaqbKIpDxIw5YdvpQBa1O+hsiVJLyd1QdKp6X4gMsrIFKEjGc8CvPb/ULmOfd9o2sexPOK0tG8QWcsiwzMElY4DgYH40AenQX0pALBdp9asrfssf711BJ4xWFGXZI1hIMKj756ZqhqeqxQMY4f3k/wDePQUAa+ta5/ZsBmkctIR8i4zz61wr+Lry7uNtzCs8Z6sg2n/Cr/nNPEz3n7wN94HnFcjLqMUU0kSI5XcQGAxQB29skN5bl4GU4Gdp4I+opYrclR7d65/w7IhYuszxuTwSOh+tdrZoJIsynLdyOB9aALGiwAT5dcAdWz2rQuCI4nkX5Vc7RS29t5SbY2HK8A026y8kargqoxQBSuMwvuJABHSoHZw25ee2aZrdw6uFCkgcAjpSW8reV8wwe1ABc5I6Dpmsa4lPm7APk7kVraidir2wPzrnnlJlwvegCyzljhn+7S2zbpMnntn0qGQDy9gHPc1YtIWIB4I6cUAblrDttCzZJY4GazdUuBb98+2K3QPKsEI4ABrg9YvN1xI8hARBnHrigDO8R3RZYoAflI3MPeuPu7YlmPAPpWlcXT3M7SufmPQDoKikVnGQOlAHG6hEwBB5I5HvWPMxIIGfpXX6pBlc459q5O7BjlO0HBoAxtXH+iknrkVh1tauSYWHpj+dYtAHTfDosPFdrsGTtf8A9BNesq225Rj2bNeTfDslfFdqR12v/wCgmvVnODnGeaAO40qQiZF3dep9a7u2IOnt3+X9a8z0ybzYo5EI3D5W9q7ywnJ09AeN38hQASkBiMVC/sBU0nDAn5s9KbszyegoAhKErjgfhU9mrK4ZSdy88U9Ys89/WrlrAowxGSaANOCd/KAcAj3qzEsR+6rIx646VnRtggHoO1Wrdv3mVGfTFAEl3Z7uUkHvmkjgmVMYz9Kr6nqcdgpV5FacjiMc7fc1gXOtXUrbhMyg8YBxQBvTIbhpMLnavPNcX4g0+7d3aBolZ+hZuFpbzUpYFCK55JJGetQQ3sd1CY2QiTtk0AcrNokNqPN1O9DnpiMZJOawby60+3uA2mrmQHkyc4/DpW74rgnZA5zg9B2FcSkEwZmx14zigD1jwlf3F5Y7rqYsG6KB+tUNQnKXTPGhBU5IPFWfBduy6LGxifO44PTGetHiCxSOVDt4bqSc80AKJ1vomilIid14INctFZobhyrNsVjuOMiuwttJWWFGiGWK9zWDdwfZxLCw2HccY6UAXbYRRBTBICOoVhit3S7mcQjCqy56dRXIW3qM4HetODVDFEEj4OeaAO3XV4xPDI6kKg2uo9K0be6srqTbE7BycjfXni3Rfvz2JqCe6khO9HYEDOc0AeiXkI2ss64YGoI0Xbkgbay/DniVdVjWzvSPtIGFLfxf/Xq7cCSKXawxQBBqQD4K5OKwpFAY4Bx1wO1dL5W7grnPSsy6ssNtUEDrigDOjj3MMNhR3I6VsW0WAo7dcjjNRQwKhAxkVdjXaRwKAL10+3Tl6E4IrzLX2zDM5YcnAru7+7jSAwvkKed3pXl+q3YurhzHkRKTjPf3oAzkBBwDVhQ5yWK5qFcM4GPwFWNjAf40AZ10vBB5P0rl9Wt8EsB712MwDZBHzDtWJqUPDEDpQB57rA/cP9R/OsOuj8RRmKKQHoSCK5ygDovATBfE1sT02uP/AB016nuyuc968n8Fj/ioIMdlc/8Ajpr0bzZFIGaAN2zvZLaTfG2DxkEZBr0rSNRS7tbeVAPnXaQfUf0ryON+Mkg+tb+h6nLDDLAuQud4z2NAHqWScZANNklwQM446Vn6ddLPZRyoeo5x2NWlUOQ2cmgC7bzBuMfMR1FadqMheMe1Y6bEAZm5rVsJfMUlT9SKALAh8ybkgDPBpmv6hHpFn8n+uccH0q9Z4Mh54AJ+leZ+JdVa+1CWZTlN5RPTAoAsJdecxeViSxyWq5aW8L2ss80uFQgBVYbia562nPzAtgHjikt7pYJRLInmorYKk9RQAl/KZJ2IwQMgVShmcyKRnitXUtQjvZ0kMaRqihQF6ke9Z5GQWjQAE0AOnuXICsVHs3NZN6TLtCwRZB+8BirN0MEGQ/NUb/Im4emaAOh8L3n2SBkk3EAHPoB7Uy+u1v2zuOP4RVHw/Mrys0pAGOQe9TakFjjHl4XnK4oA0dPvXt4+m9fX096xb/N7cl3UhQfwJqu+oGGRVboeGzUUl+8kckeQB2PegC+9vtTOQiheeeKyoW+cuGyCe9ST36vCIC2SB1rHjma3J+XKE96ANj7S24nIz1qG5unlTjIx3qjHMCrOGyPQUrSknjoe1AEkc81vcLJG5V0IZWHrXrtheJrGjW97j5mXD46hu9eKySYlUOTmvRPhffErdWBztI8xR70AdhGFC4J/xqjena5bbx2xVp38rzGbcC3Ssqa8YudmNq+poAcsobBP8qsIR7fWq0c8c2FHD46YqZDs3NjoOBQBzfirUkjtLiPowHlrj1NcEvC9c1oeKJ33xK/ync7EHuc1jLIV5X7poAuQOpII61c3Zzu5HSs3cTgqMHqashmA5PXrQBFcRtv4OFqjcKoBzycGtIjPy5z2+lUbmPByMmgDz/xcn+i7iOQcH865Cu78bR7bF29SP51wlAG54M/5D8H+63/oJr0IyZcjGMV574Lx/wAJBBnptb/0E16MgBz6+9ACmQnAwMCtDSXY3Z3N8pXmqUUZJOMemK2NDtonvohKCiMcHtQB6J4dQf2XgcLzzUr3pjVgh46VoW2kG00tYDks3OcfpWZdadNsyI2IHcDpQBItyJdpJxnjjtWjZXSwtjcSqntXNRR7ZsOxDA9GGB7VPFeAB23KVBxtzQB6HDKDplzNGeDEcfWvErudlLqzfdzXqOgXi3NjdQDO0pu615Frp23swPyjccUAWbe/wu1iAfepTdrtKKc7j1rlopMs5LZXFTLc4ZUUncKAOhil/elW5ANX1m2gYHXrXMm98qQYIHr3NXYL5XVefxzQBrXcodQduG96qNkoe3tSTXGYxhR7GqrSjPzH9aAJ4bgWz8Z3E9a0ZblnjSRh8uOtZS3EZQAjOKtxzRzIEYLgD0zmgDL1VwdskZBI5POay2vWMgZmIxwAKu6iyljxwOOBiqNjdtZ3BkRFYEbWVhkEUAblnbefp/2uLcHUEsGGVYD0I6H2NYt5MXHH1FNTUZoJLkWbGGCYnMecjFU2mAzt+Y9DmgC3auwx121YknClRn8KoxOCAMnA5qC5dwdwzjPrQBauZMurdCK7f4ZyMPFECgja8bZH4V54Mvgg133woheTxMr87YY2Y+nTFAHeeIp9j7QcBOwPU1hwXICMQA2e55/Cl1i8FxdS4zgMdtQaZbTXUjLGrb8cgdDQBYtZfnyM7unBroLFllQBjljx9ajtNKhhAkupgrY6DnFX7aGxVwRIwVfbigDyXx5GYtSZCmNhPX0rCtnDx4wDjtiut+I17bXmtqLYf6tdrP61xLZtpsg/Ix60AWgxPQGrcD7ox8uGHH1qhuAbcuTnmpYn2uQx4b3oAtyZUbjyO/FVLiQ5I7Y7VaB3pjcenWoXVNnO7d6+tAHF+N8nSZCezL/OvPa9I8chf7FnK/3l49ORXm9AGz4RIGuw56bW/ka9FVyqlsYxXnfhAZ12Ef7Lf+gmu8uGPQE46UAX9NkEsu4kgV0kMnMezggg8CuUtAFX5clj0ArsdG09wiPMCCe56CgD07w7qdxdWCRSEKVHylup+taha55CyZ+orndGUxBGUYGeT6+9dZbKr7STmgDEvlVx/p1qrJ/fUciua1bSVjIe1jZ0xnj+VehTxLjp7Vzms2pQbogxDfwg8ZoAwvC155V/sYMB90+2a53xvaIXkeJT5qsQR7V3FjYBXkuGUKxAPHf3rP8AHGnrIvnRD5nQMwUd8c0AeRwuAxUoeRg59akQbW3kYGMnimFGjvMP6069cOQR07igClc3IeRSoqe3uNreuKpyKChx1Bz+FJavskHAoA3TeyvGFPTrUXmMOWJx71WluhEuTjJqlLcNKRycUAbEd3GhAY5B9K0rWaERnk5NcnG3zfeyM1clvEjhVf4/QUAa92FkywZSM+tZdy6R+gxWRLfupwpPWlaZrmPeTznBoAJrjecKcCiPhc56VVAYtVhPukHtQBMsrY988VIJy42kD60wYMbDHA6GmRox5J4A5oAs25XAxnPpXrPwvtDBpd7fMh3SoVT6CvJraIswwOpxgV7n4Ut/s+npZ7SCkPP1OP8AGgDAa2J3PIdpJ+Udx71pWdwUVbexGHb779f1qLUk2TkYyMnHtWpoll5Vv5rL8znk4xgUAXLS3CxDzCzk9STVbWrr7PblI8gY6itNHXAUMPxrD8QoXiwMHnAxQB53qEcctxI5yHJ/Osa7gIGxsnPIro7uzeOY56Z9Ky7lGKSKVyF6EdqAMq1ZkIU846VbfaV4B3D1qqAQ/XOe9alrDJcKPLiLkd6AKsblGyMlT6VMjrJnB4PXIrVg0OUvmQBAwzgHOarXFg9tcHK4BHWgDh/HqBdEnx/eX+YrzOvUviCmNBnP+0v/AKEK8toA2vCGf7dhx/db/wBBNd4/IAC8k8e9cj8Nokm8WWySruQpJkZx/Aa9l0fTtNS4WSSDc4OQGJI/GgCt4X8Nz3o85z5cYIJcj9BXf2dn5Pl4VSp9RmiylWXACFUA4UDCj8K3rRdybSO3agCWBE8rAwBWjbbtuew6YqrHGqp0FE8626BFbk8nHagDRuW35wRnHSs++G612Ackgj2qaxu1mXDn5hwKszRIBg5560AZkEZKFHOcqazPFqeXoEM68fJtPvzxW9aKhWQrkFVOKo6/Cr6DbQSDKysUPtnoaAPDLyIF2cnMgOetZ90w8xtowD2rf1WweyvZYpeWU8Z7isW7jXexJx7UAVFQ/Nuqs+IpcNgirzOAuMjHvVO5CsB0OOKAK+oOxZWX7pHFVFuWT5W6eoq6rKVKMu5evNVZbXef3TY9moAaLk7uG5pZZ9yLk8jPNV3tJlbmMkHuOaVonAA2sBj0oAiZ+OtXbEb43zVQQSyMAqN6citKGHyY8Z+tADFG1jzgetPjIZsAZUdabIoAJpkJKj0FAFzdxgd6dCuHJaokIJyO1WUBlIAGcnp60AbPhyzE9+khIEUPztn17V6r4IvDeC4MhHmDj8K8+jtv7P0+OE8SP87+v0rtfBkTxXagD5ZIqANK/tx55LZ5bGOtXX329rhAWJ4x6U7W2VJSwB+UjOKkuJlazUxAEno31oAht2Aj3yYGB2NQyyieMmPBUjjisfXb77NP9nVtrHHBNT6NKZEOTz6UAUb22JkbeBtPqKpjT4kkOQhyORmuk1KEmHcAM1zU7YkKHO4UAYeqeGpBM0lhIrR9djHBH0Peruj6ZqAcAxLHEoyzswxirDeYQMP8uecVvaT5gjjZ9rR7MHPpQALNbYWKNFeQYBY+vtVTWLDz7d1ICkjKn0qy/kC5PlYznrirbqs0BAA346A54oA8O+JC+XoVwjH51dQfruFeTV7R8YYvK025yNrFk7f7QrxegDsvhJAbnxvaRqCSYpen+4a+hNJ0VbX5pGDMf4a8L+A6hviXpynoY5v/AEW1fUctiFOFUDB6UAUIrfjOOOnFaOmW/ck4BpbS3ZeDyPpWvZ2zAfd4oAYsMYjZiSMdB61zuqzLBId3LMe1a2r6nHaShEHmP+grlNUuVmbzPJy45GGxQBb068MV+ofBGema7O8XMQdfmVgMEV5r9pdRuSIBiPvN2NdnZ3cp06EBzuKDOfWgDQsUUyMrcbhjPasfxzK1tplpHxk5xjtzxV6O5mhQMdp9ARWH481SA6Zb3EyHEUm1ivbIoA5fX7f+1rESxoPtcI5/2xXnt9MmCp4boQOxruobjL+ZC+Uf7prC17T470vLCpS87r0D/wD16AOLYtyDjBqJonzu6rU7qVmKyAqynBBFTRr2oAqx/eA6VMkYZjkDGKNv70nA/KpYwCwB4FACSLhBsByO+attkRJ8m7jrUZwDt5IrTWMfZ1HQCgDIkOB0Gaqn5V681p3MDF8KOvaqE8XlsQeooAoTkswGKQnAwBmnEZckg+1NCFmwDQBNYxvNcJEoyWOOK7XSoYbWaKKKJZXT55GP970H0rn9PQ6fAZ3GLhwVUHqo9frT7O7eGXKs3PpQB08oN3K0mGJz1rt/BmoQ70trooLiJcxnPJX0rhI77GmMsP7tnON3XFHhDzk1l5JNxKxkBvXNAHpmpSK8jSB1aM8HJ603SJoAdsjYReQvJNUp5xIiI+0leT9aqCb9+jqpUg9jQBz3i+VpdcnwBz0NW/DlyQVWdlQZwG3gfzrn/GQZNZlwSGzkDNULdvk5yGoA9njXdBgrk9q5rULbLtlSMZqn4L11oJ0sr47oHPyOT90/4V1uq2pJ3p0PHSgDixARIiA4P863bkBAsKnCRgLx3NLFanzBJ1KHJ4qtMJFlLP3J5PegCTykePer8qenerFopWQOBzjj3qO2QyOMfd6nFXUjZB8gw9AHl/x6iVvD7XCDb+8RWHvmvn6vdvjlqRuNLmtEI2RMm8+rZFeE0AeifAPI+JunkdfKm/8ARbV9bRRtchWI4A5r5P8A2eEEnxU0xW6GKb/0W1fYUUWxhtHFAEdragkYBxUfiC6NrCIbfHmN1I/hHrW5Cgit3lP8KlifSuMuJXuZpXcct0z6UAYWo5WMHcNw5ya56HM0/D7geea2tVid1dASVJ6CqNtbrbk4J3HGQe1AC38QClUycr3Nbei3YfS4TnLL8pI7VianIF3dQuOpHWuftNd/s9prcnELHcrf3T/hQB6Hc3kSxgtgDHeuXu7qLVPtFlKALedcBmPQ9jXOXWqS30/zSlU7DPBq9pzRlGaUZZeme9AHLWU82mXjQT7vKVyGHofUVtXLG/QiDH2uMZH+2vt71panZWesJ5sX7u6Qc4PDD3rBNvc6fPGTvDLzHIoyCPrQBBNBBqAVbyMpOBhZkHP4jvWfPpM8IPlskqDup5/Ku0vdMGoQi7tV2y4zIg7H1FYsVq5mIYEAHuO9AHLyQPHhyh645qe2h3sMDOfWuo1CwV7PBTa4G4t61m2FufNVl4HSgCsluHm2EZNaJtdqndjrwKuBFWXoNxHUDpSPHibLc5FAGXLCE+Yjmsq8jBYkLXS3MRZCaxZ4WYkEcCgDOttPaddwBK5wSBVqG1htXG1cyD+I9q6PRYEawUAgAZz7mmyaYhk3Fxt69eaAMaGylv7kRRgsx5+lav8AZdnaQH7Q+X9E5rTkIsbBobGLEsy/O56gGuaNheFwj/UktQBdvpLZbRY4UwjHP3ua1vDSPZ2TvLg7uQD29Ki03SreKMS3B8+QDOP4V/Cmz6g0krKgCpnCigDaecFPl/h5NT2jCSRST8nHSsyEZT94+CfQ9aZLqcdnGyxfPKeBz92gDK8Uj7RrU7R4OxtoIrKWTy5RGx6n0rVVPNyTgueT71napaY+bvnpQBeCggAHj1Feo+DLz+1tIEcx/fQ/Ix/ka8m0uYkGGTgqOM9xXpXw0Q2jSSyni4+VR6e9AGxNa+VuUdOv1rHuELOQc8HAxXaXtqHXcAcjrXOTwFWOOMnnFAGbYJslwy4bPrW35QRWlI+VULH8BVKCILOMADnqO9a2qKY/D1+56+S3NAHzX8SSZdEu53+9JKG/Nq8nr1z4iLjwvOfVk/D5hXkdAHpv7OS7vivpg/6ZT/8Aopq+zLWI7iSBgdM18afs4f8AJWdM/wCuU/8A6KavtiwiJwDk/jQBDqTCKyZeMyDBHtXCzMLd3DdjhfcV1XiK7jjuWywxH8uPWuVZPtUjyseDzzQBjSZE7ysGyemKorHNPK0jqdo7A1vTeWjEEDI4rLv3WCBmDbc9AOtAHNeKNTe3g2qo5OMdc1wN5JNOzGToecDoK6LUi1zctnJ29BWXPbEAjqe1AGXFeTWp/d5K55B6V0Gl67GrZmyh6EEcGsW4X9xgA5FVI/l+Un86APQInQFLi3clD0ZOn0NWkmWK1kMbkqWyqkdD3xXC6Vfz2cu5fmj/AIkJ4Irel1K2dUdWdeOY/SgDodLvg04ZciQdea07qx82dJIVzu5wteZTzvLKfKlKjPCg1oWGqXVqFWK6lTB+7uoA67WY1t7EiQjLZXBrnbeIjYF7EVYuLqfU9rzNuK8cCnW6OGUMeM0ASmErPknJ9MUy/PlPG5BwOOKs3Y2vkH04rP1fd5JYcYwfxoAe7ZiZicL1rIlZ3c85BPpWhbsJYO5wM1Xdk2AAAHscUAWNJ3SQumACCMHpWrb2h3rJNhUU5yTxWAkjxMXiJ34xkVUu55duJpSSezNQB1F1LHuba6OTx8rA1WcjaTHjJ7muST92Sxb6YNaFtqqREeduYDuO1AHQySkxZJCoR8xHA4rFa9tEk3IWmbPA6CszWNWN7IsUJIgHb1pLK3EjDOAOwzQBoz6jJM2xf3aHjjrSIMr1B5zTJLTY42sGz2p1pD948gjtQBoW7HbgKPqKsNAJoiD6UWkRC5VRg1djX5wDjn260AYlvFtk5HzDIya9D8PyqdLtiGAI+XPcEGuVkt1SZumDTrOeS1kcwE7d3Kn+dAHs0RNxYxTfxEc1kXduBKQBz1qTwHfrqemyxtxLE3K57HvVzUEClulAGItuS4OBjNaWsRg+G78D/nm3H4VGgBb3PetC7i83QbuPqWRh+lAHzB8SlH/CK3Rx0dDn/gQrxuvavifti8J3MS43l03f99CvFaAPUf2axu+Lmlj/AKZT/wDopq+3lAtbRpT2UkCvib9mIA/GLSQRx5U//opq+yPEt0LfSpTnAxgUAcXcu9y7yOclmLEmq7v5aADGajkuFCghsL3qrPdM8eAABnrQA+VkALMxyetc1q9yrytng4wPaotc1yMMIIRuI6sDxmsMXfmFd/zHPNADpFRfmGOev1qjdKOMfjVi4KFCcgEe1VDOvlFWA69aAM+SIPvIyMdqzbhQv3RmtgsqSEZ+XNU7pl5IA5oAoQzZUjnIpBKBIADmqlxIY33KKYLgMVdT9RQBpSOCrEcGpYpvlAB+b371mSXORnuKSK5UdaAOl0zVdrNGflyOmK2oJN/zFgRXCLIoZWVsVqWOoYOC+WPFAHZzSZg3q3Q4rI1i4AtjyWfHftTBe/LgnisTU73IkGRwKANHTLobVyfvDpmprhxEynIOa5PS9Q24ya0rjVFMTAYyBQBdu9Q8hSVYVjS3zzucnd9e1ZMtw80gO4lSabHcYwM8nigDaSZdgYk8VHNcDbnqPSqInPl4GMdearC582UjI2DpQBq2jfMNxBJrpNMCH5ivQY5rmbIouMnOa6KwkAThcr6GgDTKncQE4/Opo4wh2nPzdagjm3AdAAelPa4xgHjmgDWslURhXByD17YqaVDnCrle5FQW8gYKODirUFwrsVPB/Q0AReUfmJJHNRRR4fOfkJwferE8iFXAYArVGO52n3zyM9qAO6+Hk62urCMH5JUK/U9a77VbcMN4UDPevHtC1LyNYtGJwokHI9K9nmPnWoGSccigDBjjAfjnFayRBtLmB43AjH4VQVCJsmtSJt1vIvt19qAPlL4oYPh6/BxlZVH/AI+K8Zr2X4tx+TZ6xGTki5H/AKHmvGqAPQ/gJr2m+GviZp2p63dLa2MUcyvKwJALRsBwAT1NfRPi/wCL3gy7sjFZ69BKWYZxFIOPxWvjQDJp6hf4gaAPpSf4keGQuF1WJ89MRvx+lY1/8RNHmUomqJ7kI4/pXgrBQMhWx9aaihm6GgD2G48X6OXGy+jKgf3G6/lRbeLtHTltQTcTn7rf4V5z4a8M3viC/ENnGRED88rdFFekyfDTQreNYnnu5rhR87rIAufYYoAJvGOhOhH21Sc/3W/wrPk8UaRk7L1cem1v8Ksv8OtFAXD3mSenmD/Ckk+HeiAkI93nAODIP8KAKbeKNL3ZF4mP91v8Khn8S6Y4/wCPpM+yn/Cta3+GemXCsYxeHbyf3g/wqF/h7ogLfPeDHQbxk/pQBz02uWDqR9oXn/ZP+FZf9rQRTFo5gynqMGu0/wCFe6Nt5ku8n/poOP0pD8PdG/v3eB1PmD/CgDlZdYs2jykw3HsQarpq8APMw/I12P8Awr/RiCQ92PTMg/woPw+0gRbs3eev+sH+FAHJLrNvg/vh+INWI9dtVwftAz9D/hXSxfD7R3BJa7AH/TUf4Un/AAr/AEcj5XuyQenmDn9KAMpPEtkFGboDHsf8KpX2vWcjZjnDZHPBrpP+Fe6QOrXXr/rRwPypW+H+ibgQ95tHH+sBLH24oA4eDVoUH+sH5Gp/7ZhOf3o6ehrsB8PdGJ4kuicZKiQZ/PFMHgDRi23fdk+vmDA/SgDjf7VgChRKOOnBqE6lCW5l/HBruz8P9EBUbr3J7GQZ/lSD4f6Nk83nsPMH+FAHDzarEY/LR+O55p9vqdvHgmUfTBruP+Fe6IFUs95kjoJB/hTF+H2jkkF7sN2HmD+eKAOatdbsw2XmUfgf8K1ovEumjAa7HHs3+FaB+HukKB813k9/MH+FA+Hujg/O92B2/eDJ/SgCKPxXpYHN4gGem1v8Kd/wlelE5a9X/vlv8Kefh7pAYDN2fbzRn+VH/CvNIOMPd+/7wcfpQBpWfjTQ0Qb79R/wBv8ACpG8b6Gr/LfoV/3W/wAKyl+HuikHLXYPbMg/wpW+HuiAgb7v0z5g/wAKANF/G2jbGH9oKfT5W/wpkPjDQg4LX6D6o3+FUP8AhX+h44e9PvvH+FPPw70XOd94o7L5gJ/lQBpJ400FJkZb+MAH+43+Fey6f8X/AAL9kjE/iCBX2DI8qTrj/drwdfh1o53Ze6AHfzB/hQfh3o3RXu89v3g/woA9rk+LHgrzyU8QQbcf88pP/iatWnxd8DKjh/EEAyOnkyf/ABNeFD4daOSDvuwvfMg/wpJfh5o4Pym79OZR1/KgCH4u+JdG1i41E6RfJcJM6MNqsM4Iz1A9K8or0Lxf4Q03R9CmurZ52uEZQAzgqMsB6V57QBJCdsgOM1dJbjzAgFUoCRKNoyassiu+0lmb17UAdlffDDxlDoR1Y6BcfYFtxeGRHRyISN2/aGLYxznHFV/A/g241ubzZj5NonzPIw/QV9MaLqXh7U9Mtbp7nSTZt4bj0m5miguF1DcIwGjWThAmcdvXnFcUTBDAlvaIIbZBhQOM+5oAZaxW2n2a2mmwiKBQASOre5qPHJAA+Xn6mrck0MsCKsAWQDG4HqazWl2jDZycgHH60ASAlFd+1MPDBhyT3pz8Io3BsmoyDtdicc4HsKAJluZ4Vm8uRlVxtIHUiq4JEeWHfpSk5cl04wMccUoIGN5yfY0AJ97JyePamt35wP50pdmACBV9fQU2JA0oAPJ555zQApHJ2htqc59PrTh2O0Adcj+dTR2c0jBcbScck8CrK6WCSxfLOf4eBQBnmQSnYuFBPJ7AUjYU5hVmXOAQK2hY2lvH+9HB+8Sf0FVpb+3jyLeHZ/vjIoAzY95UhNzE9RjrUsdvMZDtjcyn2woH0qyt6ythoyQT8x/w/wAK0IL/AO1lwJSDjBAHAHp9aAMlLO4ZmXy3JHUgdaf/AGfP9xU7Z54rfCsF2rkADBA9PekZ9nAO9MdznmgDn2s7hcBYySehpfsVzwTE3HPp+NbsXmFN7hgh4QKP6U8gZG1QX/2uAP8AGgDnPstwdx2NkDt6U/7Pdbf9XtjA5z1NdDhXO1UDY5YnjFOBGc43Ej1wKAOWVG6/ex2akYMHw559B/jXSusEmDcomOnNULv7Mi8RsD0weQv1oAyQRt+QYYcEnv8ASnFsY7ewPQ1biWGZsAo3HT7tSfYnySIEVe7ZzxQBRdgRyMN1yOaCm7aAp5HUnrVt7FlCkq7KOu08YpjWkpHyQOEXnJNAEBYx43FS47egpp6Fx8qHjnkmpmtpFVfNGFPIG2kMEu/JAx1XdxgfSgBhkwo5/wCA0gbLhY2AJ74pZEKkmQEtjmlgUOrHaFC+/NADHjO4nczHGODSAEkqOndj/Sr8UcUh4Pbr/wDWqKMR53M56/KoGfxoA5T4lJEvgy42MdweMYI6DcK8Vr3D4qI48I3LNuwXj6j/AGhXh9AEtv8A61RgnPGBXpPgjwS14Ev9VUxWgOVTu9cz8Nba3uvGFnHdp5kQDtt9SFJFe3yzGRoxgIE4GOABQA53jRFtoFCwR4VUHGKjbJ2nAwOCT603chkO4HaeDzSMwC4wcEZGDQA04DFPlzg9e5phfHG7OAAM80rZJKjoOOaMGMsfpzQA1kcENsJA49zSnZjJ3DbyQT1pGcs3pxtz3o2+ZhE+d+mByTQA0nJy2Q5XnnpT4rZ5SSsYZdv3vStC30/YhlugBkj5RzkVpsiwSAKoBKnC0AZFtpe4r5xLKBwE7mtCG1gQMseM8AhuwqxGHVGMvUrnrg1X3quWlzk5xt4xQBKiHacruA6BT1PqfaoZ7hLdcBhuAwcHiqk19I/7q0xtHU4zT1t0WNS/71j97PrQBXAnvZDtXEaj+M/yFVJVuYWLRWXnkE4wQcVsMYygVQSuM9ORSMWwhYAY6nJ/l60Ac1eX2pxMAmj3Drt3HBHT61mab4ssrm8W0uI5bO53fckXArudzKvznbzwc8Zqre6fY3E4ma3iluNuC+3JoAgS7aMkq7AA5Lt0/wDr1ag1MMV+RnQdCOP0rJmsp4NTMiMZLExZ2HAEbe1PGAv3iGYcgd6ANv8AtW2jP+tbeeNhBwKDqdvsAAyfYZ/KsHzm28qCn97HehpBglkVh32nAoA2hqYeQRw5dR989MVE2pkyldvyd8DrWarsgJVSuQPkB60X11DYWMl3JHtRB+ZoA3b6aBrRWGA7DD5JGK5HUfE+hWLut3fCV14Kx/MRXnHiXx1qGqCS3t3Nvak87eprkD83J5Pck0AewD4gaC0igfaUXoWZe30re0nxFpt8QNO1QM+eI5fl/DHevn/p0xSglSGUlSOhHagD6ei1TYdkqKuOG2jIqwt9bEcEhuynoa8Q8JeN7i1nitdUcy2xIXzOrJXqUiqu1kbcjqGDD0NAHSRyJKT5ciNnqfeoLmSB5fKAM7EZwhwB+Irn3lLfLnaPSp7WeSAM8IyzjBbGOKANS3iR2I8tVXPKtjI/GrLWcLRkBGGexOCaq6PhYiC6oxPp3+tXnJBBP3T1Y0AY4bySwChR0IJ5H41I0IYRTxsig/ewtdx4O8KweIluZ5yUSJgq85zmuV1+wksNcutOBLLA/bgc0AcL8Tw7eC7x/MLL5kY5P+2O1eHV7r8UrVE8E3coAU74wAD/ALYrwqgDqvhkceMLQn+7J/6Ca9tZBGNynJPSvEfhqM+L7T02vn/vk17Mx5JLH8aAJVlVYHVlyT0PpUQUPJuOduMDjqaQFSvAOR0NDy+XGV3Zc+vWgBOU+Urk55PXFClANvPT6/rTUDOpEeSO+P8AGrJt/I5eLGB949BQAQW7XDKuDGh6nHGK2IrWGBCIvkA6v0rGFyDJtikc4GMkda0rOaWK2lNwS+RlQ3ABoAssUiUM0mMHgk8VXn1CCE5bbLIfQ5NUb+5a6ljHlhCB8oxiqAm/i+4QeMDOP/r0AaE13JOcKpiT1Y1XT/S59iEmMD5mPG41UdjI2XyT2J71NAWkkBDBVToKANmOKNYtqZTLYCKMk+5oaGR3IL5HVieBigPtjQ71DAZ3Dt70xWJgU+ZuQn7x/nQBP5UpKhF2fxN3GKRcs+xgBJ+Yx61QnumEQPmSNzjkVNBcSRIA5jdiM7c9PTNAE77UALfNz07Z/GoyrM+W2hW5PqfarCKs0atk+d1x2BHtSW4ZyWD4GDle2aAIpYxJZtDIuyN+MbsE1k6hLa6VcabYw28lwspKmQZO0+5rZVsZk2kqOFHc/ShiXkRnj24+7EBkg0AD28cnySFS5HXaMLWRdxNbSY2AjoCPT/GtkW4HzEB5CcnJwQah1ZGEIIZQzdMjA/P1oAxzKucRuzyE9SORUd/ZR3llLb3TOwkG1iegPtipjC6IGlfC9Pl9KdIyooSEEQkYG4c0AeL6r4YudI1QJdRs1qzZWVRlSPrWVqVugnkFuMoOp9K+gA0L2bWtyC8TjlWxgVxesfD+KZJG0e7VN+T5c39D6UAcf8OvC8niPViGGLODDTP6CvYJPAmhXFi9vbwKzngSdCKp/CjSLzRNIvrS8SOOZ5Q6uDuDDFdgI7iDzZHwWP3eMHFAHzN4o0g6Lrc1kTko3GK9m0GOSPwvpq3LASeXx3IFc1qOgSa740+1XClLSM5kbB5x2rtGaHcqKAGAwFI5xQBArYYYQHnnjrT2EuACCFc8bsingSblKjkdPatQl52TzFxswfXmgCbT7dreDEgDHGdn9alDx8gE7eeOv/6hTT5suR0UDOMc01kYqojALHHReKAPSfCjy6f4ShmQKrT3QxjuorlPiWFPjC92sUZgrHb34rstVUafouh2JADKiyHjua4z4oow8XTLBtWQxRscnrx0oA8v+Kjv/wAIZdK5J+aL/wBDFeFV7l8TmVvBN58rKwkjzk8E7xXhtAHU/DTH/CX2uW2jbJz/AMBNeybwd2zIA9RXjfw0x/wl9ruwRsk4P+6a9mLtjDAEHqo7UANJkJ7Y4xjtUkUJMu0ndIccelSWlsXIOWGeemcCtKKBYn2lAxIwCPvZoAEiitYBI4G8DIOOB9KxL2eSeQs3QnoTk1pauURBCjnJ52k8AVkqCCDtIAHOTwaANvQYVeLzCoGOBx1rUwpc5XA7lv5Vi6RcyLiJ2Rd3IXHNbIQbshh657E0AVbyGG4jLAMQowSDwT6Vgzh1Jg+Qv0C9gPrW3qMqWts0Nsh3SEkkHHJ6msHaQWZHVwOCev1NACuqABQm046ls80i84yFABGGHpSCUMzhBuzjjGR+falLKcGTawXgYGMH6UAacsIfdtDKjoFLHnj6UJGEhSIB2hTpnoT3zVeC9Ee2Ntzr2yBkVa3GQP8AddyDtVf4KAIpHEgaLzFwo3MoX1+tQiURjfKF3k7Seox2xTpIjPxccIMcr1NTrFDbyR/NHgdhyRQA+0ULFKQHZzzuH+HpVaxu2N3m42upG3novvim312r/uYpC65wz5wBTo9OkZy4YlMYGD1NAGju3OQCU2jJOeP/AK1JvcyELGWXHXdz9aY3k2MOJi0hXoDwF/HvVjywV8xkk5HOw5JoAgaT7Ohdi0nYAcEVj3VxNcNulJ8v/ZHFac1mkz7vMZGOc7j0HuKz3iEEo8/cqA8bjgsPagCLDeWCkrMCeAOaVYrk4B+QE8kjNLc3SSPiABUA6YwTViyjMqgpKVC8lQ3WgCB4v3aoGIA7juaQskJ2t87dQvrXRNNDtERjJJGCMA1WuNOtmjY2zmKQfMQepoAyYrmdJB5SEAfwitVPtyQGR9yL6Sck1R0cLNqEaSAHB47ZrtJLZdjZY7QOSx4oA4ea7dz5MCHJPO3uafFYq0ZJbaxPJPWrsNmiTSNFvZS3B9KmlJhkJO4HOPXNAGXYQtb3uyQb+OCTnNasj7C3mIrA9xwBUBHnTq+1gcZHy1OpGcucqp7DOTQAFsja37sZyT6Vd0S1e+1qygiK7WkUdeoz1IqlI+EH7sHuV211vwrsEl1yW+lA2WsZbJHQ9hQBs+N5GuPEcUUbAJCVjHNcv8Xx5PiqFgAQ9tG3PsK0RcG/1yRwMl5ehHvUXxvRYvEWl8fN9lHy464oA8a+JplPgm882MAl4+fT5xXh9e5/FCRpPBF0Wj2Lvjx7/OO1eGUAdV8M0L+MLRVGSVcf+OmvborJo1zIB1wqnkGvHPg7ay3vxA023t0DySB1AP8AumvrS18K2KE28kzSXIB3bfugjtQB57ZKyEqV+bAO4GkuHEP3A7zv39BSXQf7bJHsVXUlQyDsDTF8yKSVnBcMCB7e9AGVKjSMScsxPU9KY/y8BmB67akYssZcHameW9arB1lJPXHA+lAD/NxIrAksOpU9fatuyae7RjFKVUcY4OPasIeWM4PzHgD2/pViwv3tZMKEOc5PYUAay6dIdzyyEhsnA71n3dnLDlOPLXnngYrZt9RWZAx4XoCO/wD9asjWbgzTERk7QPzoAgWYKpEanB646VGEVmbMLKRwBz+Jplsx80EfK/QKe1b1hZCLa8gHmHnIPQf1oAxY4w0xDAjHOD2qUNHCxeJc7hkZ7CpdTtiN1xbv8jnGM/qaz1nOAiAF16N0FAFsymSJUx0OS46mhpWK7FjTKnl+7e1QqjOw3HLMeQeOK6CCztlRI2AJ6knqKAMNUNzKgjUKOm7GABW7PIYwscCFlUcuBz+FZeuwyW86yQ7RbnnJ4zVy2lN1EJFXPHzAHFAChnMbrKEOefmGfwxULTtGhfcyqoyzHrTpZjvKqpAHQCkht1fKu7OpGSh/pQA5CMI7Tjc4zuI60amY5bTcp3uDglqljsyVJyEiPQN6Cs/VLuGTEMGdi9WP8RoAovsRT53Oe4/lToJUjmDiJguf4TjNRHygB0LdQc5oy6kMh3Z4HFAHTPfRy226PYhAGc9vrVZr1JUAGfMPHB6Z7Vh/vmyflI7gjjNbPh1UlvFRthMY3c+tAGvBpaARnPluOfmGCPxqLV0umhT5wIgeWX0rXLALu2mMduc5qrfbzbusgwvXdnHPpQBkESlDuOxAMe5puJmwkZBAPXFSh84DsAwPRh3+tRTPIMCFWUMecGgBcDJUMrseGbPX2qXYFUEj5wcYBpikINsIHl/xMwzuNKIirgKxDnupoAjJbcT1bqcnivQtLQ6D4CklkYream3y467a5fwtokmr63b2xGIwd0h9B3roPGmpx32qLZ2mTbW4EcSgdMcE0AWfAts11qsCsoYbgefasD4y3i3njtoo2G20hVD6ZPOK9H8H2S6JotxqckQL7P3a5xuP414/qOj6tc3N/quo27qHcyyEOrBQTjnB6cgUAcD8UpXbwVdeYAMvHjn/AGxXhle0/FJjJ4bu9n3EZPz3DpXi1AHefBHUBpfxJ0u8YZEe8kf8ANfXjlFvotQhlzaTncCOpz1FfGfwvG7xlagLu+STj/gBr6j8AaotxFNpF0wMchzCx6h6AKvjLTzpmtSCFB5E481XPcGsDAK9SAcYUf416hq2l/2zosunyjOoWmZIc9WX0ry47w5EoK7MgjHIoAV41lzG6DGPy/Csm/tkgQGIBgDycYzWsC75yR6AZ6e9NkUSKqOmIxk8jgn+tAHOAhvvA+YeSO1Tw2v2gboeFU/NnqfYVeuLNWZdnc859KvQ7YUCIwVRnjHU0AYDCa1YecDGTwoPNdhpsFvNaRlUEhI5J5zWc0cbDEi5yM4bn/8AVTrWQ2yMIcqo4z0H0FADtd0cSEPa4Vz1UdTTLeyu4EEc2WHc9fwrWtLzzk3KQCOCT0qyjKowpDu3p3oAwgOHQ4YH+DvVW80wEYhBQAcsOn4VrX8QjkMsYxlf1+tQrMByf9XjoP4j/SgDEtdKunLux2IoLcnqKigupI5Au9s5+bitsys0hVT8g4PesjUrfyZNyFsP3oAs6ldfa7dI1UHJyxB6YrPjnlgISEtuzk9wKI4JWUy5UD0HBFNjR14IOD2PU0AXYr6QYZggcDHpkVK2qLtx5IAA6GqD23yhncbs5xTSCZCEx+H+etAE9xez3QKyN5cfoDjd9aqhUOM5L9h/QVPLAFRGlbGeoPeoT5UYIjXnrnuKABVXd8yfNjtUziNYRtYl+rY71BvL/c3Ady3eo8SKfmwhPY0APYSPg/MAOinirWk3L2l0JJRiMcHIziqQabHAO3rhqu2MqRRS/aF3HHB9KAOvS7hdTKJNygeuRmsTVNSNwfJhccH5iBxj0rELLzmZkHcf4VYgUlN8IOwdjQBrRKhVSM88ZP8AF+FSEHBwoC98foKqWcwDPDN8rAZVx6elXYYidu1wR2XP60AJ97O5fT5h1A9BRlV+aNWLN8oXpmp7W1mvJxb2y+a3QsAdortNG0C10Pbf6sQ8ynMUHv60ATW8beFfBksjDbql8MAH70a1B4M0dr6+86X5YF+eWZuhAqa4juPEeurBMnmRE5GOAF/wqp4y8QQ2sH9haK+IF/4+Jh1c/wB36UAUPiV4nGuXA06yyum2pwFX/lqfX6Vh6AoSx10xqvmf2c2FxwP3kdMsH04Bk1CK5cg4QW8qpj1zlTWxpQ0lrHXhp8F6kxsTnzp1kUjenYKP50AeQ/EmPy/Bd5u/1heMk/8AAhXide7/ABVjCeCrvIw3mR9On3xXhFAHWfC4A+MrTJwNknP/AAA17ba3zWk8U0K7JI23hvxrxH4YHHjC14z8kn/oBr2u5RNgUZDAcigD2R70XFpp+vWZ3NIo3lecMOoNYHjvR1KprumpvtZz+/Rf4Gp3wcv1utP1HRLjHmMhmiHY+orW0rUIdMuZ7PUBvtZ8q8Z52+9AHl4kEqs2ApJx6DH+NShsEfxEDA9K3/F3hh9JuxLCwfSpjujdRkD2NYPG1+cqTxjqaAIyqv8AvJOSpBGOgoaSIqAwO3uB1apGIICpwCcnZ3PvUDFRcENtJP8ACORmgCZELsGLKsfTavJNIGyCfL2IeTu6iljdI5t4Ugr2Pc1N9oBKlxkjlgaAItvkMHUhmHY9KlXU4UOZgVJ5yOc/4CmqQ/3l2g9dvH5Cs+9giVRJHlSpA46fjQBNq+qGaFolIKnH3R1/Gq9lcGJdpX93jPzHkVFJFsLKMSMehQcH/wCvSG0COq5YSHqSelAGmfLKAowUZyx9ay9RvBKVjhJaNedw9au2YEuYFKslVNVtZLW4EYiPlueKAG2trKd0qY24+8eR9agkWVm5Ygno3t6+1aNvIYwsTN85GAB0Ht71Wvo5F+VsDJ+8epoAp+WhJy7F/UUBUV9udzY428c06KAEZL7Fz2qWWVDCIQoZe7Dg49PagByW81zNEJiSmMb26ZqFoIxJjIJ/ummS3IIQDcQg+VSeBUe4sWIIJzkn3oAnuPKjZMNknt1xViK6t4JFLxiWMD+IcGqSMysSVG70PQUmfMfcwO3PSgCSWRWkYpkKSdqt1ro9B02C4tfMZkI6H2rnbfY0iqil3c8AV0NrbiC3+V9w5yvTB9qAMq9shHcyLEvmLu4Q9BUUCtApJDcHkqePp9K0ZLlUl8rlWJyM8/nTbWOW4mMcSgNg7yOn50AQSypJKFhXc5HJ74966fwN4Zu/EjuImIsYmxJIeAvsPWsTR9Gudaufsdgh3lgZDjoPevWvEeo23hbw1DoGkEJcCMB3TrnuaAG3Oo6P4aVbHTFSW6ztMnUD6muWvb2W/u3eclkJKhweR9BWHp6hr4ySvvZDkg9zWn4atpNU8RwQxggMxBI/hFAHRaxenw54SXy2VdRvl2Ie6R9z+NeaEFgBufnknqTXS/EqT7b4kuIoZMRWKrCvsB1wPrXM+a0Q4H3ufbPpQBLGAzBCFKAdDwa2dCKi21wIMH+z3Oc5/wCWiVm2GoXdgXFrKYTJyw2g5x9RxW5per3l7puuwXExljFgzYKKOd6egoA8t+Kq7fBF3lw2Xjx7fOK8Ir3X4qQqPBl3JnBLRjAOc/OK8KoA6b4cuY/Flqy9Qr/+gmvcFkWRcnOCvOOp9q8V+F4z4xtRjrHJ/wCgGvXYmNjeFDuMTdN3T60AX9H1efQvEVjqMJwkTAOucZXuPyr2TxjpUOoaemuaQ3mW1woclf4civE9RiDwZVMMOhPQV2Hw18dP4aY6drKtNo0564yYye4HpQBqeHvEscCPpWro09hL8uTzs9wapeJPC0umYvLJzdabIMpLHzgehrq/FvguDUbH+0fD0ontZBvKxnOR1rk/D/iK+8Oytb3sRksGyr20g4P0HagDAjDqT5ceB0xnkingxpkvtLAdu1drdaHYa7Ab7w1IN5BLWrnBX6Vx91ay2h8u4iKzg4wwxn8aAI1EQQEOMcjJ9famsyoBmNsD8cmlaEqXwcuP5+1N8148kqcevXFAAS7KOApY5APOarT/ADLIsjFD2H941YaYSEBxt4wexFVrpGLr5bBo++egoAqxrLGUJ+Vc8EHj61NPh5A8jbIvUcZqCORMgYLDPBPeu+8CeHYPENhdzOwGw7MMM8+tAHI6OsZuUOctngdyKteJULtEwOWTgAdqj8R6VdeH7kpPE0OH/dy9m+hq2kSXmlpcSnLkevWgDmxc7Sof52Tv7/Wi5k82UF23txkjt7VdvdLIVntzvx1HcViNgMQykn2oAsSsgyNx64JHYVFuaQ7UAK9s9TSCEKpkD57YoLLncTt5/P6UAPEeAWddpHakKlzuOF469KkWbzXEch+VR19/eofMcFi45HrQApj+Xc5Kg+vQ00mQgbBgHuewoEsjPkqPoTwKUyAjdJhR6Y60AWtICxX8TsMnOMg11+0FGbgcce1cOsyhuuMDIDDk1qaZqcv2qNGJeNTk554oAsavCUkhYLwwK4HUmty6szoHhNJ5RjUL84Uf3ExS2yxajqEJwpSLLhR+mas/E6Rt+l2wO7bACeeM0AanwOtpbZdX1aUZjCCNQe59azvFWprealK4Xc7EjHeu48MQppvw1RGXZMQXcgeteXXrg3kh6ktx6/nQAtq5iDkDOB09PxrufhDaI+pXl62SIULcjGDXHSJ5FlwBvPzNkdK7vwqP7E+H+oX5Y+feny0YjnnigDzjVroT6pduv7wzTM5I5OSe9UxIFDZIJ6ew/GoUURFkkBCK3DDktVpTlv3YAP8AdPNAFrT7i2hVzfWf2nP3cylCPbitvTb2yn07XIrXTltWFgx3+aWJG9OMGsXToLW53+fepZbTgB43fd642g/rW5p1lZwadrklvqUV0xsGGxYnQgeYnOWAFAHk/wAVNq+DLwD+/Hx6fOK8Kr3T4rr/AMUfdHlcNHx2b5x3rwugDrvhWM+NLMAZ+STj/gBr3Ga1NxGu8bwvQehrxD4T4/4TezJ6BJD/AOOGvcvtLy5VCUjzyR6UAUmzCRDL80Y6/wD16mMIeIDAP+10xVgRjafMUEDnJ71Bcgs5ERO8c9OBQBueGfEGoeG5B9huCbfOWiPII+lds2r6B4lT/iYQLa37Lyyjj8a8nDSRiPdg85Ynmrcd4I3ztIOc4HU/WgDuLrwxqFiRc6ROJFUfejP86lOrw36GDWbYSSRqFDlcNn1rk7HxDe2kgNpcshJyVzn9K6qx1rTNbkMWsRra3JXas6dG/wB6gCZPD1i+n/a7e4GCeUPUUp0CyZlBkETMMgE9axNXs9R0WQM5ZoySY5F5Vl7VUF9JeHmQq6YGM4oA6xvAYu8GBgrdSB0rz/X400q+uNMlz58R4cdGzXXeE/E1zYX7Q3cx8lm2jJ6VJ8UvDI1GD/hItJPmKABPGnJ+ooA86SOMTbieRxkH5fpXWfDvXm0zxDHA5xa3TBDjp7VxUchiwCuc/kKtwSrujaIYkByvtjvQB9Ca9pdjqunvpuqIHjcko3dD2IrxTxJpV74XumjkDSWn8Dp91h2B9K9B0HxD/a/h6Yyti7tF3H1YetV4tThvLRba/USwzHD7v4B6igDhrW6hubVHDBdwPyDv61z+sQhLwhfkRgGxiuhvNLj8P6xPAx3IoLxt6qemKwJZmv7nLEK/RCelAGYWC5XOG96meHMKYbnqR61LLapGSXGD61EhjXKxnI7+tADANigKpUj8s1PCwJlMoDkjGfT3pjlQybGPP8HvQylYTLIOf9nqT6e9ACLGrsBHwc4yec02WHy2YSt+89DUpRlWOdm2uPmCjtV69vLa/tjL5IW4GMlj96gDKSzMjAbsnNaFpaxwSqSSYuhI61VhQsjGIGP1yasRTrMFSPIJ4Jx1/CgDptEhaJZ5FfO7A3p2HpWj8SU+0DSJ8HDxhSR7U2GMWmnJbhdjkbiR2NWfFDkeF9OdwHKT9e44oA7PW7s2Xh5IXxseBVx6cda8withLMWjBJzwCOBXc+MbqN7XS2YZWeFSe2OK5xmWBT5ZLR9BgZFAFa5HmCOJhubIAI6E11/xMkGleD9H0ZHCzPiRz6Af/rrO8K6WdU1+xjIBjDeY5HYD1FZPxW1NdT8YXHltuhsgIgO3HWgDmY5cIoAwvdmHJ+lPfAG/j+RNZsmoc8qMDgCnNiYjezKeuPWgDVtYrzUg/wDZ9ncXO3G5oo2bb+IFbejWGoWmn65JfWdzAn2BlzLCyAnzE4yRiuYhe4gTbFIYlPPykj86na7mlAR5JGBGCHckEUAch8VHLeDLsbNq7o8dx98V4VXuXxQBHgu9zx+8jwB2G8V4bQB1/wAKs/8ACaWu04Ply8/8ANe7xqFaMLyozgnvXhXwmyfHFlg4+ST/ANANe6s24uz4Jxg7R0+lADS4JJb5icAD1pSvyKPu5PQc5pHIVfMBwg4z3NCs2zK4CnkAd6AFaHcfnA2j3zTPKGf3fQfeapAj5Ck4JHbtTDlRhRlxyc/4UARNboFzH8pycDvUsDLGX3fMPu+n5UiO+wF1y3cnt7CmjA3MQMDoO9AHYeC9djmmbQ9cJfT5/ljlfrE3bHtVTxP4dm0PVB5jHyc7kkHRh2rmJUa5jG87d3TafmHpmvSPB2s23iLSh4d16QG5Rdttct3PpQBxF7tkYTIMgdUx1xXVeCtdn0+YLOwlt2GGjbpg1gatpd1ouqzWtypR16E9G96fbCGYKAxjcfwjpQBreN/CMOJNW0P5oJDukhH8H0rz4glyCuxvX0r07R7+aC4hidhtyPl7EVy3xB01LPX5JIF2RzjeCOhoAm8BMLZ79nbKumzJ9Kn+1R/aAhyBnCntj1rL8MRNulVD95SfrViaSGA7pshWPGByDQBb122bVtN86Bt1zbgqwHVkririMLAG5Ru3vXVRSlhIbdzGD3z1/wDr02c2V7iLU0xIThZo+v40AcjChuD/AK05A6E9aY6EAoy7GHauluPDFwqiSydZoDzvU1nLptxuWKSMud3HqKAMpY5ASF4J4I7mpD8oVAfnXqc8V0jeHZ3iKqpRiM896zW8P3qjBGHoAzpyjShix8vAHy/xUzzFkkCooRTxk1tx+FdRfgRjHrnrV2z8MSrKvnBmcDgKOv8A9agDCS5glb7PEmDjbzXU6FokNtEssi+ZIfu56ishLaLTdSMJQPIASQ3Y/Wrtlqs89yIjlcnA+lAF+6kaNG3yZIOAM8motalmn8L2yjBxd4wPcUajHtdkOGLDmp7K3U6ZJHM2ZElWZVz1wef0oA1/GBbFjF1RIVHuMCubS4mVzCik84A7muu8SussikY2GNWH+0Kq6ettpFs+r6uEFvF/qIs8yN/hQBfi1e38CeHpL66wdVvV228PdR6mvI7m6nuZZJXYl3JZz3JJzTNb1a58Q69Je3cgcu3yqeNi9gKsWECpIzMSEPc9zQAy0t+jD5s8lquIwiI3dKRlVWIHQnt2pnAfaMtx96gCUThiRGvyjqTSkAgZJJ65H9aqGIkgmQMR2HFOBkPcr29qAOc+KJH/AAh10AQfnj/LcK8Qr274mx48F3ZYANvj59fnFeI0Adh8KBnxtaD/AGJP/QDXvPUquAY1rwP4XMV8ZWhXrskx/wB8Gvcw0oULwBjcR6UAWJWjHzPGcHoPeo5FiKgKxznOSen0pmx9wZzkAZBHTNOVmZSwx+PQCgB6kQqVWQSjsDTPMJcnYCvv396haBWC/KQ7GnfPkLHJ8uehGeBQBK07iLKgkZ7/ANKZ5iYwUKj6etMZpRuJUN2ODxS/aAvykYHTJ559qAEcF2I6np8vJpturxyK8UhR0OQ3oadDKp3MQSD1OeTTLm4dUJUgAcYI6+1AHq+iX9p480g6bqjJHq8C4in4/eVwV1ZXmiavJaXURE0Z2g9vr71ytvqbw3KNGxhnBBV1OMV7Joer6X4+0v8As3VnSDW4V2pNnHm++f5igDEsZo5B5y4aRR93PX6UmpRrr+iujgi4t/mX/a9RVO80u/8AD9y0V0rRyKeDjKsPar+myIxM0QXzP4lHQUAcbpF60Ooq3Kn7u30H0rW1K2EU5ctvD/MA1M8R6fHbagL61UlGOX2n7pq1qgju7G1n4MZXnsfxoAxVnZpSQAkZ4PuPaiSPJLRpwBgZOTUDRB3JilAI6MeMfSpbVXa6Qk/u84JznNAGtpMs1mFaZmVMgkg9q3j9lylyrgqTkqo+b8a5PWSZ57i3gkCuoG0ZwK5wX11b3EUiSMsiMCSScGgD06/1FgQYsDPXI7Vlvq0a7vN+9zhR6UupKsz29wmQLpQ/HRTjmqUmmRRTgSzEgjJBOTQBeGtlkSRN2R1x0qa51qSGzuNRCf6tdoT1J71ny3tpH5scII3D5c/wn1qJIftWhX6XRJiCh22jkehoA5K41Q3U/ncmZm+6D1z61ZsGe61hYlZlVmGQo9KSOxRpIypRYVX769WrS0+MwOwtImJZTlyOfwoAl1G4Ju2MZwoO0d+KuaK1094oQGTJwc+lUodOBuAZXIJ52rU3iC/OiSwW9t8iPFu3D7zH3oA7rVIoLaK1uJCHht18tvbvgCvMfF+tya9qBjhBFpH8sajoBUt1rt5qWhxWDEbRLvLDuuOlU4gqR7FiTmgCpY2ccOSVJb+8anPzn90CzD+72q0UaQqrgEKPpTBGsTjBA9h2oAakb7QZQDxkFeMVIMY4wG9+KfbrcvguFWPpnvipHSLtgkDoTyaAK/ygjeo5HApGDgDaNq4x83b8KtooDEhwh6Zao3uUjAblwOPloA4/4msT4MugxOQ8f/oQrxKvavidctN4TuuPkLpg/wDAhXitAHX/AAqIXxrZlsY2Sf8AoBr3Jish6fID0xXhnwr2/wDCaWe84GyTtn+A17tlVXYrYZj1x0oAYULHlz5ZHQGmh5c4yCp9ug9Kmc+WdxALE4A9RUYK7gSpVs/lQBHJL1WNec/MaTzHVF3KScnGOKkCxMQNp2k9acBhiGJBPA6cUAVo2m4GeAeB1A/+vUitvlIZVbsAeAKczYDLGPl6Zx1pjkqoVBlzwTQBM8KFlA2ttG7k1UubYysc8f0qQhlJDINxxuwaX5BuLFgAPlGM0AUpLBlx5e09gRz+lRbJreVJFbbJHjDIcFfxq1++yFR8joSvUVL5QKhW+ZyMlhxQB1GkfElns103xbb/AG214VJwv7xPc+tdJZ2dpdMtxoF9Dcw5yVJAYfUV5a8cTDY7Ky9ieDVaK1mtZlezuGj75VsYoA9S1GJ7K8xLCxglBVsr/OqlzpbNpcixEMI2yvbisPTvFesxRrFdeVexekv3j/hWiPFsTWMqXNk9vJndGUOVz6UAY11p8mNySAsOXx1z71TVZ852kMM8L0NUtOu5V1zz1kaNGOXB+6R6Yro9R1WCSc/YE2RYyQRjNAGRqOnzajIL23Y/aVADxjuR3Bqa10CWaFri/wAxbR2HLU8apNDgw4QjOEqb/hIL0ptcxj0x0P1FAGvqciW/hXS5o422tujyvOMH1rkpL/My+fnb0H0ruNI8XaebMWer26tA5GCo4z6gdq2ZvB2k6/ZCWxnUqOSy43L9aAPKFnlndli5BPI7t9K7bwfpdza2V4LyFy95E0aIRkYP8TeldH4W8M6do8xgZllvAfmlYcfhWb458SRtELHRpljQZEkoPLe2aAMBbbR/DiGOV3vbztsHCmsa81O5uJ/kXyYRziPv9aiLwZJk4kAySDmiJYkgL5ZVzgDHLe4oAiTU72OZTHnPuKLv/iYyo92cyDsPSpVxMCFiOT3AOcUptWJPzFAPzJ9KAI2hQYUYGBxikeMb8ZJPqKkhVEfLRtJtzk8/rQsjM/yrs9NooAbGshP7tQIweSTUqfLnIXkZBHf2qvczKpLPL16AVUabC4AbHucCgDQuZFjjyCEdR0JzVBpZQqyJznuR/KofNXcMhn9MAUNIGBBACnt6fhQAGd3ZmMoyc9abvbdnJ479qUFQDswv4VGxGTtwD2BPWgDnPiI2fCl1yW+dPf8AiFeP16/8RGY+FboFR96M56fxCvIKAOt+FiF/GlmoOCVk/wDQDXurmNidhXOcZPfivC/hYdvjWzP+zJ/6Aa9qeRjkK+T3J/pQBJIU3ZwAT8ufT/CnKFdTn5Y+/uKZGRt3KBjpnHWnzS52ouNoHJoAVZkPzLwcYAB6mmKyvIS8hHHPHWl+XC5GR149Pajcj7dmQRz0HFACtIMhI2DE8dKibhSQflU54/lTy5U5439j2WmkF5SXY4HOQeooAZGSHwockDLccU9C7h2C9uCwpJHwTzuXqVB6VNHP5gHlqAcYBYentQAkdu3DeUFyc5Y803yg4IUnHtxmpHJKKJH4z2bgmgyZf5GXIxyTkflQBALQg75GDA8ALjj8Kc0cSDAY4A4AqXZkMWdEJP3s/wAqZKN2No4H3n7kUAVy4DDccgHop6/Wp3DkZLrjsp7VTk2JL8oAXvgc1YikURbuQCcbgKABlLRnKrs6l/WolUJkq5Oei56VbaUv8oUE4+90xSeXESu0gt6jj9KAG7HnT5SiJxl8c02aDOPLTdt6yBs0+W13n5MIoPOW61WmTZ8omERBzheDQBJb+Qo2Ipkyf4+1dL4Y1z+xJJoR/qpxiT1X3Fcp9plVAsmJAD1xg1Ml9EwVRByOMg9PxoA9H13VtqILFhK7x8yqc7Qe/wBa4K4thHtYMjMB8v8AtH3qjcXNw2ArvGg/hB/qKrtM5Y9G+p5NAEsoIcSM8bN0C4ojlUyK0zlm6DPIX6VWOS+U4PrRtJbAwHHX3oA14dQkVQpxsz1wBinPfQkZLq5HTa2SayRG5wpOD3y1NK7RjeFOf4RzQBotfttKwgAnjOKqTTPjJl68AdKgkjl7HI9u9IzNhQVwV9RmgBHGSCFz701V+bBbPse1SjJJ+YvxkhqUKuwEKo9qAIuRwSAT2IpflXGSenPYZp+0noSMe1IFG07k3GgBhCMc45H40/GMBsAD1HWkZRjH8PWk3dflU8dTQBzfxFK/8IpdAnkMmO/8Qrx6vYfiKf8Aik7kbAPmTkf7wrx6gDT8Pao2japHerEJSgYbC23ORjrXXp8S7hWB/s9CPTzT/hXntFAHo4+KVz1OmR8dP3p/wpw+Kc+7J0uMj0Mx/wDia82ooA9Jb4pzNktpUZPvMf8ACmn4oTA/LpUYHf8AfHn9K84ooA9FPxPnJJGmRDjGPNP+FIfifdn/AJcIwOw83/61ed0UAd9/wsactltPQj080/4Uo+JE3P8AxL1/CY/4VwFFAHoB+JNx/wA+CZ6czH/CkX4jzgg/2env++PP6VwFFAHoP/Cyp8YOnJj0Exx/KkPxJnJz/Zyf9/j/AIV5/RQB3x+Ish5OmRlvUzH/AAoHxGmAwdPB5yP3x4/SuBooA9CX4l3CjC6ev/f4/wCFSj4p3oUhbCMZHJ8zn+VecUUAeiN8TrhgM6cm4d/OOPyxTB8SZuc6bGT6+cf8K8+ooA78fEibjOnIT6+b/wDWpx+JMpIzpqfQTEf+y159RQB6B/wsmfn/AIl0eT384/4UqfEmUddMjb6zH/CvPqKAO/b4jykj/iWoMf8ATY5/PFKPiRIAMaYmR1PnnJ/SvP6KAPQf+FlXAI26dGB3Hm9f0o/4WVN/0DYyPQzE/wBK8+ooA79viRMTxp6gegmP+FOb4lzsoB02Mgesuf6V59RQB6A3xJlP/MLiHuJTn+VJ/wALImzn+zk/CY/4VwFFAHfj4kT7s/2ev/f4/wCFOPxKmJz/AGbH/wB/j/hXn1FAHoH/AAsiXPGmR4/67H/Cnf8ACy5eQdLiIPbzT/hXntFAHXeIfGkms6VJZPZrErlTvEhbGDn0rkaKKAP/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Type II anteroposterior compression fracture with pubic symphysis diastasis, rami fractures, and widening of the right sacroiliac joint. B) CT scan showing the injury to the anterior portion of the sacroiliac ligaments.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jim Fiechtl, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_62_23522=[""].join("\n");
var outline_f22_62_23522=null;
var title_f22_62_23523="Samarium Sm-153 lexidronam: Patient drug information";
var content_f22_62_23523=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Samarium Sm-153 lexidronam: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5027?source=see_link\">",
"     see \"Samarium Sm-153 lexidronam: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F16565519\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Quadramet&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F13365864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691759",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat bone pain caused by cancer.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F13365863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3558822",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to samarium Sm 153 lexidronam or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F13365868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697738",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug and for up to 12 months after this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F13365869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697876",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia, low white blood cell count, and low platelet count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698017",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dizziness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698167",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       More bone pain may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F13365870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F13365866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F13365871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F13365872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17080 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-220.255.2.127-02C9EFC5AA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_62_23523=[""].join("\n");
var outline_f22_62_23523=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16565519\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13365864\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13365863\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13365868\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13365869\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13365870\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13365866\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13365871\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13365872\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5027?source=related_link\">",
"      Samarium Sm-153 lexidronam: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_62_23524="Anaphylaxis wallet card";
var content_f22_62_23524=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F54466&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F54466&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 626px\">",
"   <div class=\"ttl\">",
"    Anaphylaxis wallet card",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 606px; height: 560px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Medical identification. All individuals at risk for anaphylaxis in the community need accurate medical identification. The folding wallet card shown as an example was designed with the assistance of the American Academy of Allergy, Asthma and Immunology Anaphylaxis Education Task Force.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Simons FER. Anaphylaxis, killer allergy: Long-term management in the community. J Allergy Clin Immunol 2006; 117:367. Copyright &copy; 2006 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_62_23524=[""].join("\n");
var outline_f22_62_23524=null;
var title_f22_62_23525="Biology of ehrlichiae";
var content_f22_62_23525=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Biology of ehrlichiae",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/62/23525/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/62/23525/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/62/23525/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/62/23525/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/62/23525/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/62/23525/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/62/23525/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 12, 2009.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although ehrlichiae have been known to cause disease of interest to veterinarians for over 50 years, their role as agents of human disease was not recognized until 1987. The clinical characteristics and treatment of human diseases caused by ehrlichiae are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/5/6234?source=see_link\">",
"     \"Human ehrlichiosis and anaplasmosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL CHARACTERISTICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ehrlichiae are obligate intracellular bacteria that grow within membrane-bound vacuoles in human and animal leukocytes. In humans, either monocytes (human monocytic ehrlichiosis; HME) or granulocytes (human granulocytic ehrlichiosis; HGE, the organism is now called Anaplasma phagocytophilum, and the disease anaplasmosis, HGA) may be infected. Ehrlichiae replicate within the phagosomes of the host cell, unlike rickettsiae, which grow in the cytoplasm of infected cells. A microcolony of ehrlichiae within a vacuole is called a morula (",
"    <a class=\"graphic graphic_picture graphicRef61249 graphicRef50113 \" href=\"UTD.htm?1/38/1642\">",
"     picture 1A-B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/40/31364?source=see_link\">",
"     \"Biology of Rickettsia rickettsii infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The cell walls of ehrlichiae contain glycoproteins but do not have peptidoglycans or lipopolysaccharides [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23525/abstract/1\">",
"     1",
"    </a>",
"    ]. Ehrlichiae have distinct ribosomes that are homogeneously distributed in the cytoplasm and are surrounded by thin bileaflet outer and inner membranes.",
"   </p>",
"   <p>",
"    Ehrlichiae are difficult to detect by light microscopy when they exist as single organisms; however, morulae are easily visualized when present within white blood cells. Ehrlichiae can be stained with Gram's, Giemsa, Wright, and silver stains, and by the Macchiavello method. Individual organisms are generally round, but may be pleomorphic when visualized in tissue culture cells [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23525/abstract/2\">",
"     2",
"    </a>",
"    ]. Thus far, ehrlichiae have only been cultured in eukaryotic cells and in yolk sacs.",
"   </p>",
"   <p>",
"    The gene for a 120-kD protein in E. chaffeensis contains a series of tandem repeat units, the number of which differs among isolates of E. chaffeensis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23525/abstract/3\">",
"     3",
"    </a>",
"    ]. As an example, the Arkansas and Jax strains contain four and the Sapulpa and St Vincent strains contain three repeat units [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23525/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TAXONOMY AND PHYLOGENY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The taxonomy of the diverse species of Ehrlichia has undergone a radical change [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23525/abstract/5\">",
"     5",
"    </a>",
"    ]. Until recently, the family Rickettsiaceae was divided into three tribes: Ehrlichiae, Rickettsiae, and Wolbachia. The tribe Ehrlichiae was divided into three genera: Ehrlichia, Cowdria, and Neorickettsia. In 2001, it was proposed that all members of the tribes Ehrlichiae and Wolbachiae be transferred to the family Anaplasmamataceae and the tribe structure of the family Rickettsiaceae be eliminated [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23525/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The genus Ehrlichia was originally classified on the basis of morphology, host cell tropism, and serology. However, the use of molecular methods such as the sequencing of the products of polymerase chain reaction (PCR) amplification of small subunits of ribosomal DNA has resulted in a molecular classification consisting of the following organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23525/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ehrlichia consisting of organisms known as E. canis, E. chaffeensis, E. muris, E. ruminantium, and E. ewingii.",
"     </li>",
"     <li>",
"      Anaplasma consisting of organisms previously known as E. phagocytophila, E. equi, and E. platys. The human granulocytic agent, E. phagocytophila, and E. equi are now recognized as the same organism that has been renamed Anaplasma phagocytophilum.",
"     </li>",
"     <li>",
"      Neorickettsia consisting of organisms previously known as E. sennetsu and E. risticii.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     HOST SPECIFICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individual ehrlichial species infect hosts ranging from humans to dogs, sheep, and horses (",
"    <a class=\"graphic graphic_table graphicRef71243 \" href=\"UTD.htm?42/2/43052\">",
"     table 1",
"    </a>",
"    ). Three ehrlichial species are known to infect humans: E. chaffeensis (the organism responsible for HME), Neorickettsia sennetsu, and A. phagocytophilum. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/5/6234?source=see_link\">",
"     \"Human ehrlichiosis and anaplasmosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Four cases of HGE due to Ehrlichia ewingii have been reported from Missouri; molecular techniques distinguished these cases from HGA due to A. phagocytophilum [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23525/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Cell specificity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depending upon the species, Ehrlichiae may infect circulating monocytes, granulocytes, lymphocytes, or platelets. In addition, some species, such as N. risticii, also infect tissue mast cells, macrophages, and intestinal glandular epithelial cells.",
"   </p>",
"   <p>",
"    A. phagocytophilum infects mostly neutrophils [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23525/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. In vitro, it has been hypothesized that a major surface protein (Msp2) of A. phagocytophilum binds to neutrophil surfaces via a specific platelet selectin glycoprotein ligand [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23525/abstract/10\">",
"     10",
"    </a>",
"    ]. A. phagocytophilum adheres to cells expressing Lewis x (CD15s), a sialylated ligand for cell selectins; anti-CD15s monoclonal antibodies blocked HGA infection in a variety of cell types but did not inhibit binding [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23525/abstract/7\">",
"     7",
"    </a>",
"    ]. In contrast, neuraminidase treatment disrupts sialic acid, both blocked binding and infection. Thus, expression of CD15s and a sialylated enzyme required for its synthesis appear to play a role in the selective infection by A. phagocytophilum of neutrophils.",
"   </p>",
"   <p>",
"    Monocytes are resistant to infection by A. phagocytophilum due to reduced binding and uptake of the organisms and the ability of monocytes to kill internalized organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23525/abstract/11\">",
"     11",
"    </a>",
"    ]. In comparison, granulocytic differentiation results in enhanced binding and uptake, and A. phagocytophilum selectively persists within granulocytes by evading oxidative killing [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23525/abstract/9\">",
"     9",
"    </a>",
"    ]. The organisms are confined to membrane-bound organelles that are part of the endocytic pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23525/abstract/12\">",
"     12",
"    </a>",
"    ]. Once inside neutrophils, A. phagocytophilum has complex adverse effects on neutrophils, including diminished adhesion to epithelial receptors, diminished transendothelial migration, and defective phagocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23525/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     GROWTH CHARACTERISTICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Individual ehrlichial organisms enter host cells by phagocytosis and then grow and divide in the resulting phagosome. After a few days, small, tightly packed clusters of organisms are observable as intracellular inclusions. Several days later, additional growth and replication of ehrlichiae result in large, mature inclusions called morulae. The monocytic ehrlichial species have been propagated in canine blood monocytes and in monocyte, endothelial, and macrophage cell lines from murine, primate, and canine origin [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23525/abstract/2\">",
"     2",
"    </a>",
"    ]. A. phagocytophilum has been cultivated in a cell culture system using human promyelocytic leukemia cells [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23525/abstract/13\">",
"     13",
"    </a>",
"    ] and in tick embryo cell lines [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23525/abstract/14\">",
"     14",
"    </a>",
"    ] .",
"   </p>",
"   <p>",
"    Growth in vitro may take 8 to 36 days to detect. The duration of ehrlichial viability in blood is unknown; in one case, the organism was isolated from EDTA-anticoagulated blood stored at 4&ordm;C for one week [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23525/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The metabolism of ehrlichiae is primarily aerobic, and these organisms cannot utilize glucose-6-phosphate or glucose as an energy source. Unlike rickettsiae, ehrlichiae cannot readily utilize glutamate.",
"   </p>",
"   <p>",
"    A. phagocytophilum is able to evade intracellular defenses by directly detoxifying superoxide anions and by preventing or delaying normal neutrophil apoptosis via an effect on the expression of pro and antiapoptotic genes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23525/abstract/9\">",
"     9",
"    </a>",
"    ]. In addition, A. phagocytophilum prevents fusion of neutrophil cytochrome b558-carrying granules and secretory vesicles in the cytoplasmic compartment. In essence, A. phagocytophilum seems to hijack the neutrophils by dysregulating their expression of certain genes, by scavenging oxygen, and by modifying key components of the NADPH oxidase system.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ANTIGENIC CHARACTERISTICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no serologic crossreactivity between ehrlichiae and rickettsiae. Furthermore ehrlichiae do not elicit crossreacting antibodies with Proteus antigens (Weil-Felix agglutinins).",
"   </p>",
"   <p>",
"    In the cases of HGE caused by E. ewingii, convalescent sera reacted with antigens of both E. chaffeensis and E. canis but in a pattern different from sera of patients infected with E. chaffeensis. A dog infected experimentally with E. ewingii displayed a similar serologic reaction to the four human cases [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23525/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Advances in the ability to grow A. phagocytophilum in vitro have yielded a variety of strains from horses and humans, some of which are antigenically different. One study involving sera from 35 patients tested the antigenicity of five different A. phagocytophilum using the IFA staining method. Seropositivity was highest (97 percent) in assays that used the MRK strain from California and lowest (71 percent) in tests using the NCH-1 strain from Massachusetts [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23525/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The A. phagocytophilum genome contains at least 100 genes encoding major surface proteins (Msp2). As each organism expresses only a single Msp2 protein, a population of organism can produce substantial antigenic diversity. This variable expression of surface proteins may be one reason that A. phagocytophilum is capable of producing persistent infection in its natural hosts, such as ticks and deer [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23525/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Immune responses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Specific antibody responses are elicited following ehrlichial infection, but the presence of such antibodies may not coincide with the disappearance of organisms or the establishment of protective immunity [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23525/abstract/2\">",
"     2",
"    </a>",
"    ]. As an example, dogs infected with E. canis may continue to have parasitemia for months or years after acute infection and the appearance of anti-E. canis antibodies. Furthermore, horses that develop antibodies after mild infection with A. phagocytophilum may be susceptible to rechallenge with same organism [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23525/abstract/16\">",
"     16",
"    </a>",
"    ]. On the other hand, antibodies can protect SCID mice from fatal experimental E. chaffeensis infection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23525/abstract/17\">",
"     17",
"    </a>",
"    ]. Additionally, mice that are experimentally depleted of complement or are deficient in complement receptors 1 and 2, become highly susceptible to otherwise sublethal ehrlichial infections.",
"   </p>",
"   <p>",
"    Little information exists on the development of persistent or chronic ehrlichial infection in humans. Persistent infection due to E. chaffeensis has been demonstrated in one reported patient. A 60-year-old patient residing in an endemic area with a history of HGE infection after a tick bite was reported to develop a second case of HGE three years later, again associated with a tick bite [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23525/abstract/18\">",
"     18",
"    </a>",
"    ]. Since the patient had developed an antibody response after the first infection with detectable levels still present at 10 months, this case raises questions about the long-term protective efficacy of antibody.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     MECHANISMS OF DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A wide array of veterinary ehrlichial diseases have been described (",
"    <a class=\"graphic graphic_table graphicRef71243 \" href=\"UTD.htm?42/2/43052\">",
"     table 1",
"    </a>",
"    ). Three human ehrlichial diseases are known to exist, of which HME is most common, (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/5/6234?source=see_link\">",
"     \"Human ehrlichiosis and anaplasmosis\"",
"    </a>",
"    ). As noted above, Ehrlichiae characteristically have specific tissue tropism. The major target cells of HME are mononuclear phagocytic cells and macrophages [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23525/abstract/19\">",
"     19",
"    </a>",
"    ], while the major target cell of HGA is the neutrophil [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23525/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. In animal models, N. risticii selectively infects cells of the equine intestinal wall, and E. canis has tropism for the microvasculature of the canine lung, kidney, and meninges [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23525/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Cell specificity'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    There is, as yet, an incomplete and poor understanding of the mechanisms by which ehrlichiae produce human or veterinary disease. The current knowledge about the pathologic lesions of HME is based upon five autopsies and biopsies, and one liver biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23525/abstract/19\">",
"     19",
"    </a>",
"    ]. The pathophysiologic basis for the clinical manifestations of HGA infection are similarly incompletely understood.",
"   </p>",
"   <p>",
"    As a general rule, tissues from animals or humans infected with ehrlichiae do not show cell or tissue necrosis or abscess formation. Ehrlichiae also do not produce vasculitis, thrombosis, or acute or chronic endothelial cell injury as is seen in rickettsial infections.",
"   </p>",
"   <p>",
"    The following histologic changes have been identified:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nonfollicular lymphadenopathy with disappearance of follicles and lymphocyte depletion in lymph nodes is commonly seen.",
"     </li>",
"     <li>",
"      Infection with E. chaffeensis may cause granulomatous inflammation in the bone marrow.",
"     </li>",
"     <li>",
"      Some patients with HGA infection develop secondary opportunistic infections, such as cryptococcal pneumonia or invasive Aspergillus pneumonia [",
"      <a class=\"abstract\" href=\"UTD.htm?22/62/23525/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A phagocytophilum infection in humans results in focal parenchymal and perivascular lymphohistiocytic infiltrates in areas such as the liver lobules. Paracortical lymph node hyperplasia may also occur, presumably as a result of a T-cell immune response to infection [",
"      <a class=\"abstract\" href=\"UTD.htm?22/62/23525/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Studies in animals experimentally infected with HGA suggest that hematological abnormalities are not due to bone marrow suppression, but rather to increase peripheral destruction [",
"      <a class=\"abstract\" href=\"UTD.htm?22/62/23525/abstract/20\">",
"       20",
"      </a>",
"      ]. However, it is unlikely that Anaplasma-mediated cytolysis is the primary cause of leucopenia [",
"      <a class=\"abstract\" href=\"UTD.htm?22/62/23525/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A lack of correlation observed between bacterial tissue burden and histopathological severity has led some experts to assume that the inflammatory response is the primary mechanism of disease due to A. phagocytophilum infection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23525/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some of the clinical (fever, leukopenia, thrombocytopenia) and histologic features (lymphohistiocytic infiltrates) of HGA are suggestive of the macrophage activation syndrome. Support for this hypothesis comes from a study of 29 patients with HGA who, compared to matched controls, had higher serum levels of ferritin, interleukin-10, interleukin-12 p70, and interferon gamma [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23525/abstract/20\">",
"     20",
"    </a>",
"    ]. In addition, several patients with severe disease fulfilled the diagnostic criteria for macrophage activation syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/5/6234?source=see_link&amp;anchor=H14#H14\">",
"     \"Human ehrlichiosis and anaplasmosis\", section on 'Laboratory findings'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/5/41050?source=see_link&amp;anchor=H33#H33\">",
"     \"Hemophagocytic lymphohistiocytosis\", section on 'Macrophage activation syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast to the findings in HGA, studies using mouse models of HME suggest that overproduction of TNF-alpha by antigen-specific CD8 T cells is important in the pathogenesis of clinical infection with this organism [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23525/abstract/1,21\">",
"     1,21",
"    </a>",
"    ]. Studies in animal models suggest that CD8+ T cells and natural killer T cells are important in the pathogenesis of HME infection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23525/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23525/abstract/1\">",
"      Walker DH. Ehrlichia under our noses and no one notices. Arch Virol Suppl 2005; :147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23525/abstract/2\">",
"      Hess PR, English RV, Hegarty BC, et al. Experimental Ehrlichia canis infection in the dog does not cause immunosuppression. Vet Immunol Immunopathol 2006; 109:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23525/abstract/3\">",
"      Yu XJ, Crocquet-Valdes P, Walker DH. Cloning and sequencing of the gene for a 120-kDa immunodominant protein of Ehrlichia chaffeensis. Gene 1997; 184:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23525/abstract/4\">",
"      Paddock CD, Sumner JW, Shore GM, et al. Isolation and characterization of Ehrlichia chaffeensis strains from patients with fatal ehrlichiosis. J Clin Microbiol 1997; 35:2496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23525/abstract/5\">",
"      Dumler JS, Barbet AF, Bekker CP, et al. Reorganization of genera in the families Rickettsiaceae and Anaplasmataceae in the order Rickettsiales: unification of some species of Ehrlichia with Anaplasma, Cowdria with Ehrlichia and Ehrlichia with Neorickettsia, descriptions of six new species combinations and designation of Ehrlichia equi and 'HGE agent' as subjective synonyms of Ehrlichia phagocytophila. Int J Syst Evol Microbiol 2001; 51:2145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23525/abstract/6\">",
"      Buller RS, Arens M, Hmiel SP, et al. Ehrlichia ewingii, a newly recognized agent of human ehrlichiosis. N Engl J Med 1999; 341:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23525/abstract/7\">",
"      Goodman JL, Nelson CM, Klein MB, et al. Leukocyte infection by the granulocytic ehrlichiosis agent is linked to expression of a selectin ligand. J Clin Invest 1999; 103:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23525/abstract/8\">",
"      Dumler JS, Choi KS, Garcia-Garcia JC, et al. Human granulocytic anaplasmosis and Anaplasma phagocytophilum. Emerg Infect Dis 2005; 11:1828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23525/abstract/9\">",
"      Carlyon JA, Fikrig E. Mechanisms of evasion of neutrophil killing by Anaplasma phagocytophilum. Curr Opin Hematol 2006; 13:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23525/abstract/10\">",
"      Bakken JS, Dumler S. Human granulocytic anaplasmosis. Infect Dis Clin North Am 2008; 22:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23525/abstract/11\">",
"      Klein MB, Hayes SF, Goodman JL. Monocytic differentiation inhibits infection and granulocytic differentiation potentiates infection by the agent of human granulocytic ehrlichiosis. Infect Immun 1998; 66:3410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23525/abstract/12\">",
"      Webster P, IJdo JW, Chicoine LM, Fikrig E. The agent of Human Granulocytic Ehrlichiosis resides in an endosomal compartment. J Clin Invest 1998; 101:1932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23525/abstract/13\">",
"      Goodman JL, Nelson C, Vitale B, et al. Direct cultivation of the causative agent of human granulocytic ehrlichiosis. N Engl J Med 1996; 334:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23525/abstract/14\">",
"      Munderloh UG, Tate CM, Lynch MJ, et al. Isolation of an Anaplasma sp. organism from white-tailed deer by tick cell culture. J Clin Microbiol 2003; 41:4328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23525/abstract/15\">",
"      Magnarelli LA, IJdo JW, Dumler JS, et al. Reactivity of human sera to different strains of granulocytic ehrlichiae in immunodiagnostic assays. J Infect Dis 1998; 178:1835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23525/abstract/16\">",
"      Nyindo MB, Ristic M, Lewis GE Jr, et al. Immune response of ponies to experimental infection with Ehrlichia equi. Am J Vet Res 1978; 39:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23525/abstract/17\">",
"      Yager E, Bitsaktsis C, Nandi B, et al. Essential role for humoral immunity during Ehrlichia infection in immunocompetent mice. Infect Immun 2005; 73:8009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23525/abstract/18\">",
"      Horowitz HW, Aguero-Rosenfeld M, Dumler JS, et al. Reinfection with the agent of human granulocytic ehrlichiosis. Ann Intern Med 1998; 129:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23525/abstract/19\">",
"      Walker DH, Dumler JS. Human monocytic and granulocytic ehrlichioses. Discovery and diagnosis of emerging tick-borne infections and the critical role of the pathologist. Arch Pathol Lab Med 1997; 121:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23525/abstract/20\">",
"      Dumler JS, Barat NC, Barat CE, Bakken JS. Human granulocytic anaplasmosis and macrophage activation. Clin Infect Dis 2007; 45:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23525/abstract/21\">",
"      Ismail N, Soong L, McBride JW, et al. Overproduction of TNF-alpha by CD8+ type 1 cells and down-regulation of IFN-gamma production by CD4+ Th1 cells contribute to toxic shock-like syndrome in an animal model of fatal monocytotropic ehrlichiosis. J Immunol 2004; 172:1786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23525/abstract/22\">",
"      Stevenson HL, Crossley EC, Thirumalapura N, et al. Regulatory roles of CD1d-restricted NKT cells in the induction of toxic shock-like syndrome in an animal model of fatal ehrlichiosis. Infect Immun 2008; 76:1434.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7903 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-197.136.42.3-9ACE31C43F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_62_23525=[""].join("\n");
var outline_f22_62_23525=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL CHARACTERISTICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TAXONOMY AND PHYLOGENY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      HOST SPECIFICITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Cell specificity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      GROWTH CHARACTERISTICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ANTIGENIC CHARACTERISTICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Immune responses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      MECHANISMS OF DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/7903\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7903|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/1/13334\" title=\"picture 1A\">",
"      Intracellular HME EM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/43/25269\" title=\"picture 1B\">",
"      HGE in neutrophil EM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7903|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/2/43052\" title=\"table 1\">",
"      Ehrlichial infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/40/31364?source=related_link\">",
"      Biology of Rickettsia rickettsii infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/5/41050?source=related_link\">",
"      Hemophagocytic lymphohistiocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/5/6234?source=related_link\">",
"      Human ehrlichiosis and anaplasmosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_62_23526="Tinea barbae 1";
var content_f22_62_23526=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86999&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86999&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Tinea barbae",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Large erythematous papulopustular lesions in the beard area of a patient with",
"    <em>",
"     Trichophyton",
"    </em>",
"    infection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_62_23526=[""].join("\n");
var outline_f22_62_23526=null;
var title_f22_62_23527="Initial staging and evaluation of men with newly diagnosed prostate cancer";
var content_f22_62_23527=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Initial staging and evaluation of men with newly diagnosed prostate cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/62/23527/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/62/23527/contributors\">",
"     Philip W Kantoff, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/62/23527/contributors\">",
"     Mary-Ellen Taplin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/62/23527/contributors\">",
"     Joseph A Smith, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/62/23527/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/62/23527/contributors\">",
"     Nicholas Vogelzang, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/62/23527/contributors\">",
"     W Robert Lee, MD, MS, MEd",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/62/23527/contributors\">",
"     Jerome P Richie, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/62/23527/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/62/23527/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/62/23527/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H686719695\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prostate cancer is the second most common cancer in men worldwide, with an estimated 900,000 cases and 258,000 deaths in 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23527/abstract/1\">",
"     1",
"    </a>",
"    ]. In the United States there will be an estimated 239,000 cases and 29,700 deaths in 2013 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23527/abstract/2\">",
"     2",
"    </a>",
"    ]. The clinical behavior of prostate cancer ranges from a microscopic, well-differentiated tumor that may never be clinically significant to an aggressive, invasive cancer that ultimately results in metastases, morbidity, and death.",
"   </p>",
"   <p>",
"    Once the diagnosis of prostate cancer is established, further evaluation that incorporates known risk factors is required to determine appropriate treatment options. The prostate cancer staging system and staging evaluation are reviewed here.",
"   </p>",
"   <p>",
"    The initial clinical presentation including indications for biopsy, the ramifications of risk stratification, and the approach to treatment are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36101?source=see_link\">",
"       \"Clinical presentation and diagnosis of prostate cancer\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/30/9704?source=see_link\">",
"       \"Prostate cancer: Risk stratification, other prognostic factors, and predictive tools\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36101?source=see_link\">",
"       \"Clinical presentation and diagnosis of prostate cancer\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/30/9704?source=see_link\">",
"       \"Prostate cancer: Risk stratification, other prognostic factors, and predictive tools\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16969?source=see_link\">",
"       \"Initial approach to low-risk clinically localized prostate cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/26/21930?source=see_link\">",
"       \"Initial management of regionally localized intermediate and high risk prostate cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H686719702\">",
"    <span class=\"h1\">",
"     STAGING SYSTEM",
"    </span>",
"    &nbsp;&mdash;&nbsp;A staging system developed jointly by the American Joint Committee on Cancer (AJCC) and the International Union for Cancer Control (UICC) is used in men with newly diagnosed prostate cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23527/abstract/3\">",
"     3",
"    </a>",
"    ]. The 2010 update of this system combines information about the extent of the primary tumor (T), lymph node (N) involvement, and presence or absence of distant metastases (M) with the Gleason score of the primary tumor and the serum prostate specific antigen (PSA) level to classify men according to their risk of recurrence (",
"    <a class=\"graphic graphic_table graphicRef75565 \" href=\"UTD.htm?40/19/41277\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef67222 \" href=\"UTD.htm?10/43/10941\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23527/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H686719716\">",
"    <span class=\"h2\">",
"     Clinical versus pathologic staging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Men with newly diagnosed prostate cancers are assigned a clinical stage, which is based upon information from the prostate biopsy, digital rectal examination (DRE), and in some cases imaging studies.",
"   </p>",
"   <p>",
"    Patients who subsequently undergo a radical prostatectomy are then assigned a pathologic (\"p\") stage, based upon a histologic examination of the surgical resection specimen. Men who do not undergo prostatectomy are not assigned a pathologic stage and are treated based upon their clinical stage.",
"   </p>",
"   <p>",
"    Clinical staging can underestimate or overestimate the extent of disease when compared with results based upon pathologic examination of a resection specimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H686719730\">",
"    <span class=\"h2\">",
"     Tumor (T)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H686719737\">",
"    <span class=\"h3\">",
"     Clinical T stage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical staging of the tumor provides the basis for the initial decisions regarding the extent of evaluation and treatment options. (See",
"    <a class=\"local\" href=\"#H686719786\">",
"     'Evaluating extent of local disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Clinical staging is based upon the results of digital rectal examination, transrectal ultrasound (TRUS)-guided biopsy findings, and imaging studies in some cases (",
"    <a class=\"graphic graphic_table graphicRef75565 \" href=\"UTD.htm?40/19/41277\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      T1 lesions are neither palpable nor detectable by imaging. T1a and T1b lesions are those detected incidentally in pathology specimens of resected prostate tissue. T1c lesions are those diagnosed in a prostate biopsy performed because of an elevated PSA or prostatic symptoms in the absence of an abnormality on digital rectal examination.",
"     </li>",
"     <li>",
"      T2 lesions are palpable but appear to be confined to the prostate. Unilateral T2 lesions are subdivided into T2a and T2b based upon the extent of involvement; if there is bilateral involvement, lesions are classified as T2c.",
"     </li>",
"     <li>",
"      T3 lesions extend through the prostatic capsule (T3a). If there is involvement of the seminal vesicles, these are classified as T3b lesions.",
"     </li>",
"     <li>",
"      T4 tumors are fixed to or invade adjacent structures.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although clinical staging is necessary for planning initial treatment, both digital rectal examination and imaging procedures can significantly underestimate the extent of disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H686719744\">",
"    <span class=\"h3\">",
"     Pathologic T stage",
"    </span>",
"    &nbsp;&mdash;&nbsp;A more accurate assessment of the extent of disease is possible in patients who undergo radical prostatectomy, which permits pathologic staging (",
"    <a class=\"graphic graphic_table graphicRef75565 \" href=\"UTD.htm?40/19/41277\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      T2 lesions are confined to the prostate. These lesions are subdivided based upon whether disease is unilateral or bilateral and the extent of involvement.",
"     </li>",
"     <li>",
"      T3 lesions have extraprostatic extension. Pathologic T3a lesions have extraprostatic extension or microscopic invasion of the bladder neck. Seminal vesicle invasion categorizes a lesion as pT3b.",
"     </li>",
"     <li>",
"      T4 lesions have invasion of the rectum, pelvic wall,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      levator muscles.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H686719751\">",
"    <span class=\"h2\">",
"     Node (N)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both clinical and pathologic staging define regional lymph nodes as not assessed (NX), negative (N0), or positive (N1) (",
"    <a class=\"graphic graphic_table graphicRef75565 \" href=\"UTD.htm?40/19/41277\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H686719758\">",
"    <span class=\"h2\">",
"     Metastasis (M)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients are classified as either not having distant metastasis (M0) or distant metastasis present (M1). Patients with metastases are subclassified based upon the site(s) of disease (",
"    <a class=\"graphic graphic_table graphicRef75565 \" href=\"UTD.htm?40/19/41277\">",
"     table 1",
"    </a>",
"    ). Patients with metastasis are subdivided into those with nonregional lymph node involvement (M1a), bone metastases (M1b), or other sites with or without bone metastases (M1c).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H686723046\">",
"    <span class=\"h2\">",
"     Serum PSA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The serum PSA level at presentation provides important prognostic information that is useful for determining the extent of work-up required after the initial biopsy and for planning subsequent treatment. A higher baseline serum PSA is associated with an increased risk of identifying more advanced disease as well as of subsequent disease progression. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36101?source=see_link&amp;anchor=H74636032#H74636032\">",
"     \"Clinical presentation and diagnosis of prostate cancer\", section on 'PSA screening'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/2/41001?source=see_link&amp;anchor=H9#H9\">",
"     \"Measurement of prostate specific antigen\", section on 'Causes of an elevated serum PSA'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H686723062\">",
"    <span class=\"h2\">",
"     Gleason score",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Gleason grading system, which is based solely upon architectural features of prostate cancer cells, closely correlates with clinical behavior. A higher score indicates a greater likelihood of having non-organ confined disease, as well as a worse outcome after treatment of localized disease. The Gleason score is the preferred system for grading tumors and has been incorporated in the AJCC",
"    <span class=\"nowrap\">",
"     /",
"    </span>",
"    UICC staging system for prostate cancer (",
"    <a class=\"graphic graphic_table graphicRef67222 \" href=\"UTD.htm?10/43/10941\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/52/24394?source=see_link&amp;anchor=H12#H12\">",
"     \"Interpretation of prostate biopsy\", section on 'Gleason score'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Biopsy obtained from extraprostatic disease (bone marrow, lymph node) is not assigned a Gleason score.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H686719765\">",
"    <span class=\"h2\">",
"     Prognostic groups",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2010 version AJCC",
"    <span class=\"nowrap\">",
"     /",
"    </span>",
"    UICC staging system uses anatomic (TNM) information along with the pretreatment serum PSA and the Gleason score to define prognostic groups for adenocarcinoma of the prostate (",
"    <a class=\"graphic graphic_table graphicRef67222 \" href=\"UTD.htm?10/43/10941\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23527/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Group I &ndash; Low risk, localized tumors: anatomically T1 or T2a AND a serum PSA &lt;10",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      AND Gleason score &le;6",
"     </li>",
"     <li>",
"      Group IIA &ndash; Localized tumors with at least one feature associated with an intermediate level of risk: anatomically T2b OR serum PSA &ge;10",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      and &lt;20",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      OR a Gleason score of 7",
"     </li>",
"     <li>",
"      Group IIB &ndash; Localized tumors with at least one feature associated with a high risk for recurrence: anatomically T2c OR serum PSA &ge;20",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      OR Gleason score &ge;8",
"     </li>",
"     <li>",
"      Group III &ndash; Locally advanced tumors, with extracapsular extension (T3 disease), regardless of the serum PSA or Gleason score",
"     </li>",
"     <li>",
"      Group IV &ndash; Any cancer with T4 spread OR positive lymph nodes (N1) OR distant metastases (M1)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The addition of pretreatment serum PSA level and Gleason score to anatomic TNM staging to create these prognostic groups is based upon multiple studies that demonstrate that these parameters are important determinants of outcome in addition to the TNM evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23527/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Even within these groups, there is substantial heterogeneity that may have important implications for patient management. Additional features of the tumor which may have prognostic significance are the number and percentage of positive core biopsies, the presence of tumor perineural invasion, and the presence of lymphovascular invasion. Although the 2010 TNM risk assessment classification system does not take these measures into account, other prognostic models may incorporate some of these features. The routine use of these features and their incorporation into the staging system await further validation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/30/9704?source=see_link&amp;anchor=H8#H8\">",
"     \"Prostate cancer: Risk stratification, other prognostic factors, and predictive tools\", section on 'Other prognostic factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H686719772\">",
"    <span class=\"h1\">",
"     STAGING EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once a biopsy establishes the diagnosis of prostate cancer, additional evaluation may be required to determine the anatomic extent of disease and prognostic grouping (",
"    <a class=\"graphic graphic_table graphicRef75565 \" href=\"UTD.htm?40/19/41277\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef67222 \" href=\"UTD.htm?10/43/10941\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/30/9704?source=see_link\">",
"     \"Prostate cancer: Risk stratification, other prognostic factors, and predictive tools\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H215593\">",
"    <span class=\"h2\">",
"     General approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The extent of the clinical staging evaluation is determined in part by multiple factors include life expectancy, comorbidity, the presence or absence of symptoms, extent of primary tumor as determined by the digital rectal examination, serum PSA, and Gleason score. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/30/9704?source=see_link\">",
"     \"Prostate cancer: Risk stratification, other prognostic factors, and predictive tools\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For asymptomatic patients with a favorable risk cancer and a life expectancy less than 10 years, treatment is generally withheld unless there is evidence of disease progression or the development of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23527/abstract/4\">",
"     4",
"    </a>",
"    ]. Thus, no further staging workup generally is indicated beyond the initial biopsy.",
"   </p>",
"   <p>",
"    In patients with prostate cancer that has higher risk features and in men with a longer life expectancy, additional evaluation may be required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H686719786\">",
"    <span class=\"h2\">",
"     Evaluating extent of local disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of local disease extent is typically accomplished with the combination of digital rectal examination (DRE) and transrectal ultrasound (TRUS) at the time of biopsy. Some institutions also use endorectal coil MRI, although its value has not been established.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      DRE &ndash; DRE has clear limitations for defining local disease extent but is an important staging method. There can be significant interobserver variability. Although most tumors occur in the posterior portion of the prostate, some are located anteriorly and are not palpable.",
"     </li>",
"     <li>",
"      TRUS &ndash; TRUS is capable of imaging some prostate cancers that may have a characteristic hypoechoic appearance. Newer methods for dynamic contrast enhance ultrasound imaging may provide improved results but studies have not shown ultrasound to be superior to DRE for staging local extent of prostate cancer.",
"     </li>",
"     <li>",
"      Endorectal MRI &ndash; There is increasing enthusiasm for the use of endorectal MRI to stage prostate cancer. The use of an endorectal probe with MRI can improve spatial resolution and thus better assess the likelihood of seminal vesicle involvement or extraprostatic extension in men who are thought to have localized prostate cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?22/62/23527/abstract/5-8\">",
"       5-8",
"      </a>",
"      ]. Whether the information from an endorectal coil MRI should influence treatment is unclear. Endorectal coil MRI is not routinely used at most institutions due to lack of availability, concerns about whether a positive scan should influence the choice of treatment, cost-effectiveness, and the patient discomfort associated with the procedure",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H686719807\">",
"    <span class=\"h2\">",
"     Evaluation of regional lymph nodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The extent and means of evaluating the pelvic lymph nodes should incorporate both the plans for definitive treatment as well as the likelihood of lymph node involvement.",
"   </p>",
"   <p>",
"    Pelvic lymph node dissection is the only accurate means for assessing pelvic lymph node involvement and is generally performed in conjunction with radical prostatectomy. However, this approach can add morbidity to the surgery and is limited to those patients at significant risk for lymph node involvement, based upon the local extent of disease (T stage), serum PSA, and Gleason grade. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24313?source=see_link&amp;anchor=H24077780#H24077780\">",
"     \"Radical prostatectomy for localized prostate cancer\", section on 'Pelvic lymph node dissection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pelvic lymph node dissection is generally not appropriate for patients who will be treated with radiation therapy (external beam or brachytherapy) rather than surgery. In this setting, the decision on whether or not to treat pelvic lymph nodes is based upon the probability of regional nodal involvement. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/47/23290?source=see_link&amp;anchor=H17#H17\">",
"     \"External beam radiation therapy for localized prostate cancer\", section on 'Whole pelvis versus prostate only RT'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Imaging studies such as pelvic CT or MRI can be used to assess regional lymph node enlargement. However, imaging is not indicated unless the tumor has poor risk features (prognostic group IIB, III, or IV: PSA &gt;20",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    Gleason score 8 or greater, or a T3 or T4 tumor). A CT directed biopsy can be used to confirm metastasis if pathologically enlarged lymph nodes are seen. (See",
"    <a class=\"local\" href=\"#H686719765\">",
"     'Prognostic groups'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Sentinel lymph node biopsies are not routinely used because of the high variability in the primary lymphatic drainage of the prostate. Immunoscintigraphy using a radiolabeled monoclonal antibody to detect prostate specific molecules such as prostate specific membrane antigen (Prostascint) does not have sufficient sensitivity and specificity to be useful and is not recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23527/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H686719814\">",
"    <span class=\"h2\">",
"     Evaluation for distant metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prostate cancer metastasizes preferentially to bone, and early involvement of other sites is uncommon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H686719821\">",
"    <span class=\"h3\">",
"     Radionuclide bone scan",
"    </span>",
"    &nbsp;&mdash;&nbsp;Technecium 99 radionuclide bone scan remains the preferred technique for identifying bone metastases. However, bone scan is only recommended for symptomatic patients and asymptomatic men considered to be at increased risk for occult metastases (prognostic groups IIB, III, or IV: serum PSA &gt;20",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    or serum PSA&gt;10",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    with a T2 primary tumor, or a Gleason 8 lesion, or a T3 or T4 primary tumor.) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23527/abstract/4\">",
"     4",
"    </a>",
"    ]. A positive bone scan in the absence of these high risk features is far more likely to represent a false positive than a true positive. (See",
"    <a class=\"local\" href=\"#H686719765\">",
"     'Prognostic groups'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A positive radionuclide bone scan in a high risk patient in the absence of an alternative explanation on plain radiographs is thought to have a relatively high sensitivity for metastases. Men with a positive or equivocal bone scan are usually evaluated by plain radiographs. If radiographic findings are inconclusive, an MRI or a CT scan is performed. A positive radionuclide bone scan that is confirmed by plain radiographs or MRI indicates the presence of distant metastases.",
"   </p>",
"   <p>",
"    In a review of 23 studies that examined the role of staging bone scans at the initial diagnosis, the detection rates for men with serum PSA levels of &lt;10, 10.1-19.9 and 20 to 50",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    were 2, 5, and 16 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23527/abstract/9\">",
"     9",
"    </a>",
"    ]. Combining the Gleason grade and serum PSA concentration with clinical stage may be particularly useful to predict the likelihood of a positive bone scan. As an example, in one series, only 3 of 308 men with Gleason grade 2 to 7 tumors, serum PSA concentration of 50",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    or less, and clinical stage T2b or less had a positive bone scan [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23527/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/30/9704?source=see_link\">",
"     \"Prostate cancer: Risk stratification, other prognostic factors, and predictive tools\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The potential role of other radionuclide imaging modalities to improve the sensitivity of bone scan is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/31/20983?source=see_link&amp;anchor=H81456336#H81456336\">",
"     \"Rising serum PSA following local therapy for prostate cancer: Diagnostic evaluation\", section on 'Other imaging modalities'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H686719842\">",
"    <span class=\"h3\">",
"     Axial skeleton MRI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance imaging (MRI) of the axial skeleton may be more sensitive than radionuclide bone scanning for the detection of occult metastases. However, experience is limited and MRI has not replaced radionuclide bone scan in the initial staging workup of men with newly diagnosed prostate cancer.",
"   </p>",
"   <p>",
"    MRI of the axial skeleton was compared to the standard sequential workup in a series of men considered to be at high risk for bone metastases [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23527/abstract/11\">",
"     11",
"    </a>",
"    ]. The study included men with newly diagnosed prostate cancer with a biopsy Gleason score &ge;8 and a PSA &ge;20",
"    <span class=\"nowrap\">",
"     mg/mL,",
"    </span>",
"    a rapidly rising PSA within three years after radical prostatectomy, or a rapidly rising PSA in men receiving androgen deprivation therapy. Bone metastases were identified in 41 of 66 men. Screening axial skeleton MRI identified metastases in 7 of 23 men (30 percent) considered negative and 8 of 17 (46 percent) considered equivocal by other strategies, and the initial treatment plan was modified in 15 patients (22 percent) as a consequence of the MRI findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H686719852\">",
"    <span class=\"h3\">",
"     PET",
"    </span>",
"    &nbsp;&mdash;&nbsp;Positron emission tomography (PET) has limited utility in clinically localized prostate cancer. Cellular uptake of 18-F-fluorodeoxyglucose (FDG) is highly variable [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23527/abstract/12\">",
"     12",
"    </a>",
"    ]. Furthermore, FDG accumulation within the bladder can obscure visualization of the prostate gland, limiting its utility in detecting locoregional disease. Even in men with advanced castration-resistant disease, the utility of FDG-PET scans is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23527/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    FDG-PET is not more sensitive than radionuclide bone scan for the detection of bone metastases, and detection of soft tissue metastases is also suboptimal [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23527/abstract/13\">",
"     13",
"    </a>",
"    ]. Other tracers (11-C acetate, 11-C choline, 18-F choline, 18-F-DHT) may ultimately be better to detect and localize prostate cancer both within and outside the prostate [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23527/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/31/20983?source=see_link&amp;anchor=H8#H8\">",
"     \"Rising serum PSA following local therapy for prostate cancer: Diagnostic evaluation\", section on 'PET scan'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H686719859\">",
"    <span class=\"h2\">",
"     Circulating prostate cancer cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although circulating prostate cancer cells can be detected in some patients at the time of diagnosis, the prognostic significance of this finding is unknown. The implications of the presence of circulating tumor cells in patients with advanced disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/12/10442?source=see_link&amp;anchor=H501733350#H501733350\">",
"     \"Overview of the treatment of disseminated prostate cancer\", section on 'Circulating tumor cells'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/3/2099?source=see_link\">",
"       \"Patient information: Prostate cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/39/40565?source=see_link\">",
"       \"Patient information: Prostate cancer treatment; stage I to III cancer (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?41/41/42643?source=see_link\">",
"       \"Patient information: Treatment for advanced prostate cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H686719874\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The diagnosis of prostate cancer requires a tissue diagnosis, which is generally obtained using a transrectal biopsy. Once a diagnosis of prostate cancer has been established, patients should be staged and assigned to a risk group based upon the",
"      <span class=\"nowrap\">",
"       AJCC/UICC",
"      </span>",
"      staging system (",
"      <a class=\"graphic graphic_table graphicRef75565 \" href=\"UTD.htm?40/19/41277\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef67222 \" href=\"UTD.htm?10/43/10941\">",
"       table 2",
"      </a>",
"      ). Factors influencing the extent of the staging evaluation include the patient&rsquo;s age and life expectancy, clinical stage of the primary tumor based upon the digital rectal examination, serum PSA, and Gleason score. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/30/9704?source=see_link\">",
"       \"Prostate cancer: Risk stratification, other prognostic factors, and predictive tools\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H686719772\">",
"       'Staging evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pretreatment assessment of the anatomic extent of the primary tumor (T) is based primarily upon the digital rectal examination. Imaging procedures such as endorectal coil MRI and transrectal ultrasonography may provide additional information in selected cases. This information is supplemented by information from the serum PSA and Gleason grade to assign patients to prognostic groups. (See",
"      <a class=\"local\" href=\"#H686719786\">",
"       'Evaluating extent of local disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H686719765\">",
"       'Prognostic groups'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The assessment of regional lymph nodes (N) should be based upon the likelihood of their involvement by tumor. (See",
"      <a class=\"local\" href=\"#H686719807\">",
"       'Evaluation of regional lymph nodes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In men with low-risk, localized prostate cancer (ie, anatomic prognostic groups I and IIA [clinical stage T1 or T2a AND PSA &lt;10",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      AND Gleason score &lt;7]) (",
"      <a class=\"graphic graphic_table graphicRef67222 \" href=\"UTD.htm?10/43/10941\">",
"       table 2",
"      </a>",
"      ), formal staging of regional lymph nodes is not indicated.",
"     </li>",
"     <li>",
"      For patients with intermediate- or high-risk localized prostate cancer (anatomic prognostic groups IIB and III, [clinical stage T2b OR higher PSA &ge;10",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      OR Gleason score &ge;7]) who will be managed with radical prostatectomy (",
"      <a class=\"graphic graphic_table graphicRef67222 \" href=\"UTD.htm?10/43/10941\">",
"       table 2",
"      </a>",
"      ), an extended pelvic lymph node dissection is generally performed in conjunction with the prostatectomy to assess the regional lymphatics.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Radionuclide bone scan is the initial screening procedure for symptomatic patients and those considered to be at increased risk for bone metastases (serum PSA &gt;20",
"      <span class=\"nowrap\">",
"       ng/mL,",
"      </span>",
"      or serum PSA&gt;10",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      with a T2 primary tumor, or a Gleason 8 lesion, or a T3 or T4 primary tumor). Axial skeleton MRI may be useful when the bone scan is equivocal. (See",
"      <a class=\"local\" href=\"#H686719814\">",
"       'Evaluation for distant metastases'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23527/abstract/1\">",
"      Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23527/abstract/2\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11.",
"     </a>",
"    </li>",
"    <li>",
"     Prostate. In: AJCC Cancer Staging Manual, Springer, New York 2010. p.457.",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23527/abstract/5\">",
"      D'Amico AV, Schnall M, Whittington R, et al. Endorectal coil magnetic resonance imaging identifies locally advanced prostate cancer in select patients with clinically localized disease. Urology 1998; 51:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23527/abstract/6\">",
"      Sanchez-Chapado M, Angulo JC, Ibarburen C, et al. Comparison of digital rectal examination, transrectal ultrasonography, and multicoil magnetic resonance imaging for preoperative evaluation of prostate cancer. Eur Urol 1997; 32:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23527/abstract/7\">",
"      Wang L, Hricak H, Kattan MW, et al. Prediction of organ-confined prostate cancer: incremental value of MR imaging and MR spectroscopic imaging to staging nomograms. Radiology 2006; 238:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23527/abstract/8\">",
"      Riaz N, Afaq A, Akin O, et al. Pretreatment endorectal coil magnetic resonance imaging findings predict biochemical tumor control in prostate cancer patients treated with combination brachytherapy and external-beam radiotherapy. Int J Radiat Oncol Biol Phys 2012; 84:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23527/abstract/9\">",
"      Abuzallouf S, Dayes I, Lukka H. Baseline staging of newly diagnosed prostate cancer: a summary of the literature. J Urol 2004; 171:2122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23527/abstract/10\">",
"      Lee N, Fawaaz R, Olsson CA, et al. Which patients with newly diagnosed prostate cancer need a radionuclide bone scan? An analysis based on 631 patients. Int J Radiat Oncol Biol Phys 2000; 48:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23527/abstract/11\">",
"      Lecouvet FE, Geukens D, Stainier A, et al. Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies. J Clin Oncol 2007; 25:3281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23527/abstract/12\">",
"      Price DT, Coleman RE, Liao RP, et al. Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol 2002; 168:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23527/abstract/13\">",
"      Morris MJ, Akhurst T, Osman I, et al. Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer. Urology 2002; 59:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23527/abstract/14\">",
"      Morris MJ, Akhurst T, Larson SM, et al. Fluorodeoxyglucose positron emission tomography as an outcome measure for castrate metastatic prostate cancer treated with antimicrotubule chemotherapy. Clin Cancer Res 2005; 11:3210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23527/abstract/15\">",
"      Kwee SA, Coel MN, Lim J, Ko JP. Prostate cancer localization with 18fluorine fluorocholine positron emission tomography. J Urol 2005; 173:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23527/abstract/16\">",
"      Beheshti M, Imamovic L, Broinger G, et al. 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. Radiology 2010; 254:925.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16992 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-A6750C7309-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_62_23527=[""].join("\n");
var outline_f22_62_23527=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H686719874\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H686719695\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H686719702\">",
"      STAGING SYSTEM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H686719716\">",
"      Clinical versus pathologic staging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H686719730\">",
"      Tumor (T)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H686719737\">",
"      - Clinical T stage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H686719744\">",
"      - Pathologic T stage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H686719751\">",
"      Node (N)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H686719758\">",
"      Metastasis (M)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H686723046\">",
"      Serum PSA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H686723062\">",
"      Gleason score",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H686719765\">",
"      Prognostic groups",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H686719772\">",
"      STAGING EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H215593\">",
"      General approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H686719786\">",
"      Evaluating extent of local disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H686719807\">",
"      Evaluation of regional lymph nodes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H686719814\">",
"      Evaluation for distant metastases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H686719821\">",
"      - Radionuclide bone scan",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H686719842\">",
"      - Axial skeleton MRI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H686719852\">",
"      - PET",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H686719859\">",
"      Circulating prostate cancer cells",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H686719874\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/16992\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/16992|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/19/41277\" title=\"table 1\">",
"      TNM staging prostate CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/43/10941\" title=\"table 2\">",
"      TNM group prostate CA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/16/36101?source=related_link\">",
"      Clinical presentation and diagnosis of prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/47/23290?source=related_link\">",
"      External beam radiation therapy for localized prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/36/16969?source=related_link\">",
"      Initial approach to low-risk clinically localized prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/26/21930?source=related_link\">",
"      Initial management of regionally localized intermediate and high risk prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/52/24394?source=related_link\">",
"      Interpretation of prostate biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/2/41001?source=related_link\">",
"      Measurement of prostate specific antigen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/12/10442?source=related_link\">",
"      Overview of the treatment of disseminated prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/3/2099?source=related_link\">",
"      Patient information: Prostate cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/39/40565?source=related_link\">",
"      Patient information: Prostate cancer treatment; stage I to III cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/41/42643?source=related_link\">",
"      Patient information: Treatment for advanced prostate cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/30/9704?source=related_link\">",
"      Prostate cancer: Risk stratification, other prognostic factors, and predictive tools",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/47/24313?source=related_link\">",
"      Radical prostatectomy for localized prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/31/20983?source=related_link\">",
"      Rising serum PSA following local therapy for prostate cancer: Diagnostic evaluation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_62_23528="Genetics and pathogenesis of arrhythmogenic right ventricular cardiomyopathy";
var content_f22_62_23528=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Genetics and pathogenesis of arrhythmogenic right ventricular cardiomyopathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/62/23528/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/62/23528/contributors\">",
"     William J McKenna, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/62/23528/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/62/23528/contributors\">",
"     Benjamin A Raby, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/62/23528/contributors\">",
"     Alan Cheng, MD, FACC, FAHA, FHRS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/62/23528/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/62/23528/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/62/23528/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 22, 2009.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arrhythmogenic right ventricular cardiomyopathy (ARVC), also called arrhythmogenic right ventricular dysplasia (ARVD), is an under-recognized clinical entity characterized by ventricular arrhythmias and a specific ventricular pathology [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23528/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. ARVC is characterized macroscopically by a fatty appearance of the RV free wall. The fibrofatty replacement of the RV myocardium initially produces typical regional wall motion abnormalities that later become global, producing RV dilation. The tissue replacement can also involve the area of the left ventricle (LV) with relative sparing of the septum [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23528/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevalence in the general population is estimated to be 1:1000 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23528/abstract/1\">",
"     1",
"    </a>",
"    ]. ARVC is an important cause of sudden cardiac death (SCD) in young adults in northern Italy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23528/abstract/2,5\">",
"     2,5",
"    </a>",
"    ], accounting for approximately 11 percent of cases overall and 22 percent in athletes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23528/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, ARVC has been rarely diagnosed in the United States. This may reflect a difference in genetic prevalence, but is more likely due to under-recognition of disease. In a series of 100 ARVC patients from a single referral center in the United States, clinical profiles and event rates were similar to those reported in Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23528/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The anatomy, histology, genetics, and pathogenesis of ARVC will be reviewed here. The clinical manifestations, diagnostic criteria (including the potential role of genetic testing), evaluation, treatment, and prognosis of ARVC are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/56/6025?source=see_link\">",
"     \"Treatment and prognosis of arrhythmogenic right ventricular cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32106?source=see_link\">",
"     \"Clinical manifestations and diagnosis of arrhythmogenic right ventricular cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY AND HISTOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anatomic and histologic findings associated with ARVC fall into several categories. Structurally, the hallmark findings are RV dilation and myocardial thinning although some patients also have LV involvement. Histologically, fibrofatty infiltration of the myocardium is the most common finding. In addition, electron microscopy has shown abnormalities of desmosomes in the RV myocardium, which is consistent with mutations in genes encoding desmosomal proteins being responsible for ARVC in most patients. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Genetics'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Anatomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Localized or generalized dilatation of the RV and myocardial thinning in the regions of dilation are the typical anatomic findings in ARVC. Sites of involvement are in the so-called triangle of dysplasia: the apex, the inflow tract, and outflow tract [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23528/abstract/7\">",
"     7",
"    </a>",
"    ]. The RV myocardium is typically replaced by fibrous tissue and fat, with scattered residual myocardial cells (",
"    <a class=\"graphic graphic_picture graphicRef78104 \" href=\"UTD.htm?18/9/18580\">",
"     picture 1",
"    </a>",
"    ). The extent of replacement is variable.",
"   </p>",
"   <p>",
"    Although less prominent than right ventricular disease, LV involvement can occur in patients with ARVC [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23528/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. In a report of 42 patients with ARVC diagnosed at autopsy or heart transplantation, 76 percent had fibrofatty involvement of the left ventricle [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23528/abstract/9\">",
"     9",
"    </a>",
"    ]. The likelihood of this occurring increases with age, suggesting that ARVC is a progressive disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23528/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The long-term outcome is worse in patients with LV involvement, being associated with a higher incidence of arrhythmia and clinical heart failure (HF) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23528/abstract/9\">",
"     9",
"    </a>",
"    ]. Such patients with advanced disease may be difficult to distinguish from those with dilated cardiomyopathy of other disorders that affect the right ventricle. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32106?source=see_link\">",
"     \"Clinical manifestations and diagnosis of arrhythmogenic right ventricular cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast to classic ARVC in which pathologic changes predominantly involve the RV, patients with left-dominant arrhythmogenic cardiomyopathy have predominantly LV pathology. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Left-dominant arrhythmogenic cardiomyopathy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Histology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histologic examination of patients who have died suddenly often reveals an active inflammatory process consisting of patchy mononuclear infiltrates surrounding degenerated",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    necrotic myocytes. This may represent the acute or 'hot' phase of the disease in which disrupted intercellular connections result in myocyte cell death and an inflammatory repair process.",
"   </p>",
"   <p>",
"    It was initially suggested that there are two distinct types of ARVC with differing histologic features [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23528/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. In a series of 30 hearts from patients with presumed ARVC, 18 had the fibrolipomatous (fibrofatty) pattern and 12 had the lipomatous (fatty) pattern [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23528/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The fibrolipomatous (fibrofatty) pattern is characterized by myocardial atrophy and thinning with replacement of myocardium by both fibrous and fatty tissue, as well as patchy inflammatory infiltrates. RV aneurysms and LV involvement are each found in about three-quarters of patients with fibrofatty disease [",
"      <a class=\"abstract\" href=\"UTD.htm?22/62/23528/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The lipomatous (fatty) pattern is characterized by normal or increased myocardial thickness with exclusively fatty replacement and infrequent inflammation. In the autopsy series of 12 hearts with the fatty pattern, patchy inflammatory infiltrates were found in only two, RV aneurysms in one, and LV involvement in none [",
"      <a class=\"abstract\" href=\"UTD.htm?22/62/23528/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, at least some cases of fatty infiltration of the RV without fibrosis may represent a distinct pathologic process unrelated to ARVC. This was illustrated in an autopsy study of subjects who died from noncardiac causes, which compared the clinical and pathologic features of 25 hearts with fibrofatty ARVC, 7 with only fatty replacement, and 18 control hearts [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23528/abstract/12\">",
"     12",
"    </a>",
"    ]. None of the subjects with fatty replacement had a history of arrhythmias or a family history of SCD. In contrast, more than one-half of those with fibrofatty ARVC had these historical features. Epicardial fat infiltration is part of the \"normal aging\" process of the right ventricle and may confound interpretation of magnetic resonance imaging and autopsy, particularly in adult patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Electron microscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the gene mutations in ARVC involve proteins that make up desmosomes, which are intracellular adhesion complexes that provide mechanical connections between cardiac myocytes. Support for a pathogenic role of these mutations was provided in an electron microscopy study of RV myocardium from 21 ARVC probands [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23528/abstract/14\">",
"     14",
"    </a>",
"    ]. A variety of abnormalities in desmosomal structure, size, number, or location were noted in up to 75 percent of patients with ARVC, but in none of ten controls or ten patients with dilated cardiomyopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     GENETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from clinical genetic studies suggest that 30 percent of cases of ARVC are familial [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23528/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. However, this probably represents an underestimate since detailed pedigree evaluation is infrequently documented.",
"   </p>",
"   <p>",
"    Two patterns of inheritance have been described in ARVC: an autosomal dominant form, which is most common, and an autosomal recessive form called Naxos disease, in which ARVC is part of a cardiocutaneous syndrome including hyperkeratosis of the palms and soles and woolly hair.",
"   </p>",
"   <p>",
"    Although less common, autosomal recessive disease is of particular interest because it was the association of the cutaneous manifestations and cardiomyopathy that led to the identification of the first disease-causing gene.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Autosomal recessive disease and Naxos disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Naxos disease, first recognized in the Cycladian island of Naxos, is an autosomal recessive cardiocutaneous disorder is characterized by typical features of ARVC accompanied by nonepidermolytic palmoplantar keratosis, a disorder of the epidermis causing hyperkeratosis of the palms and soles, and woolly hair [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23528/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13979106\">",
"    <span class=\"h3\">",
"     Plakoglobin gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cutaneous manifestations of Naxos disease, plus the almost 100 percent penetrance of cardiac disease by adolescence, facilitated recognition of affected patients and mapping of the genetic locus to chromosome 17q21 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23528/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Affected individuals were then found to be homozygous for a 2 base pair deletion in the plakoglobin gene [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23528/abstract/20\">",
"     20",
"    </a>",
"    ]. Like desmoplakin, plakoglobin is a key component of desmosomes and participates in maintaining tight cell-cell adhesion.",
"   </p>",
"   <p>",
"    All patients who are homozygotes for Naxos disease have diffuse palmoplantar keratosis and woolly hair in infancy; children usually have no cardiac symptoms, but may have electrocardiographic abnormalities and nonsustained ventricular arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23528/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. The cardiac disease is 100 percent penetrant by adolescence, being manifested by symptomatic arrhythmias, ECG abnormalities (92 percent), right ventricular structural alterations (100 percent), and LV involvement (27 percent). A minority of heterozygotes have minor ECG and echocardiographic changes, but clinically significant disease is not seen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32106?source=see_link&amp;anchor=H10#H10\">",
"     \"Clinical manifestations and diagnosis of arrhythmogenic right ventricular cardiomyopathy\", section on '12-lead ECG'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one series of 26 patients followed for 10 years, 62 percent had structural progression of right ventricular abnormalities, and 27 percent developed heart failure due to LV involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23528/abstract/21\">",
"     21",
"    </a>",
"    ]. Twelve patients (46 percent) developed symptomatic arrhythmias and the annual cardiac and SCD mortality were 3 and 2.3 percent, respectively, which are marginally higher than seen in autosomal dominant forms of ARVC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Desmoplakin gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;In an Arab family, a recessive mutation in the desmoplakin gene caused ARVC, woolly hair, and a pemphigus-like skin disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23528/abstract/23\">",
"     23",
"    </a>",
"    ]. A different autosomal recessive disease, Carvajal syndrome, is also associated with a desmoplakin gene mutation, and is manifested by woolly hair, epidermolytic palmoplantar keratoderma, and cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23528/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both of these mutations are located in exon 24 of the desmoplakin gene [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23528/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. The cardiomyopathy of Carvajal syndrome was thought to have a predilection for the left ventricle, but subsequent evaluation of a deceased child revealed typical ARVC changes in both ventricles [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23528/abstract/25\">",
"     25",
"    </a>",
"    ]. The cardiac phenotype in the Arab family appeared to be classic ARVC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Autosomal dominant disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disease loci for the autosomal dominant disorder have been mapped to chromosomes 14q23-q24 (ARVC1) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23528/abstract/26\">",
"     26",
"    </a>",
"    ], 1q42-q43 (ARVC2) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23528/abstract/27\">",
"     27",
"    </a>",
"    ], 14q12-q22 (ARVC3) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23528/abstract/28\">",
"     28",
"    </a>",
"    ], 2q32 (ARVC4) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23528/abstract/29\">",
"     29",
"    </a>",
"    ], 3p25 (ARVC5) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23528/abstract/30,31\">",
"     30,31",
"    </a>",
"    ], 10p12-p14 (ARVC6) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23528/abstract/32\">",
"     32",
"    </a>",
"    ], 10q22, 6p24 (ARVC8) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23528/abstract/16,33\">",
"     16,33",
"    </a>",
"    ], and 12p11 (ARVC9) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23528/abstract/34\">",
"     34",
"    </a>",
"    ]. The relative frequency of several of these disorders was assessed in a review of 28 Italian families that underwent linkage analysis: six had ARVC1, four had ARVC2; and four had ARVC4 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23528/abstract/35\">",
"     35",
"    </a>",
"    ]. No linkage with known loci was found in four families (only ARVC1 through ARVC5 were tested) and uninformative results were obtained in ten.",
"   </p>",
"   <p>",
"    The responsible gene has been identified in some of these disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Desmoplakin gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;Desmoplakin was the first disease-causing gene identified in autosomal dominant ARVC; the affected family had a missense mutation linked to 6p24 (ARVC8) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23528/abstract/16\">",
"     16",
"    </a>",
"    ]. The mutation affected the N-terminal of desmoplakin, in the region of the plakoglobin-binding domain. The phenotype of this and four additional families with ARVC caused by desmoplakin mutations was of \"classic ARVC\" with a clinical presentation of arrhythmia, sudden death, and LV involvement as the disease progresses [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23528/abstract/16,36,37\">",
"     16,36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Desmoplakin is a key component of desmosomes and adherens junctions that is important for maintaining the tight adhesion of many cell types, including those in the heart and skin. When these junctions are disrupted, cell death and fibrofatty replacement occur. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Pathogenesis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Desmoplakin gene mutations have also been associated with left-sided ARVC and, as noted above, with autosomal recessive disease. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Autosomal recessive disease and Naxos disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Plakophilin-2 gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;The gene at locus 12p11 (ARVC9) encodes the desmosomal protein plakophilin-2. In a genetic analysis of 120 unrelated individuals with ARVC, 32 had 25 different mutations in the gene encoding plakophilin-2 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23528/abstract/34\">",
"     34",
"    </a>",
"    ]. Three additional series, enrolling between 56 and 100 unrelated index patients who fulfilled published task force diagnostic criteria for ARVC, evaluated the incidence and clinical significance of PKP2 mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23528/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      PKP2 mutations were found in 11 to 43 percent of the patients.",
"     </li>",
"     <li>",
"      In a Dutch study, 43 percent of ARVC probands had a mutation in PKP2. Haplotype analysis suggested founder mutations were responsible for 4 of the 14 different mutations identified. Among index patients with a positive family history of ARVC, 70 percent had a PKP2 mutation [",
"      <a class=\"abstract\" href=\"UTD.htm?22/62/23528/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with PKP2 mutation presented at a younger age (28 versus 36 years), but had similar rates of appropriate ICD discharges compared to patients without PKP2 mutations [",
"      <a class=\"abstract\" href=\"UTD.htm?22/62/23528/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, PKP2 appears to be a relatively common mutation, particularly in cases with a documented family history. However, there does not appear to be a substantial phenotypic distinction from other mutations, and due to relatively small sample sizes and the potential for referral bias, the incidence of PKP2 mutations in a broader population may be lower [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23528/abstract/38,41\">",
"     38,41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Desmoglein-2 gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;Desmoglein is another component of the desmosome and desmoglein-2 (DSG2) is the only isoform expressed in cardiac myocytes. Due to the known association of ARVC with defects in other desmosomal proteins, a series of patients with ARVC were screened for mutations in DSG2 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23528/abstract/42\">",
"     42",
"    </a>",
"    ]. Among 80 unrelated probands, 26 were known to have desmoplakin or plakophilin-2 mutations. Direct sequencing of DSG2 in the other 54 patients revealed nine distinct mutations in eight individuals. These individuals demonstrated typical clinical characteristics of ARVC, although four had some evidence of LV involvement. DSG2 is on chromosome 18q12.1, which does not correspond with any of the loci identified in linkage analysis studies (ie, ARVC1-9).",
"   </p>",
"   <p>",
"    An analogous study of 86 ARVC probands identified eight novel DSG2 mutations in nine probands. Clinical evaluation of family members with DSG2 mutations revealed penetrance of 58 percent using Task Force criteria and 75 percent using proposed modified criteria. Morphological abnormalities of the right ventricle were present in 66 percent of gene carriers, LV involvement in 25 percent, and classical right precordial T-wave inversion in only 26 percent. The authors noted that disease expression of DSG2 mutations was of variable severity, but that overall penetrance was high and LV involvement prominent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23528/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Desmocollin-2 gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;Desmocollin is an important desmosomal cadherin. Two heterozygous mutations (a deletion and in insertion) were identified in 4 of 77 probands with ARVC. Both DSC2 mutations resulted in frameshifts and premature truncation of the desmocollin-2 protein. The identification of the fifth desmosomal cell adhesion gene abnormality further supports the hypothesis that ARVC is a disease of cell adhesion [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23528/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     TMEM43 gene",
"    </span>",
"    &nbsp;&mdash;&nbsp;A missense mutation in the TMEM43 gene causes ARVC5, a fully penetrant, sex-influenced, high risk form of ARVC [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23528/abstract/31,45\">",
"     31,45",
"    </a>",
"    ]. The TMEM43 gene contains the response element for PPAR gamma, an adipogenic transcription factor. If the TMEM43 gene mutation causes dysregulation of an adipogenic pathway regulated by PPAR gamma, this dysregulation may explain the fibrofatty replacement of myocardium in ARVC patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Other genes",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      RyR2 gene &mdash; The gene at locus 1q42-q43 (ARVC2) encodes the cardiac ryanodine receptor RyR2, which has been described in only one family in Italy [",
"      <a class=\"abstract\" href=\"UTD.htm?22/62/23528/abstract/46\">",
"       46",
"      </a>",
"      ]. Affected patients have exercise-induced polymorphic VT [",
"      <a class=\"abstract\" href=\"UTD.htm?22/62/23528/abstract/47\">",
"       47",
"      </a>",
"      ]. Mutations in RyR2 have primarily been associated with familial polymorphic VT without ARVC [",
"      <a class=\"abstract\" href=\"UTD.htm?22/62/23528/abstract/48\">",
"       48",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37641?source=see_link&amp;anchor=H4#H4\">",
"       \"Catecholaminergic polymorphic ventricular tachycardia and other polymorphic ventricular tachycardias with a normal QT interval\", section on 'Genetics'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    RyR2 mediates the release of calcium from the sarcoplasmic reticulum that is required for myocardial contraction. The FK506 binding protein (FKBP12.6) stabilizes RyR2, preventing aberrant activation. The mutations in RyR2 interfere with the interaction with FKBP12.6, increasing channel activity under conditions that simulate exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23528/abstract/49\">",
"     49",
"    </a>",
"    ]. The mutations in ARVC appear to act differently from those in familial polymorphic VT without ARVC [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23528/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      TGF-beta-3 gene &mdash; The gene for transforming growth factor-beta-3 (TGF-beta-3) has been mapped to the ARVC1 locus on chromosome 14. Sequencing studies failed to identify any disease-causing mutations in the exonic regions of TGF-beta-3 [",
"      <a class=\"abstract\" href=\"UTD.htm?22/62/23528/abstract/51\">",
"       51",
"      </a>",
"      ]. This led to screening of the promoter and untranslated regions, where a mutation of the TGF-beta-3 gene was found in all clinically affected members of a large family with ARVC1 [",
"      <a class=\"abstract\" href=\"UTD.htm?22/62/23528/abstract/52\">",
"       52",
"      </a>",
"      ]. The mutation is predicted to produce an amino acid substitution in a short peptide with an inhibitory role in TGF-beta-3 regulation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The implication of these observations is that regulatory mutations resulting in overexpression of TGF-beta-3 may contribute to the development of ARVC in these families. The TGF-beta family of cytokines stimulates production of components of the extracellular matrix. It is therefore possible that enhanced TGF-beta activity can lead to myocardial fibrosis. However, genetic analysis of two other families with ARVC1 failed to identify mutations in any of the regions of the TGF-beta-3 gene [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23528/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Left-dominant arrhythmogenic cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, the pathologic process in ARVC predominantly involves the right ventricle, although it may extend to the left ventricle [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23528/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. In contrast, patients with left-dominant arrhythmogenic cardiomyopathy (LDAC, also known as left-sided ARVC or arrhythmogenic left ventricular cardiomyopathy) have typical pathological changes predominantly involving the LV [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23528/abstract/53,54\">",
"     53,54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar to ARVC, some patients with LDAC have desmosomal gene mutations. Genetic testing was performed in a series of 42 individuals diagnosed with LDAC with unexplained (infero)lateral T-wave inversion, arrhythmia of LV origin,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    proven LDAC [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23528/abstract/55\">",
"     55",
"    </a>",
"    ]. Disease causing mutations in known desmosomal genes were identified in 8 of 24 families (33 percent), a rate of desmosomal mutations similar to that observed in ARVC populations [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23528/abstract/56\">",
"     56",
"    </a>",
"    ]. Six of the mutations involved the desmoplakin gene, one involved the plakophilin-2 gene and one involved the desmoglein-2 gene. The clinical characteristics of LDAC are discussed separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32106?source=see_link&amp;anchor=H1492721#H1492721\">",
"     \"Clinical manifestations and diagnosis of arrhythmogenic right ventricular cardiomyopathy\", section on 'Left-dominant arrhythmogenic cardiomyopathy'",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Five established disease-causing genes in ARVC encode desmosomal proteins &mdash; plakoglobin, desmoplakin, plakophilin-2, desmoglein, and desmocollin in autosomal dominant disease and plakoglobin and desmoplakin in Naxos disease &mdash; support a new model for the pathogenesis of ARVC [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23528/abstract/57\">",
"     57",
"    </a>",
"    ]. Impaired desmosome function when subjected to mechanical stress causes myocyte detachment and cell death. The myocardial injury may be accompanied by inflammation as the initial phase of the repair process, which ultimately results in fibrofatty replacement of damaged myocytes.",
"   </p>",
"   <p>",
"    The impaired cell adhesion hypothesis is consistent with a number of the hallmark features of ARVC, including its anatomical progression:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Early ARVC shows a predilection for the thinnest portions of the right ventricle, the triangle of dysplasia (the apex, the inflow tract, and outflow tract), while LV involvement is often restricted to the relatively thin posterolateral wall, with sparing of the thicker septum. The heterogeneous distribution of mechanical stress within the ventricle accounts for regional disease expression and aneurysm formation. Athletes often have structurally severe disease, possibly resulting from the intense and prolonged mechanical stress on the heart during physical training.",
"     </li>",
"     <li>",
"      Cutaneous disease caused by desmosomal dysfunction is confined to areas exposed to pressure, stress, or abrasion, and the palmar and plantar surfaces.",
"     </li>",
"     <li>",
"      The penetrance of ARVC is often incomplete [",
"      <a class=\"abstract\" href=\"UTD.htm?22/62/23528/abstract/58\">",
"       58",
"      </a>",
"      ]. This observation suggests that mutant desmosomal proteins can maintain tissue integrity unless exposed to excessive mechanical stress. The incomplete penetrance of ARVC may therefore be related to a lack of stress on the heart, in contrast to athletes, who may present with symptomatic arrhythmia at a young age.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The impact of exercise on the development of ARVC has been demonstrated in a mouse model [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23528/abstract/59\">",
"     59",
"    </a>",
"    ]. Among heterozygous plakoglobin-deficient mice, the phenotypic expression of ARVC (RV dysfunction and arrhythmias) was accelerated by endurance training.",
"   </p>",
"   <p>",
"    The predominantly LV involvement in left-sided ARVC may be related to disrupted binding of the C-terminal end of desmoplakin to desmin filaments, analogous to the loss of cytoskeletal integrity that is considered the pathogenetic determinant of dilated cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23528/abstract/57\">",
"     57",
"    </a>",
"    ]. Conversely, defects in the N-terminal of desmoplakin, which would be predicted to disrupt binding to plakoglobin, result in a primary dysfunction of cell adhesion and predominant right ventricular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23528/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23528/abstract/1\">",
"      Gemayel C, Pelliccia A, Thompson PD. Arrhythmogenic right ventricular cardiomyopathy. J Am Coll Cardiol 2001; 38:1773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23528/abstract/2\">",
"      Corrado D, Fontaine G, Marcus FI, et al. Arrhythmogenic right ventricular dysplasia/cardiomyopathy: need for an international registry. Study Group on Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy of the Working Groups on Myocardial and Pericardial Disease and Arrhythmias of the European Society of Cardiology and of the Scientific Council on Cardiomyopathies of the World Heart Federation. Circulation 2000; 101:E101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23528/abstract/3\">",
"      Sen-Chowdhry S, Lowe MD, Sporton SC, McKenna WJ. Arrhythmogenic right ventricular cardiomyopathy: clinical presentation, diagnosis, and management. Am J Med 2004; 117:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23528/abstract/4\">",
"      Richardson P, McKenna W, Bristow M, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation 1996; 93:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23528/abstract/5\">",
"      Corrado D, Basso C, Schiavon M, Thiene G. Screening for hypertrophic cardiomyopathy in young athletes. N Engl J Med 1998; 339:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23528/abstract/6\">",
"      Dalal D, Nasir K, Bomma C, et al. Arrhythmogenic right ventricular dysplasia: a United States experience. Circulation 2005; 112:3823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23528/abstract/7\">",
"      Marcus FI, Fontaine GH, Guiraudon G, et al. Right ventricular dysplasia: a report of 24 adult cases. Circulation 1982; 65:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23528/abstract/8\">",
"      Pinamonti B, Sinagra G, Salvi A, et al. Left ventricular involvement in right ventricular dysplasia. Am Heart J 1992; 123:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23528/abstract/9\">",
"      Corrado D, Basso C, Thiene G, et al. Spectrum of clinicopathologic manifestations of arrhythmogenic right ventricular cardiomyopathy/dysplasia: a multicenter study. J Am Coll Cardiol 1997; 30:1512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23528/abstract/10\">",
"      Tabib A, Loire R, Chalabreysse L, et al. Circumstances of death and gross and microscopic observations in a series of 200 cases of sudden death associated with arrhythmogenic right ventricular cardiomyopathy and/or dysplasia. Circulation 2003; 108:3000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23528/abstract/11\">",
"      Thiene G, Corrado D, Nava A, et al. Right ventricular cardiomyopathy: is there evidence of an inflammatory aetiology? Eur Heart J 1991; 12 Suppl D:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23528/abstract/12\">",
"      Burke AP, Farb A, Tashko G, Virmani R. Arrhythmogenic right ventricular cardiomyopathy and fatty replacement of the right ventricular myocardium: are they different diseases? Circulation 1998; 97:1571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23528/abstract/13\">",
"      Basso C, Thiene G, Corrado D, et al. Arrhythmogenic right ventricular cardiomyopathy. Dysplasia, dystrophy, or myocarditis? Circulation 1996; 94:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23528/abstract/14\">",
"      Basso C, Czarnowska E, Della Barbera M, et al. Ultrastructural evidence of intercalated disc remodelling in arrhythmogenic right ventricular cardiomyopathy: an electron microscopy investigation on endomyocardial biopsies. Eur Heart J 2006; 27:1847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23528/abstract/15\">",
"      Hermida JS, Minassian A, Jarry G, et al. Familial incidence of late ventricular potentials and electrocardiographic abnormalities in arrhythmogenic right ventricular dysplasia. Am J Cardiol 1997; 79:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23528/abstract/16\">",
"      Rampazzo A, Nava A, Malacrida S, et al. Mutation in human desmoplakin domain binding to plakoglobin causes a dominant form of arrhythmogenic right ventricular cardiomyopathy. Am J Hum Genet 2002; 71:1200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23528/abstract/17\">",
"      Protonotarios N, Tsatsopoulou A, Patsourakos P, et al. Cardiac abnormalities in familial palmoplantar keratosis. Br Heart J 1986; 56:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23528/abstract/18\">",
"      Coonar AS, Protonotarios N, Tsatsopoulou A, et al. Gene for arrhythmogenic right ventricular cardiomyopathy with diffuse nonepidermolytic palmoplantar keratoderma and woolly hair (Naxos disease) maps to 17q21. Circulation 1998; 97:2049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23528/abstract/19\">",
"      Rogaev EI, Rogaeva EA, Ginter EK, et al. Identification of the genetic locus for keratosis palmaris et plantaris on chromosome 17 near the RARA and keratin type I genes. Nat Genet 1993; 5:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23528/abstract/20\">",
"      McKoy G, Protonotarios N, Crosby A, et al. Identification of a deletion in plakoglobin in arrhythmogenic right ventricular cardiomyopathy with palmoplantar keratoderma and woolly hair (Naxos disease). Lancet 2000; 355:2119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23528/abstract/21\">",
"      Protonotarios N, Tsatsopoulou A, Anastasakis A, et al. Genotype-phenotype assessment in autosomal recessive arrhythmogenic right ventricular cardiomyopathy (Naxos disease) caused by a deletion in plakoglobin. J Am Coll Cardiol 2001; 38:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23528/abstract/22\">",
"      Kaplan SR, Gard JJ, Protonotarios N, et al. Remodeling of myocyte gap junctions in arrhythmogenic right ventricular cardiomyopathy due to a deletion in plakoglobin (Naxos disease). Heart Rhythm 2004; 1:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23528/abstract/23\">",
"      Alcalai R, Metzger S, Rosenheck S, et al. A recessive mutation in desmoplakin causes arrhythmogenic right ventricular dysplasia, skin disorder, and woolly hair. J Am Coll Cardiol 2003; 42:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23528/abstract/24\">",
"      Norgett EE, Hatsell SJ, Carvajal-Huerta L, et al. Recessive mutation in desmoplakin disrupts desmoplakin-intermediate filament interactions and causes dilated cardiomyopathy, woolly hair and keratoderma. Hum Mol Genet 2000; 9:2761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23528/abstract/25\">",
"      Kaplan SR, Gard JJ, Carvajal-Huerta L, et al. Structural and molecular pathology of the heart in Carvajal syndrome. Cardiovasc Pathol 2004; 13:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23528/abstract/26\">",
"      Rampazzo A, Nava A, Danieli GA, et al. The gene for arrhythmogenic right ventricular cardiomyopathy maps to chromosome 14q23-q24. Hum Mol Genet 1994; 3:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23528/abstract/27\">",
"      Rampazzo A, Nava A, Erne P, et al. A new locus for arrhythmogenic right ventricular cardiomyopathy (ARVD2) maps to chromosome 1q42-q43. Hum Mol Genet 1995; 4:2151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23528/abstract/28\">",
"      Severini GM, Krajinovic M, Pinamonti B, et al. A new locus for arrhythmogenic right ventricular dysplasia on the long arm of chromosome 14. Genomics 1996; 31:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23528/abstract/29\">",
"      Rampazzo A, Nava A, Miorin M, et al. ARVD4, a new locus for arrhythmogenic right ventricular cardiomyopathy, maps to chromosome 2 long arm. Genomics 1997; 45:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23528/abstract/30\">",
"      Ahmad F, Li D, Karibe A, et al. Localization of a gene responsible for arrhythmogenic right ventricular dysplasia to chromosome 3p23. Circulation 1998; 98:2791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23528/abstract/31\">",
"      Hodgkinson KA, Parfrey PS, Bassett AS, et al. The impact of implantable cardioverter-defibrillator therapy on survival in autosomal-dominant arrhythmogenic right ventricular cardiomyopathy (ARVD5). J Am Coll Cardiol 2005; 45:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23528/abstract/32\">",
"      Li D, Ahmad F, Gardner MJ, et al. The locus of a novel gene responsible for arrhythmogenic right-ventricular dysplasia characterized by early onset and high penetrance maps to chromosome 10p12-p14. Am J Hum Genet 2000; 66:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23528/abstract/33\">",
"      Melberg A, Oldfors A, Blomstrom-Lundqvist C, et al. Autosomal dominant myofibrillar myopathy with arrhythmogenic right ventricular cardiomyopathy linked to chromosome 10q. Ann Neurol 1999; 46:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23528/abstract/34\">",
"      Gerull B, Heuser A, Wichter T, et al. Mutations in the desmosomal protein plakophilin-2 are common in arrhythmogenic right ventricular cardiomyopathy. Nat Genet 2004; 36:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23528/abstract/35\">",
"      Nava A, Bauce B, Basso C, et al. Clinical profile and long-term follow-up of 37 families with arrhythmogenic right ventricular cardiomyopathy. J Am Coll Cardiol 2000; 36:2226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23528/abstract/36\">",
"      Bauce B, Basso C, Rampazzo A, et al. Clinical profile of four families with arrhythmogenic right ventricular cardiomyopathy caused by dominant desmoplakin mutations. Eur Heart J 2005; 26:1666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23528/abstract/37\">",
"      Sen-Chowdhry S, Syrris P, McKenna WJ. Desmoplakin disease in arrhythmogenic right ventricular cardiomyopathy: early genotype-phenotype studies. Eur Heart J 2005; 26:1582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23528/abstract/38\">",
"      Syrris P, Ward D, Asimaki A, et al. Clinical expression of plakophilin-2 mutations in familial arrhythmogenic right ventricular cardiomyopathy. Circulation 2006; 113:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23528/abstract/39\">",
"      Dalal D, Molin LH, Piccini J, et al. Clinical features of arrhythmogenic right ventricular dysplasia/cardiomyopathy associated with mutations in plakophilin-2. Circulation 2006; 113:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23528/abstract/40\">",
"      van Tintelen JP, Entius MM, Bhuiyan ZA, et al. Plakophilin-2 mutations are the major determinant of familial arrhythmogenic right ventricular dysplasia/cardiomyopathy. Circulation 2006; 113:1650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23528/abstract/41\">",
"      Corrado D, Thiene G. Arrhythmogenic right ventricular cardiomyopathy/dysplasia: clinical impact of molecular genetic studies. Circulation 2006; 113:1634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23528/abstract/42\">",
"      Pilichou K, Nava A, Basso C, et al. Mutations in desmoglein-2 gene are associated with arrhythmogenic right ventricular cardiomyopathy. Circulation 2006; 113:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23528/abstract/43\">",
"      Syrris P, Ward D, Asimaki A, et al. Desmoglein-2 mutations in arrhythmogenic right ventricular cardiomyopathy: a genotype-phenotype characterization of familial disease. Eur Heart J 2007; 28:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23528/abstract/44\">",
"      Syrris P, Ward D, Evans A, et al. Arrhythmogenic right ventricular dysplasia/cardiomyopathy associated with mutations in the desmosomal gene desmocollin-2. Am J Hum Genet 2006; 79:978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23528/abstract/45\">",
"      Merner ND, Hodgkinson KA, Haywood AF, et al. Arrhythmogenic right ventricular cardiomyopathy type 5 is a fully penetrant, lethal arrhythmic disorder caused by a missense mutation in the TMEM43 gene. Am J Hum Genet 2008; 82:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23528/abstract/46\">",
"      Tiso N, Stephan DA, Nava A, et al. Identification of mutations in the cardiac ryanodine receptor gene in families affected with arrhythmogenic right ventricular cardiomyopathy type 2 (ARVD2). Hum Mol Genet 2001; 10:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23528/abstract/47\">",
"      Bauce B, Nava A, Rampazzo A, et al. Familial effort polymorphic ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy map to chromosome 1q42-43. Am J Cardiol 2000; 85:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23528/abstract/48\">",
"      Priori SG, Napolitano C, Memmi M, et al. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia. Circulation 2002; 106:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23528/abstract/49\">",
"      Wehrens XH, Lehnart SE, Huang F, et al. FKBP12.6 deficiency and defective calcium release channel (ryanodine receptor) function linked to exercise-induced sudden cardiac death. Cell 2003; 113:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23528/abstract/50\">",
"      Tiso N, Salamon M, Bagattin A, et al. The binding of the RyR2 calcium channel to its gating protein FKBP12.6 is oppositely affected by ARVD2 and VTSIP mutations. Biochem Biophys Res Commun 2002; 299:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23528/abstract/51\">",
"      Rampazzo A, Beffagna G, Nava A, et al. Arrhythmogenic right ventricular cardiomyopathy type 1 (ARVD1): confirmation of locus assignment and mutation screening of four candidate genes. Eur J Hum Genet 2003; 11:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23528/abstract/52\">",
"      Beffagna G, Occhi G, Nava A, et al. Regulatory mutations in transforming growth factor-beta3 gene cause arrhythmogenic right ventricular cardiomyopathy type 1. Cardiovasc Res 2005; 65:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23528/abstract/53\">",
"      Michalodimitrakis M, Papadomanolakis A, Stiakakis J, Kanaki K. Left side right ventricular cardiomyopathy. Med Sci Law 2002; 42:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23528/abstract/54\">",
"      Norman M, Simpson M, Mogensen J, et al. Novel mutation in desmoplakin causes arrhythmogenic left ventricular cardiomyopathy. Circulation 2005; 112:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23528/abstract/55\">",
"      Sen-Chowdhry S, Syrris P, Prasad SK, et al. Left-dominant arrhythmogenic cardiomyopathy: an under-recognized clinical entity. J Am Coll Cardiol 2008; 52:2175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23528/abstract/56\">",
"      Sen-Chowdhry S, Syrris P, McKenna WJ. Role of genetic analysis in the management of patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol 2007; 50:1813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23528/abstract/57\">",
"      Sen-Chowdhry S, Syrris P, McKenna WJ. Genetics of right ventricular cardiomyopathy. J Cardiovasc Electrophysiol 2005; 16:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23528/abstract/58\">",
"      Dalal D, James C, Devanagondi R, et al. Penetrance of mutations in plakophilin-2 among families with arrhythmogenic right ventricular dysplasia/cardiomyopathy. J Am Coll Cardiol 2006; 48:1416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23528/abstract/59\">",
"      Kirchhof P, Fabritz L, Zwiener M, et al. Age- and training-dependent development of arrhythmogenic right ventricular cardiomyopathy in heterozygous plakoglobin-deficient mice. Circulation 2006; 114:1799.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4929 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.150.3.100-F1EFE81ED1-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_62_23528=[""].join("\n");
var outline_f22_62_23528=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY AND HISTOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Histology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Electron microscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      GENETICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Autosomal recessive disease and Naxos disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13979106\">",
"      - Plakoglobin gene",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Desmoplakin gene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Autosomal dominant disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Desmoplakin gene",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Plakophilin-2 gene",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Desmoglein-2 gene",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Desmocollin-2 gene",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - TMEM43 gene",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Other genes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Left-dominant arrhythmogenic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/4929\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4929|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/9/18580\" title=\"picture 1\">",
"      Morphologic features ARVD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37641?source=related_link\">",
"      Catecholaminergic polymorphic ventricular tachycardia and other polymorphic ventricular tachycardias with a normal QT interval",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32106?source=related_link\">",
"      Clinical manifestations and diagnosis of arrhythmogenic right ventricular cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/56/6025?source=related_link\">",
"      Treatment and prognosis of arrhythmogenic right ventricular cardiomyopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_62_23529="Aspirin in the primary prevention of cardiovascular disease and cancer";
var content_f22_62_23529=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Aspirin in the primary prevention of cardiovascular disease and cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/62/23529/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/62/23529/contributors\">",
"     Frederick A Spencer, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/62/23529/contributors\">",
"     Gordon Guyatt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/62/23529/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/62/23529/contributors\">",
"     Robert H Fletcher, MD, MSc",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/62/23529/contributors\">",
"     Christopher P Cannon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/62/23529/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/62/23529/contributors\">",
"     H Nancy Sokol, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/62/23529/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/62/23529/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1761517\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiovascular disease and cancer are the leading causes of morbidity and mortality worldwide, representing 24 and 13 percent of all deaths, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23529/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    produces statistically-significant and clinically-important reductions in cardiovascular events in survivors of a wide range of occlusive cardiovascular disease events, including coronary heart disease (CHD); its net benefit (reduction in cardiovascular events minus an increase in major bleeding events) warrants its use as secondary prevention. On the other hand, aspirin use for primary prevention in apparently healthy subjects (without either known CHD or moderate to high risk for CHD) is less clear. With a lower incidence of cardiovascular events in this population, the ratio of benefit to risk is lower. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=see_link&amp;anchor=H32#H32\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\", section on 'Estimating the benefit to risk ratio'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Historically, only the potential cardiovascular benefits of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , including reductions in the rates of cardiovascular death, myocardial infarction, or stroke, have been considered when making decisions about its use for primary prevention. Accumulating data suggest aspirin may also have a favorable impact on cancer incidence, metastasis, and mortality. These effects of aspirin on the development of cancer and subsequent adverse outcomes might alter recommendations for the use of aspirin for primary prevention. A personalized approach to the decision whether or not to advise aspirin use for primary prevention, factoring an individual&rsquo;s health risks and personal values, is likely to be optimal [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23529/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/24/42378?source=see_link\">",
"     \"Cancer prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will summarize the evidence from clinical trials and observational studies regarding the potential benefits and risks of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    for primary prophylaxis. We will provide estimates of benefit and risks of aspirin for apparently healthy individuals at varying risk for both cardiovascular and cancer outcomes conditions. These summaries are intended to facilitate discussions between clinicians and patients regarding use of aspirin as primary prophylaxis.",
"   </p>",
"   <p>",
"    Discussion of the role of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    in secondary and primary prevention of cardiovascular disease, including individuals at moderate to high risk for CVD, is presented separately. The role of aspirin in the prevention of colorectal cancer in the absence of considerations of preventing CVD events is discussed separately as well. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=see_link\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22666?source=see_link\">",
"     \"NSAIDs (including aspirin): Role in prevention of cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1761524\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (75 to 100 mg) produces an antithrombotic effect by irreversibly acetylating cyclooxygenase-1 (COX-1), thus inhibiting platelet generation of thromboxane A2. Higher doses of aspirin also inhibit COX-2, which blocks prostaglandin production leading to analgesic and antipyretic effects. Platelet inhibition decreases the likelihood of coronary artery thrombosis, the pathogenic mechanism of acute ischemic events. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=see_link\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/47/2807?source=see_link\">",
"     \"Aspirin: Mechanism of action, major toxicities, and use in rheumatic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Putative mechanisms for the anticancer effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    include induction of cell apoptosis as well as inhibition of cyclooxygenase-catalyzed prostaglandin production. In colorectal cancer, aspirin may also influence the PIK3CA pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23529/abstract/5\">",
"     5",
"    </a>",
"    ]. &nbsp;Prostaglandins are associated with tumor angiogenesis, cell proliferation, and inhibition of immune surveillance and apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23529/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4167?source=see_link\">",
"     \"The role of platelets in coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22666?source=see_link\">",
"     \"NSAIDs (including aspirin): Role in prevention of cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1761531\">",
"    <span class=\"h1\">",
"     PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 2012 meta-analysis of nine large-scale trials of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    for the primary prevention of cardiovascular disease (CVD) involving over 100,000 men and women without established cardiovascular disease (mean age 57 years, most participants with increased risk for CVD, though risk was widely variable across studies) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23529/abstract/7\">",
"     7",
"    </a>",
"    ]. An earlier (2009) meta-analysis of six primary prevention trials (95,000 individuals and including individual participant data) provided additional data on the outcomes of non-fatal stroke and non-fatal extracranial bleed [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23529/abstract/8\">",
"     8",
"    </a>",
"    ]. For all outcomes, quality of evidence is moderate. Findings suggest that aspirin produces (",
"    <a class=\"graphic graphic_table graphicRef86941 \" href=\"UTD.htm?39/47/40702\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 20 percent relative risk reduction in non-fatal myocardial infarction (MI) (OR 0.80, 95% CI 0.67-0.96) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/62/23529/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      No significant impact on non-fatal stroke (including ischemic and hemorrhagic stroke) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/62/23529/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      No significant impact on CVD mortality.",
"     </li>",
"     <li>",
"      A 54 percent increase in the relative risk of non-fatal extracranial bleeding (RR 1.54, 95% CI 01.30-1.82) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/62/23529/abstract/8\">",
"       8",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other meta-analyses have shown similar results [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23529/abstract/9-13\">",
"     9-13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1761545\">",
"    <span class=\"h1\">",
"     PRIMARY PREVENTION OF CANCER",
"    </span>",
"    &nbsp;&mdash;&nbsp;A growing body of evidence suggests that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and other nonsteroidal antiinflammatory drugs (NSAIDs) inhibit colorectal carcinogenesis, metastases, and related mortality. There is also growing evidence that aspirin use is associated with a decreased incidence of other solid cancer types and associated mortality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22666?source=see_link\">",
"     \"NSAIDs (including aspirin): Role in prevention of cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1761552\">",
"    <span class=\"h2\">",
"     Aspirin and cancer incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous randomized trials have evaluated the role of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    in the primary and secondary prevention of occlusive cardiovascular diseases. Long-term follow-up from these trials has provided an opportunity to explore whether aspirin is associated with risks of cancer in patients who were assigned to aspirin or placebo. In randomized trials, long-term (a minimum of three to five years) daily aspirin use may decrease the incidence of a broad spectrum of cancers. Survival curves begin to separate, however, only after a period of at least four years of follow-up.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3356540\">",
"    <span class=\"h3\">",
"     Colorectal cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from a large number of studies evaluating",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and other NSAIDS suggest a reduction in risk of colorectal adenomas and cancer, depending on dose and duration of therapy. In a systematic review of cohort studies prepared for the US Preventive Services Task Force (USPSTF), regular aspirin use was associated with a 22 percent relative risk reduction in the incidence of colorectal cancer (CRC) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23529/abstract/14\">",
"     14",
"    </a>",
"    ]. However, while observational studies suggested a reduction in CRC with aspirin use, especially when used beyond 10 years, two randomized controlled trials (RCTs) failed to demonstrate a reduction in CRC incidence with aspirin use [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23529/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Based on these data and given concerns regarding harms related to aspirin (gastrointestinal toxicity and bleeding), the USPSTF in 2007 did not recommend routine aspirin use for the primary prevention of CRC.",
"   </p>",
"   <p>",
"    In a subsequent analysis, investigators performed long-term follow-up (median 18.3 years) on over 14,000 Swedish or United Kingdom individuals enrolled in four RCTs of primary prevention of vascular disease, comparing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (75 to 300 mg daily) to control and came to the following conclusions [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23529/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Daily",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      reduced the 20-year risk of colon cancer (incidence HR 0.76, 95% CI 0.63-0.94).",
"     </li>",
"     <li>",
"      Benefit increased with the duration of treatment (&ge;5 years).",
"     </li>",
"     <li>",
"      Benefit in the overall cohort was not observed until approximately 8 to 10 years of follow-up.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3357234\">",
"    <span class=\"h3\">",
"     Other cancers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence is emerging that supports a plausible beneficial effect for low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    used over prolonged periods for the prevention of a broad spectrum of cancers. As part of a larger meta-analysis employing individual patient-level data from 51 RCTs, the effect of aspirin on overall cancer incidence was analyzed utilizing data from six primary prevention trials of daily low-dose aspirin (75 to 100 mg) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23529/abstract/18\">",
"     18",
"    </a>",
"    ]. Individual patient data on all non-fatal and fatal cancers was available in five of the six trials (only data on fatal cancers was provided in the sixth study). Low-quality evidence (limitations of imprecision: 95% CI bordered no effect of aspirin on cancer incidence; and risk of bias with the exclusion of two large RCTs, see below) suggested the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Daily",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      use was associated with a significant reduction in all cancers during follow-up (HR 0.88, 95% CI 0.80-0.98).",
"     </li>",
"     <li>",
"      Benefit was noted starting at four years of follow-up and increased thereafter. Analysis restricted to the period of five years or greater after starting",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      showed a HR of 0.71 (95% CI 0.57-0.89).",
"     </li>",
"     <li>",
"      Benefit after four years was independent of age, gender, and smoking status.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Combining these data from primary prevention trials with 21 other trials of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (for secondary prevention of vascular events) for which the site of fatal cancer was known, aspirin was associated with a significant reduction in the subgroups of non-fatal and fatal cancers of the female reproductive tract, lymphoma, and sarcoma [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23529/abstract/18\">",
"     18",
"    </a>",
"    ]. The number of cases was too small to adequately assess the association between aspirin and cancer at other sites.",
"   </p>",
"   <p>",
"    A limitation of this meta-analysis was the exclusion of data from the large Physician&rsquo;s Health and Women&rsquo;s Health studies [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23529/abstract/15,16\">",
"     15,16",
"    </a>",
"    ] that evaluated the impact of every-other-day dosing of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    . The authors suggest this exclusion was based on observational data suggesting",
"    <strong>",
"     daily",
"    </strong>",
"    aspirin use may be required for antineoplastic effects. However, the observational data are inconsistent, and therefore, the rationale for exclusion of these two large studies is unconvincing. The Women&rsquo;s Health Study, which included almost 40,000 women followed approximately 10 years, found no effect of every-other-day, low-dose aspirin on cancer incidence (RR 1.01, 95% CI 0.94-1.08) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23529/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1761559\">",
"    <span class=\"h2\">",
"     Aspirin and cancer mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from studies of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    for the primary and secondary prevention of cardiovascular disease also suggest that long-term aspirin use is associated with a decrease in cancer-related mortality, as well as nonvascular mortality. Reduction in cancer mortality may relate both to cancer prevention as well as to a decrease in the risk of cancer metastasis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23529/abstract/19\">",
"     19",
"    </a>",
"    ]. The effect of aspirin on cancer mortality only appears after several years, and therefore, shorter-term studies may identify a smaller magnitude of mortality benefit than longer-term studies.",
"   </p>",
"   <p>",
"    A meta-analysis published in 2011 reported data from randomized clinical trials comparing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    to no aspirin for the prevention of vascular events (both primary and secondary prevention) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23529/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In eight eligible studies (25,570 patients), treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      was associated with a reduction in cancer death (OR 0.79, 95% CI 0.68-0.92).",
"     </li>",
"     <li>",
"      Individual patient data (23,535 patients) was available from seven of the studies. Reduction in cancer deaths was seen only after five years of follow-up (total cancer: HR 0.66, 95% CI 0.50-0.87; GI cancers: 0.46, 95% CI 0.27-0.77).",
"     </li>",
"     <li>",
"      Three of the trials conducted in the United Kingdom continued to collect mortality data up to 20 years. In these studies, the 20 year risk of death from solid cancers remained 20 percent lower in patients receiving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      during the treatment phase (HR 0.80, 95% CI 0.72-0.88). Benefit increased with increasing duration of aspirin treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a meta-analysis of 51 RCTs, data on cancer-related mortality was available from 34 of these trials (n = 69,224) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23529/abstract/18\">",
"     18",
"    </a>",
"    ]. In these trials, 58 percent of nonvascular deaths were due to cancer.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      was associated with an overall reduction in cancer-related mortality (OR 0.85, 95% CI 0.76-0.96).",
"     </li>",
"     <li>",
"      Although numbers of cancer deaths by subgroup was small,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      was associated with a reduction in mortality in several specific cancer groups including colorectal (OR 0.58, 95% CI 0.38-0.89) and lymphoma (OR 0.52, 95% CI 0.26-1.00).",
"     </li>",
"     <li>",
"      When stratified by follow-up duration (&lt;3.0 years, 3.0 to 4.9 years, &ge;5.0 years), only patients followed for &gt;5 years demonstrated a benefit of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      on cancer mortality (OR 0.63, 95% CI 0.49-0.82).",
"     </li>",
"     <li>",
"      Treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      was also associated with a significant decrease in nonvascular mortality, including cancer-related mortality (OR 0.88, 95% CI 0.78-0.96).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the 12 trials limited to primary prevention (n = 44,068),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    was associated with a similar decrease in the risk of nonvascular death (OR 0.88, 95% CI 0.78-0.98) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23529/abstract/18\">",
"     18",
"    </a>",
"    ]. One potential limitation of this analysis is exclusion of two primary prevention studies utilizing every-other-day aspirin. In the Physician's Health Study, which compared aspirin 325 mg every other day to control, there was no significant difference in nonvascular mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23529/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. A rationale for exclusion is a postulated difference in effect associated with alternate day dosage in both studies.",
"   </p>",
"   <p>",
"    In a separate meta-analysis of nine RCTs comparing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    to placebo for primary prevention (that included the Women&rsquo;s Health Study and Physician&rsquo;s Health Study data), aspirin was not associated with a significant reduction in cancer mortality (OR 0.93, 95% RR 0.84-1.03) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23529/abstract/7\">",
"     7",
"    </a>",
"    ]. It was associated with a modest reduction in total nonvascular mortality, but with confidence intervals that included no effect (OR 0.92, 95% CI 0.85-1.00).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H989550\">",
"    <span class=\"h1\">",
"     TOTAL MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    in studies of primary prevention of cardiovascular events on all-cause mortality has been evaluated in two separate meta-analyses [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23529/abstract/7,12\">",
"     7,12",
"    </a>",
"    ]. Both suggested a reduction in all-cause mortality with aspirin but with confidence intervals that include no effect (RR 0.94, 95% CI 0.88-1.00 in each study). These results are consistent with a larger meta-analysis of 51 randomized controlled trials that included both primary and secondary prevention trials that also suggested a reduction in total mortality (OR 0.92, 95% CI 0.85-1.00) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23529/abstract/18\">",
"     18",
"    </a>",
"    ]. These benefits are largely driven by a reduction in non-cardiovascular mortality.",
"   </p>",
"   <p>",
"    Many would consider total mortality the most important outcome in the decision whether or not to use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    for primary prevention. The interpretation of the mortality data then becomes critical. Because the confidence interval includes 1.0 (no difference between aspirin and no aspirin) some might conclude aspirin has no effect. A more appropriate interpretation would focus on the point estimate (a 6 percent relative risk reduction in one meta-analysis and an 8 percent relative risk reduction in the other) acknowledging that the confidence interval is wide enough to leave us only moderately confident of the small mortality reduction with aspirin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1761566\">",
"    <span class=\"h1\">",
"     ADVERSE EFFECTS OF ASPIRIN",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1898937\">",
"    <span class=\"h2\">",
"     Bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary adverse effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    is bleeding. Bleeding most commonly occurs in the gastrointestinal tract and is not usually fatal. However, bleeding also occurs at other sites, with intracranial bleeding (hemorrhage) being the most serious.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H990318\">",
"    <span class=\"h3\">",
"     Rates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies of the adverse effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    report rates of major bleeding (typically defined as intracranial bleeding plus bleeding from the gastrointestinal tract or other sites that requires hospitalization",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    transfusion). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29130?source=see_link&amp;anchor=H8#H8\">",
"     \"Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The relative and absolute risks of bleeding found in randomized trials comparing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    to placebo are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       GI bleeding",
"      </strong>",
"      &mdash; In a meta-analysis of 24 randomized controlled trials (RCTs) of almost 66,000 people taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      for greater than one year, there was an increased risk of gastrointestinal hemorrhage in those taking aspirin compared to placebo (OR 1.68, 95% CI 1.51-1.88) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/62/23529/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Intracranial hemorrhage",
"      </strong>",
"      &mdash; In an individual patient data meta-analysis of six primary prevention trials,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      was associated with a relative increase in the rate of hemorrhagic stroke (RR 1.32, 95% CI 1.00-1.75) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/62/23529/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Major bleeding",
"      </strong>",
"      &mdash; In the same meta-analysis,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      was associated with an increased risk of major bleeding (gastrointestinal and other extracranial) compared to patients not taking aspirin (RR 1.54, 95% 1.30-1.82) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/62/23529/abstract/8\">",
"       8",
"      </a>",
"      ]. The excess risk was in non-fatal bleeds; there were actually fewer fatal bleeds among aspirin users than non-aspirin users (although event rates were very low for both).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The incidence of major bleeding is likely to be higher in the general population than among participants in randomized trials. In general, randomized trials did not include individuals who were felt to be at increased risk for bleeding complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1761580\">",
"    <span class=\"h3\">",
"     Risk factors for aspirin-associated bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    -associated gastrointestinal (GI) bleeding have been identified and are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link&amp;anchor=H2#H2\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The US Preventive Services Task Force (USPSTF) report on the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    for the primary prevention of cardiovascular disease (CVD) suggested that the relative risk was two to three times higher in patients with a history of GI ulcer and twice as high for men as women [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23529/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link&amp;anchor=H5#H5\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\", section on 'Low dose aspirin for cardiovascular protection'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link&amp;anchor=H2#H2\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the aforementioned meta-analysis of six primary prevention trials, individual cardiovascular risk factors (with the exception of increasing cholesterol) were each significantly associated with an increase in major extracranial bleeding (advancing age by decade, male sex, diabetes, current smoking, increasing blood pressure, and increasing BMI) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23529/abstract/8\">",
"     8",
"    </a>",
"    ]. Thus, the predicted absolute rates of nonfatal major extracranial bleeding with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    over five years in this meta-analysis increased with increasing Framingham risk score:",
"   </p>",
"   <p>",
"    Five-year risk of bleeding according to CAD risk category:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      CAD risk &lt;5 percent: bleeding risk 0.4 percent",
"     </li>",
"     <li>",
"      CAD risk 5 to 10 percent: bleeding risk 1.0 percent",
"     </li>",
"     <li>",
"      CAD risk &gt;10 percent: bleeding risk 2.7 percent &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1761587\">",
"    <span class=\"h3\">",
"     Primary prevention of aspirin-induced GI bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of a proton pump inhibitor (PPI) to prevent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    -induced GI bleeding is not cost-effective for people with an average GI bleeding risk [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23529/abstract/23\">",
"     23",
"    </a>",
"    ]. Some experts consider older individuals to be at increased risk for bleeding and 2009 guidelines from the American College of Gastroenterology [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23529/abstract/24\">",
"     24",
"    </a>",
"    ] suggest using a PPI for older patients (age &gt;65 years) who are maintained on chronic aspirin therapy. However, a 2008 consensus statement representing the American College of Cardiology Foundation, the American Heart Association and the American College of Gastroenterology does not consider age alone (&ge;60 years) an indication for PPI use with chronic aspirin therapy in the absence of another risk factor (a history of ulcer",
"    <span class=\"nowrap\">",
"     disease/bleeding/dual",
"    </span>",
"    antiplatelet or concomitant anticoagulant",
"    <span class=\"nowrap\">",
"     therapy/steroid",
"    </span>",
"    <span class=\"nowrap\">",
"     use/dyspepsia",
"    </span>",
"    or gastroesophageal reflux disease). Issues related to the primary prevention of gastrointestinal toxicity from nonsteroidal antiinflammatory drugs are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=see_link&amp;anchor=H10#H10\">",
"     \"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity\", section on 'Prevention strategies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1899027\">",
"    <span class=\"h2\">",
"     Aspirin sensitivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;A very small minority of patients are unable to tolerate",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    because of hypersensitivity, which is most often manifested clinically as respiratory symptoms including rhinitis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    asthma and less frequently as",
"    <span class=\"nowrap\">",
"     urticaria/angioedema",
"    </span>",
"    (7 to 20 per 10,000 treated) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23529/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. With some forms of aspirin sensitivity, cross-reactions occur with other NSAIDs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/59/31672?source=see_link\">",
"     \"NSAIDs (including aspirin): Allergic and pseudoallergic reactions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H460031903\">",
"    <span class=\"h1\">",
"     DOSING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall benefits of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy may be achieved with doses in the range of 75 to 100 mg daily. While such doses appear to achieve all the benefit possible for cardiovascular disease, the data for cancer benefit are not entirely consistent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H460031910\">",
"    <span class=\"h2\">",
"     Prevention of cardiovascular events",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best evidence for the effects of different",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    doses on vascular events comes from subgroup analyses from the Antithrombotic Trialists Collaboration meta-analyses of antiplatelet therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23529/abstract/28\">",
"     28",
"    </a>",
"    ]. These analyses included direct and indirect comparisons of different daily doses of aspirin (500 to 1500 mg versus 160 to 325 mg versus 75 to 160 mg versus &lt;75 mg) in patients with pre-existing vascular disease at high risk for future events. In this study and others, aspirin appears to be equally effective for the prevention of vascular events at doses between 75 and 325 mg per day. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=see_link&amp;anchor=H20#H20\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\", section on 'Dosing and cardiovascular benefit'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H460031917\">",
"    <span class=\"h2\">",
"     Prevention of cancer events",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early randomized trials of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    for the prevention of colonic adenoma provide strong evidence that aspirin reduces adenoma incidence but limited data on the optimal dose [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23529/abstract/29-32\">",
"     29-32",
"    </a>",
"    ]. The preponderance of cohort studies suggests aspirin&rsquo;s preventive effect on development of adenomas",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    colorectal cancer increases with increasing number of aspirin doses per week [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23529/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. As noted previously, pooled individual data from five randomized controlled trials (RCTs) demonstrated daily low-dose aspirin (75 to 100 mg) was associated with a significant reduction in all cancers during five or more years follow-up. However, the only RCT of aspirin with colorectal cancer as its primary endpoint tested 600 mg of daily aspirin and found a long-term reduction in risk of cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23529/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22666?source=see_link&amp;anchor=H4#H4\">",
"     \"NSAIDs (including aspirin): Role in prevention of cancer\", section on 'Aspirin trials'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H460031924\">",
"    <span class=\"h2\">",
"     Bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;In indirect comparisons in the meta-analysis conducted by the Antithrombotic Trialists' Collaboration, there were no significant differences in risk of major extracranial bleeding across dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    from 75 to 325",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23529/abstract/28\">",
"     28",
"    </a>",
"    ]. However, a number of studies have suggested a potential relationship between increased aspirin doses and bleeding. In a systematic review of &gt;190,000 patients enrolled in 31 RCTs, aspirin dosage greater than 200 mg per day was associated with an approximate 30 percent relative increase in major bleeding compared to lower doses [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23529/abstract/36\">",
"     36",
"    </a>",
"    ]. The investigators also reported an increase in non-major bleeding in patients receiving 100 to 200 mg of aspirin per day compared to patients taking less than 100 mg per day.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1761594\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS FOR PRIMARY PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A decision regarding",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    use for primary prevention (of both cancer and cardiovascular disease events) should be made with the patient, after presenting an understandable summary of the likely patient-specific benefits and risks. The discussion below will outline an approach to estimating patient-specific benefits and risks.",
"   </p>",
"   <p>",
"    For individuals age 50 years or greater without underlying documented cardiovascular disease and without excess bleeding risks, we suggest daily",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    at a dose of 75 to 100 mg. Patients who are more concerned about the bleeding risks than the potential benefits may reasonably choose to not take aspirin for primary prevention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1761601\">",
"    <span class=\"h2\">",
"     Estimating benefits and risks",
"    </span>",
"    &nbsp;&mdash;&nbsp;In summary, pooled data from randomized controlled trials (RCTs) suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    is associated with:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An approximate 20 percent relative risk reduction in non-fatal myocardial infarction (MI)",
"     </li>",
"     <li>",
"      No significant effect on non-fatal stroke (including hemorrhagic stroke)",
"     </li>",
"     <li>",
"      An approximate 12 percent relative risk reduction in cancer incidence, potentially greater with prolonged treatment and occurring after a prolonged latency period (up to 8 to 10 years)",
"     </li>",
"     <li>",
"      An approximate 10 percent relative risk reduction in nonvascular (including cancer) mortality, particularly with prolonged treatment and follow-up",
"     </li>",
"     <li>",
"      An approximate 50 percent increase in the relative risk of major non-fatal extracranial bleeding",
"     </li>",
"     <li>",
"      A possible reduction in the relative risk of overall mortality (of the order of 6 to 8 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the absolute risk reduction of each of the outcomes is small or very small since all of these events are infrequent in primary prevention populations. The magnitude of absolute benefits and harms will vary based on individual patient risk for each of these outcomes.",
"   </p>",
"   <p>",
"    Based on these estimates,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    use in 1000 patients at age 60 years and at average risk for coronary artery disease (10 to 20 percent over 10 years) and at average risk of any malignancy (approximately 12 percent) over a 10-year period would be expected to result in (",
"    <a class=\"graphic graphic_table graphicRef86941 \" href=\"UTD.htm?39/47/40702\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      6 fewer deaths",
"     </li>",
"     <li>",
"      19 fewer non-fatal MIs",
"     </li>",
"     <li>",
"      14 fewer cancers",
"     </li>",
"     <li>",
"      no significant reduction in non-fatal strokes (includes both ischemic and hemorrhagic strokes)",
"     </li>",
"     <li>",
"      16 more major bleeding events (intracranial bleeding plus bleeding from the gastrointestinal tract or other sites that requires hospitalization",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      transfusion)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The quality of evidence supporting cancer incidence estimate is low; the quality of evidence for all other outcomes is moderate.",
"   </p>",
"   <p>",
"    In terms of net benefits with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , these estimates may be conservative for two reasons. First, benefits of aspirin with respect to cancer (and cancer associated mortality) appear to increase with longer treatment (eg, greater than five years), and most participants in the studies on which these estimates are based were not followed for 10 or more years. Second, bleeding rates are highest during initial treatment as susceptible individuals suffer bleeds early. Irrespective of these considerations, when one considers the 10-year time frame of the estimates, both benefits and risks are very small (",
"    <a class=\"graphic graphic_table graphicRef86941 \" href=\"UTD.htm?39/47/40702\">",
"     table 1",
"    </a>",
"    ).",
"    <br/>",
"   </p>",
"   <p>",
"    The American College of Chest Physicians Antithrombotic Therapy and Prevention of Guidelines, 9th edition (AT9) estimated the absolute risks and benefits associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    in primary prevention over a time frame of a decade for the outcomes of total mortality, non-fatal MI, non-fatal stroke (including hemorrhagic), and major extracranial bleeding (",
"    <a class=\"graphic graphic_table graphicRef86941 \" href=\"UTD.htm?39/47/40702\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23529/abstract/37\">",
"     37",
"    </a>",
"    ]. Estimates were derived based on data from two meta-analyses [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23529/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The table presented in AT9 has been modified, incorporating data relative to the incidence of cancer and a baseline risk estimate for typical cancer risk from a meta-analysis (",
"    <a class=\"graphic graphic_table graphicRef86941 \" href=\"UTD.htm?39/47/40702\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/62/23529/abstract/18\">",
"     18",
"    </a>",
"    ]. Unfortunately, calculators assessing an individual&rsquo;s risk for any cancer event in the next 10 years do not exist, although calculators do exist for specific cancer types (eg,",
"    <a class=\"external\" href=\"file://www.cancer.gov/colorectalcancerrisk/\">",
"     colorectal",
"    </a>",
"    ,",
"    <a class=\"external\" href=\"file://nomograms.mskcc.org/Lung/RiskAssessment.aspx\">",
"     lung cancer",
"    </a>",
"    ,",
"    <a class=\"external\" href=\"file://www.cancer.gov/bcrisktool/Default.aspx\">",
"     breast cancer risk assessment",
"    </a>",
"    ). Such calculators may be used by clinicians to estimate specific cancer risks in the subsequent 10 years. In patients with particularly low or high cancer risk, the possible absolute benefits of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    for cancer prevention will be correspondingly lower or higher.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1722732\">",
"    <span class=\"h2\">",
"     Individualizing decisions for aspirin prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ideally one would assess the net benefit of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    (reduction in MI plus reduction in cancer incidence minus an increase in the risk of major bleeding) while considering the impact on total mortality. After this assessment, clinicians should discuss the anticipated effects on each individual outcome as well as the net benefit with the patient. Individual patients will place different values on each outcome, particularly when considering a long-term therapy with low absolute benefit and risk. For example, some patients may place greater value on prevention of cancer events than vascular events or bleeding events. Others may determine that the absolute net benefit of aspirin therapy is not of sufficient magnitude to warrant the inconvenience of long-term medication use.",
"   </p>",
"   <p>",
"    Clinicians can use these estimates as a starting point for discussions with individual patients. Not all informed patients will choose to use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , and individual discussion is imperative. Factors to be considered in this discussion include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Individualized clinical assessment of patient risk for each of the above outcomes. As an example, a patient may have an increased risk of future malignancy (eg, colorectal) based on family history, prior medical history (eg, colonic polyps), etc. Such a history would increase the possible absolute benefit of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      use.",
"     </li>",
"     <li>",
"      Previous guidelines suggested that recommendations may differ depending on the degree of cardiovascular risk, with more potential cardiovascular benefit of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      in patients at greater cardiovascular risk. It is very likely, however, that bleeding risk also increases with increasing cardiac risk, limiting the gradient in net benefit across cardiovascular risk.",
"     </li>",
"     <li>",
"      Use of concomitant medications known to increase bleeding risk associated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      , NSAIDs) would reduce the net benefit associated with aspirin use.",
"     </li>",
"     <li>",
"      Assessment of the value a patient places on preventing a specific outcome relative to others. For example, patients may place greater value on avoiding a cancer (even if at low risk) than they do on avoiding vascular events or bleeding.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1761638\">",
"    <span class=\"h2\">",
"     Recommendations of others",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations regarding the daily use of low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    vary from guideline to guideline. The following represent recommendations of guidelines:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      2012 guidelines from the American College of Chest Physicians (ACCP) suggest the use of low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (75 to 100 mg daily) for persons age 50 years or older without symptomatic cardiovascular disease [",
"      <a class=\"abstract\" href=\"UTD.htm?22/62/23529/abstract/37\">",
"       37",
"      </a>",
"      ]. This is the only guideline to discuss the potential impact of aspirin on cancer incidence and mortality and include data on the potential impact of aspirin on total mortality when considering recommendations. The guidelines note that benefits are small, and a substantial proportion of people will likely decline aspirin for primary prophylaxis. The ACCP guidelines also recommend against the use of aspirin or other platelet agents in patients who are managed on anticoagulant therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?22/62/23529/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      2012 guidelines from the European Society of Cardiology, which did not consider cancer risk, advise against the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      in individuals without cardiovascular or cerebrovascular disease due to the risk of major bleeding [",
"      <a class=\"abstract\" href=\"UTD.htm?22/62/23529/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      2009 guidelines from the US Preventive Services Task Force (USPSTF) encourage the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      in selected populations, considering the relative cardiovascular benefit and GI hemorrhage risk; issues of cancer prevention were not incorporated [",
"      <a class=\"abstract\" href=\"UTD.htm?22/62/23529/abstract/40\">",
"       40",
"      </a>",
"      ]. In individuals for whom the potential harm of GI hemorrhage does not outweigh potential benefit, the USPSTF recommends aspirin in men aged 45 to 79 for prevention of myocardial infarction and in women aged 55 to 79 for prevention of stroke (",
"      <a class=\"graphic graphic_table graphicRef86940 \" href=\"UTD.htm?28/56/29581\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/54/40803?source=see_link\">",
"       \"Patient information: Aspirin and cardiovascular disease (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1761645\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      modestly decreases the risk of non-fatal myocardial infarction (moderate-quality evidence), cancer incidence (low-quality evidence), and overall mortality (moderate-quality evidence) in patients without underlying cardiovascular disease and at average cancer risk, but increases the risk of major bleeding. The net magnitude of benefits is very small. (See",
"      <a class=\"local\" href=\"#H1761531\">",
"       'Primary prevention of cardiovascular disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1761545\">",
"       'Primary prevention of cancer'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H989550\">",
"       'Total mortality'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1898937\">",
"       'Bleeding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Estimates of absolute benefits and risks of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      in primary prevention are provided in a table (",
"      <a class=\"graphic graphic_table graphicRef86941 \" href=\"UTD.htm?39/47/40702\">",
"       table 1",
"      </a>",
"      ). Clinicians can use these estimates as a starting point for discussions with individual patients. Not all informed patients will choose to use aspirin and individual discussion is imperative. (See",
"      <a class=\"local\" href=\"#H1761601\">",
"       'Estimating benefits and risks'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Factors to be considered in this discussion include assessment of the individual&rsquo;s risk for each outcome (cardiovascular events, cancer, bleeding, and total mortality); assessment of the relative value the individual places on preventing specific outcomes; assessment of the patient&rsquo;s attitude to inconvenience of long-term daily therapy; and value placed on immediate increase in risk of bleeding versus delayed potential benefit on cancer and death. (See",
"      <a class=\"local\" href=\"#H1722732\">",
"       'Individualizing decisions for aspirin prophylaxis'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      In many adults, the benefits of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      exceed the risks (principally bleeding). For individuals age &ge;50 years without excess bleeding risk, we suggest low-dose daily aspirin (75 to 100 mg) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Patients who are more concerned about the bleeding risks than the potential benefits (prevention of cardiovascular events and cancer) may reasonably choose to not take aspirin for primary prevention. (See",
"      <a class=\"local\" href=\"#H1761594\">",
"       'Recommendations for primary prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      dose for the prevention of colorectal cancer in patients with hereditary nonpolyposis colorectal cancer or familial adenomatous polyposis is discussed separately, as is the potential role of aspirin for primary prevention when cardiovascular events and colorectal cancer are considered as individual outcomes. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22666?source=see_link&amp;anchor=H16#H16\">",
"       \"NSAIDs (including aspirin): Role in prevention of cancer\", section on 'Summary and recommendations'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=see_link\">",
"       \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     The top 10 causes of death. World Health Organization; 2011. file://www.who.int/mediacentre/factsheets/fs310/en/index.html (Accessed on October 27, 2011).",
"    </li>",
"    <li>",
"     World Health Organization. Cancer Fact Sheet. Updated Febuary 2012. Available at: file://www.who.int/mediacentre/factsheets/fs297/en (Accessed on October 24, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23529/abstract/3\">",
"      Kaiser J. Will an aspirin a day keep cancer away? Science 2012; 337:1471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23529/abstract/4\">",
"      Chan AT, Cook NR. Are we ready to recommend aspirin for cancer prevention? Lancet 2012; 379:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23529/abstract/5\">",
"      Liao X, Lochhead P, Nishihara R, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 2012; 367:1596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23529/abstract/6\">",
"      Dannenberg AJ, Lippman SM, Mann JR, et al. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol 2005; 23:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23529/abstract/7\">",
"      Seshasai SR, Wijesuriya S, Sivakumaran R, et al. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med 2012; 172:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23529/abstract/8\">",
"      Antithrombotic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373:1849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23529/abstract/9\">",
"      Fowkes FG, Price JF, Stewart MC, et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA 2010; 303:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23529/abstract/10\">",
"      Ogawa H, Nakayama M, Morimoto T, et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008; 300:2134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23529/abstract/11\">",
"      Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008; 337:a1840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23529/abstract/12\">",
"      Raju N, Sobieraj-Teague M, Hirsh J, et al. Effect of aspirin on mortality in the primary prevention of cardiovascular disease. Am J Med 2011; 124:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23529/abstract/13\">",
"      Bartolucci AA, Tendera M, Howard G. Meta-analysis of multiple primary prevention trials of cardiovascular events using aspirin. Am J Cardiol 2011; 107:1796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23529/abstract/14\">",
"      Dub&eacute; C, Rostom A, Lewin G, et al. The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med 2007; 146:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23529/abstract/15\">",
"      Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med 1989; 321:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23529/abstract/16\">",
"      Cook NR, Lee IM, Gaziano JM, et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA 2005; 294:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23529/abstract/17\">",
"      Rothwell PM, Wilson M, Elwin CE, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010; 376:1741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23529/abstract/18\">",
"      Rothwell PM, Price JF, Fowkes FG, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 2012; 379:1602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23529/abstract/19\">",
"      Rothwell PM, Wilson M, Price JF, et al. Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials. Lancet 2012; 379:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23529/abstract/20\">",
"      Rothwell PM, Fowkes FG, Belch JF, et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011; 377:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23529/abstract/21\">",
"      Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ 2000; 321:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23529/abstract/22\">",
"      US Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2009; 150:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23529/abstract/23\">",
"      Earnshaw SR, Scheiman J, Fendrick AM, et al. Cost-utility of aspirin and proton pump inhibitors for primary prevention. Arch Intern Med 2011; 171:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23529/abstract/24\">",
"      Lanza FL, Chan FK, Quigley EM, Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 2009; 104:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23529/abstract/25\">",
"      Stevenson DD. Aspirin and NSAID sensitivity. Immunol Allergy Clin North Am 2004; 24:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23529/abstract/26\">",
"      Jenkins C, Costello J, Hodge L. Systematic review of prevalence of aspirin induced asthma and its implications for clinical practice. BMJ 2004; 328:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23529/abstract/27\">",
"      Grattan CE. Aspirin sensitivity and urticaria. Clin Exp Dermatol 2003; 28:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23529/abstract/28\">",
"      Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23529/abstract/29\">",
"      Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003; 348:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23529/abstract/30\">",
"      Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003; 348:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23529/abstract/31\">",
"      Benamouzig R, Uzzan B, Deyra J, et al. Prevention by daily soluble aspirin of colorectal adenoma recurrence: 4-year results of the APACC randomised trial. Gut 2012; 61:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23529/abstract/32\">",
"      Logan RF, Grainge MJ, Shepherd VC, et al. Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology 2008; 134:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23529/abstract/33\">",
"      Chan AT, Giovannucci EL, Schernhammer ES, et al. A prospective study of aspirin use and the risk for colorectal adenoma. Ann Intern Med 2004; 140:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23529/abstract/34\">",
"      Chan AT, Giovannucci EL, Meyerhardt JA, et al. Aspirin dose and duration of use and risk of colorectal cancer in men. Gastroenterology 2008; 134:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23529/abstract/35\">",
"      Burn J, Gerdes AM, Macrae F, et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 2011; 378:2081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23529/abstract/36\">",
"      Serebruany VL, Steinhubl SR, Berger PB, et al. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol 2005; 95:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23529/abstract/37\">",
"      Vandvik PO, Lincoff AM, Gore JM, et al. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e637S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23529/abstract/38\">",
"      You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e531S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23529/abstract/39\">",
"      Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012; 33:1635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/62/23529/abstract/40\">",
"      Wolff T, Miller T, Ko S. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2009; 150:405.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16291 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-7DB0BEB7E6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_62_23529=[""].join("\n");
var outline_f22_62_23529=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1761645\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1761517\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1761524\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1761531\">",
"      PRIMARY PREVENTION OF CARDIOVASCULAR DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1761545\">",
"      PRIMARY PREVENTION OF CANCER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1761552\">",
"      Aspirin and cancer incidence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3356540\">",
"      - Colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3357234\">",
"      - Other cancers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1761559\">",
"      Aspirin and cancer mortality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H989550\">",
"      TOTAL MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1761566\">",
"      ADVERSE EFFECTS OF ASPIRIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1898937\">",
"      Bleeding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H990318\">",
"      - Rates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1761580\">",
"      - Risk factors for aspirin-associated bleeding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1761587\">",
"      - Primary prevention of aspirin-induced GI bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1899027\">",
"      Aspirin sensitivity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H460031903\">",
"      DOSING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H460031910\">",
"      Prevention of cardiovascular events",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H460031917\">",
"      Prevention of cancer events",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H460031924\">",
"      Bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1761594\">",
"      RECOMMENDATIONS FOR PRIMARY PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1761601\">",
"      Estimating benefits and risks",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1722732\">",
"      Individualizing decisions for aspirin prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1761638\">",
"      Recommendations of others",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1761645\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/16291\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/16291|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?39/47/40702\" title=\"table 1\">",
"      Aspirin for CVD and cancer prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/56/29581\" title=\"table 2\">",
"      Aspirin and CVD USPSTF rec",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/47/2807?source=related_link\">",
"      Aspirin: Mechanism of action, major toxicities, and use in rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/12/37066?source=related_link\">",
"      Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/24/42378?source=related_link\">",
"      Cancer prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/59/31672?source=related_link\">",
"      NSAIDs (including aspirin): Allergic and pseudoallergic reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/31/38393?source=related_link\">",
"      NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/8/22666?source=related_link\">",
"      NSAIDs (including aspirin): Role in prevention of cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/54/40803?source=related_link\">",
"      Patient information: Aspirin and cardiovascular disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/28/29130?source=related_link\">",
"      Spontaneous intracerebral hemorrhage: Pathogenesis, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/4/4167?source=related_link\">",
"      The role of platelets in coronary heart disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_62_23530="Laryngeal anatomy coronal";
var content_f22_62_23530=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F58555%7EONC%2F72411&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F58555%7EONC%2F72411&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 539px\">",
"   <div class=\"ttl\">",
"    Laryngeal anatomy in the coronal plane from a posterior view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 519px; height: 460px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Garrett CG, Ossoff RH. Hoarseness. Med Clin N Am 1999; 83:115. Copyright 1999 W.B. Saunders Company.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 580px\">",
"   <div class=\"ttl\">",
"    Diagrammatic representation of laryngeal anatomy in the sagittal plane",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 560px; height: 461px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_62_23530=[""].join("\n");
var outline_f22_62_23530=null;
var title_f22_62_23531="OTC fiber supplements PI";
var content_f22_62_23531=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F79264&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F79264&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Over-the-counter fiber supplements",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Product",
"      </td>",
"      <td class=\"subtitle1\">",
"       Amount",
"      </td>",
"      <td class=\"subtitle1\">",
"       Frequency",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"3\">",
"       Metamucil",
"      </td>",
"      <td>",
"       12 years and over: 1 teaspoon or 1 tablespoon, depending on concentration and formulation",
"      </td>",
"      <td colspan=\"1\" rowspan=\"3\">",
"       1-3 times daily",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       6 to 12 years: 1/2 to 1 teaspoon or 1/2 tablespoon, depending on concentration and formulation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Under age 6: 1/4 to 1/2 teaspoon",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"3\">",
"       Benefiber",
"      </td>",
"      <td>",
"       12 years and over: 1 to 2 tablespoons",
"      </td>",
"      <td colspan=\"1\" rowspan=\"3\">",
"       1-3 times daily",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       7 to 11 years: 1/2 to 1 tablespoon",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Under age 7: 1/4 to 1/2 tablespoon",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\" rowspan=\"3\">",
"       Citrucel",
"      </td>",
"      <td>",
"       12 years and over: 1 rounded tablespoon",
"      </td>",
"      <td colspan=\"1\" rowspan=\"3\">",
"       1-3 times daily",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       6 to 12 years: 1/2 tablespoon",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Under age 6: 1/4 to 1/2 tablespoon",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_62_23531=[""].join("\n");
var outline_f22_62_23531=null;
var title_f22_62_23532="Monitoring immunosuppressives";
var content_f22_62_23532=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F58710&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F58710&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Suggested monitoring for immunosuppressive drugs",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug or class",
"       </td>",
"       <td class=\"subtitle1\">",
"        Toxicities",
"       </td>",
"       <td class=\"subtitle1\">",
"        Monitoring",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Glucocorticoids",
"       </td>",
"       <td>",
"        Hypertension, hyperglycemia, hyperlipidemia, cataracts, and osteoporosis",
"       </td>",
"       <td>",
"        Periodic blood pressure, serum glucose, lipid profile, eye exam, and bone densitometry",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Methotrexate",
"       </td>",
"       <td>",
"        Myelosuppression and hepatotoxicity, including cirrhosis",
"       </td>",
"       <td>",
"        CBC, liver enzymes, albumin, creatinine every 1 to 2 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hydroxychloroquine",
"       </td>",
"       <td>",
"        Macular damage",
"       </td>",
"       <td>",
"        Fundoscopic and visual field exams every 6 to 12 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sulfasalazine",
"       </td>",
"       <td>",
"        Myelosuppression",
"       </td>",
"       <td>",
"        CBC monthly for 3 months, then every 3 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Azathioprine",
"       </td>",
"       <td>",
"        Myelosuppression, hepatotoxicity, and lymphoproliferative disorders",
"       </td>",
"       <td>",
"        CBC, liver enzymes every 1 to 2 months (CBC every 1 to 2 weeks with change in dose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cyclophosphamide",
"       </td>",
"       <td>",
"        Myelosuppression, myeloproliferative disorders, hemorrhagic cystitis, bladder cancer, and other neoplasms",
"       </td>",
"       <td>",
"        CBC, urinalysis every 2 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chlorambucil",
"       </td>",
"       <td>",
"        Myelosuppression, myeloproliferative disorders, and other neoplasms",
"       </td>",
"       <td>",
"        CBC every 2 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cyclosporine and FK 506",
"       </td>",
"       <td>",
"        Renal insufficiency, anemia, and hypertension",
"       </td>",
"       <td>",
"        Blood pressure and creatinine every month (every 2 weeks with change in dose), periodic CBC, potassium, and liver enzymes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Leflunomide",
"       </td>",
"       <td>",
"        Diarrhea, alopecia, and asymptomatic liver transaminase elevations",
"       </td>",
"       <td>",
"        CBC, liver enzymes, and creatinine every 1 to 2 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Etanercept",
"       </td>",
"       <td>",
"        Infection, injection site reactions",
"       </td>",
"       <td>",
"        PPD prior to therapy; periodic CBC",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infliximab",
"       </td>",
"       <td>",
"        Infection",
"       </td>",
"       <td>",
"        PPD prior to therapy; periodic CBC",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_62_23532=[""].join("\n");
var outline_f22_62_23532=null;
var title_f22_62_23533="Loop mark";
var content_f22_62_23533=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F79515&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F79515&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Loop mark",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 146px; height: 216px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note the characteristic bruising pattern.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Joan E Shook, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_62_23533=[""].join("\n");
var outline_f22_62_23533=null;
var title_f22_62_23534="Jersey finger";
var content_f22_62_23534=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F53137&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F53137&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Flexor digitorum profundus avulsion fracture (jersey finger)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 336px; height: 170px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Flexor digitorum profundus avulsion fracture of the distal phalanx (jersey finger). This bony avulsion is apparent on radiographs, indicating the extent of proximal migration.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Kozin SH, Waters PM. Fractures and dislocations of the hand and carpus in children. In: Rockwood and Wilkins' Fractures in Children, 7th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_62_23534=[""].join("\n");
var outline_f22_62_23534=null;
var title_f22_62_23535="Pathogenesis PCOS";
var content_f22_62_23535=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F64337&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F64337&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Potential mechanisms underlying the development of PCOS",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 353px; height: 437px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Inherited factors act to create a susceptible genotype, most commonly identifiable by a positive family history for PCOS or related features. This susceptible genotype, in isolation or in association with environmental or acquired factors, may result in intermediate forms of functional hyperandrogenism. Continued exposure to environmental factors, or an increasing load of genetic variants favoring its occurrence, leads to the development of clinically evident PCOS.",
"    <div class=\"footnotes\">",
"     AA: adrenal androgen; CNS: central nervous system; FSH: follicle stimulating hormone; HA: hyperandrogenemia; IR: insulin resistance; LH: luteinizing hormone; PCOM: polycystic ovarian morphology.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ricardo Azziz, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_62_23535=[""].join("\n");
var outline_f22_62_23535=null;
